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Abstract 
 
Overwhelming evidence indicates that higher levels of high-density lipoprotein cholesterol 
(HDL-C) correlate with reduced risk of coronary heart disease (CHD). HDL can efflux excess 
cholesterol by reverse cholesterol transport (RCT). Hence, reducing acute plaque accumulation by 
direct infusion of cholesterol-free synthetic HDL (sHDL) has generated considerable interest. 
sHDL consists of a phospholipid bilayer held together by apolipoprotein A-I (ApoA-I). Due to the 
high manufacturing cost of recombinant ApoA-I, ApoA-I mimetic peptides complexed with a 
variety of lipids have been studied as treatments for various pathologies. However, the best 
methods of administration and formulation remain controversial. For sHDL products consisting of 
ApoA-I mimetic peptides like ETC-642, rapid elimination can limit their clinical application and 
subsequent development. Thus, prolonging the circulation time of sHDL can potentially improve 
its anti-atherosclerosis effect. In addition, designing novel nanoparticles mimicking sHDL can 
eliminate the need for the ApoA-I protein/peptide component in sHDL while preserving the core 
pharmacological activity of sHDL.  
We first studied the influence of administration route and lipidation of ApoA-I mimetic 
peptide 22A on plasma peptide levels, cholesterol mobilization, and lipoprotein remodeling in 
vivo. The mean circulation half-life for 22A-sHDL (T1/2 = 6.27 h) was longer than for free 22A 
(T1/2 = 3.81 h). The amount of 22A absorbed by the vascular compartment after intraperitoneal (IP) 
dosing was ~50% for both 22A and 22A-sHDL. The strongest pharmacologic response was 
observed after intravenous (IV) injection of 22A-sHDL compared to IP injection and 
administration of free peptide. Both the route of administration and the formulation of 22A 
significantly affected the peptide’s pharmacokinetic and pharmacodynamic properties. Following 
this study, sHDL surface modification with polyethylene glycol (PEG) was investigated for its 
potential to extend sHDL circulation in vivo. The circulation half-life of sHDL was extended both 
by adding more PEG or using PEG of longer chain lengths. Addition of PEG also increased the 
AUC for the phospholipid component of sHDL, leading to higher mobilization of free cholesterol 
in plasma due to prolonged circulation and increased stability.  
 xviii 
To extend this research into biomimetic nanomaterial development, we formulated 
nanomicelles (NanoMCLs), structural nano-mimetics of sHDL with small particle size (12-14 nm) 
and a hydrophobic core and hydrophilic exterior. NanoMCLs were shown to be functionally 
similar to sHDL and exhibited up to 14-fold more efficient inhibition of inflammatory cytokine 
release in vitro compared to sHDL. When administered as a 6-week treatment to ApoE-/- mice fed 
a high-fat diet, sHDL and NanoMCL reduced atheroma by 21% and 40%, respectively. In addition, 
NanoMCL treatment significantly depleted atheroma macrophages.  
Lastly, the application of sHDL as an anti-cancer drug delivery system was explored for 
treatment of glioma. Chemotherapeutic agent docetaxel (DTX) and immune-stimulatory toll-like 
receptor-9 (TLR-9) agonist cholesterol-CpG1826 (cholCpG) were co-incorporated in sHDL 
nanoparticles. The sHDL composition was optimized to maximize DTX retention in plasma. In a 
murine glioma model, intracranial injection of DTX-sHDL-cholCpG system exhibited significant 
anti-tumor efficacy with 20% of animals surviving past 90 days.  
In summary, this thesis systemically studied the effect of sHDL lipid composition on 
cholesterol mobilization and established sHDL-PEG and NanoMCL systems to improve the anti-
atherosclerosis effect of sHDL. In addition, DTX-sHDL-CpG nanoparticles were developed and 
applied in glioma therapy. We have shown that sHDL is a versatile nanoparticle with utility in 
atherosclerosis treatment and drug delivery.   
.   
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Chapter 1 : Introduction 
 
1.1 High density lipoprotein (HDL)  
1.1.1      HDL structure and metabolism 
High-density lipoproteins (HDL) are small, natural nanoparticles circulating throughout 
the body, and are best known for their anti-atherosclerosis function and anti-inflammatory effect 
by facilitating reversal cholesterol transport (RCT) from vascular cell macrophages. Their size 
ranges from 7 to 13 nm in diameter.1 Plasma levels of HDL cholesterol are negatively correlated 
with the risk of developing atherosclerosis, and, because of this, HDL is known as “good 
cholesterol”.2 HDL consists of a phospholipid- bilayer held together by the amphipathic, alpha-
helical protein, apolipoprotein A-I (ApoA-I). Human ApoA-I is a 243 amino acid protein with an 
average molecular weight of 28.1 kDa.3-4 It is the main protein associated with HDL and 
constitutes about 70% of the protein content in HDLs.5 Other apolipoproteins associated with 
HDLs include apoA-II, apoE and others.6 
The lipid species present in HDL are important, not only because they provide the overall 
structure to HDL, but also because they act as substrates for a variety of receptors and enzymes 
associated with HDL and its metabolic properties. There are more than 200 different identified 
lipid species contained in HDLs, notably phospholipids, unesterified (free) sterols, cholesteryl 
esters, and triglycerides.  Phospholipids together with sphingomyelin (SM) make up 40-60 wt% 
of total HDL lipids and they constitute the surface lipid monolayer of HDL.7 Among all the 
phospholipids, phosphatidylcholines (PC) are by far the largest population of HDL lipids, making 
up 33-45 wt% of total HDL lipids. Other phospholipids present in HDL  include 
lysophosphatidylcholines (lyso PC), phosphatidylethanolamines (PE),  phosphatidylinositols (PI), 
phosphatidylserines (PS), phosphatidylglycerols (PG), plasmologens, cardiolipin, and 
phosphatidic acids. In addition to PCs, sphingolipids including sphingomyelin (SM), ceramides, 
sphingosylphosphorylcholine, and sphingosine-1-phosphate make up roughly 5-10 wt% of total 
HDL lipids. 7 SM accounts for 5-10 wt% of total lipids in HDL and is essential for determining 
the surface pressure in lipid membranes. Lecithin cholesterol acyltransferase (LCAT) is a 
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glycoprotein that has both a phospholipase A2 and an acyltransferase action. It is essential for the 
normal maturation, interconversion and rearrangements of all lipoprotein classes and is involved 
in reverse cholesterol transport process of HDL. SM has been found to inhibit the LCAT reaction 
in discoidal HDL.8 The low abundance of SM and free cholesterol in small, dense HDL may 
elevate the fluidity of surface lipids.9 These lipids vary in structure, molecular weight, and 
transition temperature as a result of their different physical and biological properties. The lipidome 
of HDL can be altered under pathophysiological conditions, such as low HDL-cholesterol 
hypertriglyceridemic states, acute phase, and Niemann-Pick disease type B.10 
HDLs can be classified into different subclasses by density, size, shape, composition and 
surface charge. Based on particle shape and gel electrophoresis, HDLs are subdivided into 
discoidal pre-β HDL with β-mobility on electrophoresis and the α subfraction of HDL with α-
mobility on electrophoresis, which can be further classified into four categories from α-1 (large, 
spherical) to α-4 (small, discoidal) HDL.6 Based on density, HDLs are divided into  large, lipid-
rich HDL2 and smaller HDL3, which can be further divided into five subpopulations with 
decreasing size: HDL2b, HDL2a, HDL3a, HDL3b, and HDL3c.5  
HDL is able to carry cholesterol from peripheral cells to the liver though reverse cholesterol 
transport (RCT) process. The intravascular metabolism of HDL is shown in Fig. 1.1.11 Briefly, 
lipid-free ApoA-I, the major structural protein of HDL is synthesized in the liver and small 
intestine in humans. ApoA-I associates with cholesterol and phospholipids after its secretion in the 
blood to form discoidal nascent pre-β HDL. Unesterified cholesterol and phospholipids from 
peripheral cells, as well as from liver and intestine, are effluxed by ATP-binding cassette subfamily 
A member 1 (ABCA1) transporter. Pre-β HDL is lipidated by the cholesterol and lipids to form 
discoidal α-4 HDL. The cholesterol in HDL is then esterified by lecithin-cholesterol acyl 
transferase (LCAT). The movement of more hydrophobic cholesterol ester (CE) to the core of the 
HDL particle converts the α-4 HDL into larger, spherical HDL3. This process is known as 
maturation of HDL. The spherical HDL3 can further pick up cholesterol from peripheral tissues 
by ATP-binding cassette transporter G1 (ABCG1) and Scavenger receptor class B type 1 (SR-BI) 
and convert it to the cholesterol ester with the help of LCAT to form HDL2.  Both HDL2 and 
HDL3 can also exchange their cholesterol ester for triglycerides (TG) from TG-rich lipoproteins, 
such as LDL and VLDL. This process is mediated by cholesterol ester transfer protein (CETP), 
resulting in the formation of HDL with a hydrophobic core composed of cholesterol ester and 
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triglycerides. Some of this HDL will directly return back to the liver and deliver the HDL cargoe 
to hepatocytes for metabolism through HDL receptors. Other HDL will be hydrolyzed by  plasma 
enzymes, such as hepatic lipase (HL), endothelial lipase (EL), and secretory phospholipase A2, 
which results in the removal and recycling of phospholipids and ApoA-I protein contained in HDL 
and reversely transforms the spherical HDL to discoidal HDL. The liver then takes up CE released 
from these HDLs through a SR-BI-mediated process. The whole process is also accompanied by 
the catabolism of free ApoA-I and pre-β HDL by the kidney which are excreted in the urine.  
 
Figure 1.1: Metabolism of HDL in vivo.11 
1.1.2  HDL function 
HDLs are reported to play multiple roles in various diseases due to their unique interactions 
with different target sites. The most well-known function of HDL is its effect on atherosclerosis 
and cardiovascular diseases by facilitating reverse cholesterol transport (RCT), which is a multi-
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step process resulting in the net movement of cholesterol from peripheral tissues back to the liver 
via the plasma compartment as described in section 1.1.1. 12 In addition, HDLs also achieve anti-
atherosclerosis effects through other cardio-protective mechanisms. For instance, HDLs can 
reduce inflammation at the site of atherosclerotic lesions. 13 Due to the intrinsic targeting capability 
for the atherosclerotic plaques, HDL can facilitate targeted delivery of anti-inflammatory 
therapeutics to plaques. 14-15 Also, HDLs can be used to deliver certain imaging reagents to plaques 
for early diagnosis. Moreover, HDLs possess antioxidant and antithrombotic effects, which can 
help with endothelial integrity and repair. 13, 16   HDLs inhibit the accumulation of peroxidation 
products on the surface of LDLs which reduce oxidative stress, a risk factor associated with 
cardiovascular disease.  The antithrombotic activity of HDL is achieved by activating endothelial-
derived nitric oxide (NO) synthesis, which plays an important role in vasodilation and vascular 
endothelial integrity. 17 
1.2 Current development of synthetic HDL 
A number of reconstituted HDL products have advanced to different stages of clinical 
trials.18 These reconstituted HDL products (rHDL) are intended for administration following an 
initial cardiovascular event in patients with acute coronary syndrome (ACS) to remove excess 
cholesterol from arterial plaques and reduce the chance of a secondary event. Since rHDL is amied 
to remove cholesterol from peripheral tissues or macrophages, in clinical trials, one of the 
biomarker for successful cholesterol efflux or mobilization is the transient increase of plasma 
cholesterol levels including total cholesterol (TC) or free cholesterol (FC). But along with the 
further elimination of HDL-cholesterol, the TC and FC level return back to baseline normally. 19-
20 The summary of clinical trials examining the doses, routes of administration, molecular 
composition, pharmacokinetic parameters, and safety profiles of HDL products is provided in 
Table 1.1. At least seven different HDL products have been evaluated in clinical trials, including 
(a) HDL based on ApoA-I purified from human plasma, such as SRC-rHDL, CSL-111 and CSL-
112; (b) HDL based on recombinant ApoA-I and its variants, such as proApoA-I-liposomes, ETC-
216, and CER-001; and (c) rHDL based on synthetic ApoA-I mimetic peptides, such as ETC-642. 
The maximum tolerated doses of HDL in human patients vary depending on the composition of 
each product and their respective impurities. In general, the HDL products have been reported to 
be safe when administered once per week by prolonged intravenous infusion at up to 80 mg/kg for 
SRC-rHDL (~ 6.5 g of ApoA-I/dose or 33 g of total HDL/dose), 135 mg/kg for CSL-112 (~ 10 g 
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of ApoA-I/dose or 35 g of total HDL/dose), 45 mg/kg for CER-001 (~ 4 g of ApoA-I/dose or 15 g 
of total HDL/dose), and 30 mg/kg for ETC-642 (~ 3 g of ApoA-I peptide/dose or 9 g total 
HDL/dose). Potential safety concerns associated with HDL products include transient elevation of 
liver transaminases (ALT and AST) along with other minor liver toxicities. These concerns arise 
as a result of the hyper-pharmacology of HDL products, as a significant amount of cholesterol is 
rapidly mobilized from peripheral organs and delivered to the liver for metabolism.  The half-life 
of ApoA-I in plasma following HDL administration ranges between 6 and 24 hours, depending on 
the dose and product composition. Overall, various Phase I and II clinical trials performed to date 
in over 800 patients and healthy volunteers have demonstrated that HDL products are well 
tolerated without any major complications or severe side effects. 
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Table 1.1: Summary of clinical pharmacokinetics and safety profiles of HDL infusions. 
Drug  Composition* Clinical Study Dose of ApoA-I protein or 
peptide 
Pharmacokinetics  Safety Ref. 
SRC-rHDL 
(ZLB) 
ApoA-I/sPC 
(1:4.2)  
Phase 1                                 
Single dose in healthy subjects (n = 7) 15 and 40 mg/kg  
 
T1/2 of ApoA-I> 24hr; T1/2 of total 
PL ~ 8hr 
No data reported 21-22 
Phase 1                                 
Single dose in hypercholestero-lemic 
men (n = 24) 
80 mg/kg  No data reported No data reported 23 
Phase 1                                 
Single dose in ABCA-1 heterozygotes 
and control subjects (n = 9) 
80 mg/kg  No data reported No data reported 24 
 
CSL-111 
(CSL 
Behring) 
 
ApoA-I/sPC 
(1:4.2) 
Phase 1                                 
Single dose in type 2 diabetes patients 
(n = 7) 
80 mg/kg  ApoA-I increased from 
1.2 (baseline) to 2.8 g/L and 
returned to baseline on day 7 
No data reported 25 
Phase 1                               
Single dose in patients with vascular 
disease (n = 20) 
Placebo and 80 mg/kg The level of HDL cholesterol 
increased by 20% after infusion of 
rHDL 
No liver function changes 26 
Phase 1                                 
Single dose in type 2 diabetes patients 
(n = 17) 
 
Placebo and 20 mg/kg 
 
T1/2 of ApoA-I~ 72 hr 
No report 
No data reported 27 
Phase 2                            
Multiple doses in ACS patients  
(n = 183) 
4 weekly infusions of placebo, 
40 and 80 mg/kg  
 
No report Liver function abnormalities 
in 80 mg/kg group; 40 mg/kg 
is well tolerated 
28 
CSL-112 
(CSL 
Behring) 
ApoA-I/sPC 
(1:1.5)  
Phase 1                                 
Single dose in healthy subjects  
(n = 57) 
Placebo, 5, 15, 40, 70, 105 and 
135 mg/kg  
Tmax of ApoA-I = 2 hr; For doses 
>70 mg/kg; T1/2 of ApoA-I=14.7 ~ 
99.5 hr. 
No safety issues 20, 
29 
Phase 1               
Multiple doses in healthy subjects  
(n = 36) 
Four weekly infusion of 
placebo, 3.4 and 6.8 g/dose 
Eight bi-weekly of 3.4 g/dose 
Tmax of ApoA-I = 2hr; T1/2 of 
ApoA-I = 19.3 hr ~ 92.8 hr 
Safe and well tolerated 20, 
30-31 
Phase 2a 
Single dose in patients with stable 
atherothrombotic disease (n = 45) 
Placebo, 1.7, 3.4 and 6.8 g/dose Tmax of ApoA-I ≈ 2 hr; T1/2 of 
ApoA-I ≈ 12 hr. 
 
Good safety 32 
Phase 2b (AEGIS-I) 
Patients with acute myocardial 
infarction (n = 1258) 
Four weekly infusions 
Placebo, 2 and 6 g/dose  
 Well-tolerated, no significant 
alterations in liver or kidney 
function or other safety 
concern 
33-34 
  Phase 3 (AEGIS-II) 
Patient with  acute coronary 
syndrome (ACS) (n=17,400) 
Currently recruiting Currently recruiting  Currently recruiting 35 
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Abbreviations: sPC: soybean phosphatidylcholine; rApoA-I: recombinant ApoA-I; ACS: acute coronary syndrome; POPC: palmitoyloleoylphosphatidyl choline; SM: and sphingomyelin; DPPG: 
dipalmitoylphosphatidyl-glycerol; FH: familial hypercholesterolimea; HoFH: heterozygous familial hypercholesterolemia; FPHA: familial primary hypoalphalipoproteinemia; DPPC: 
dipalmitoylphosphatidylcholine. * Indicates weight ratio, literature reported molar ratios were converted to weight ratios 
ProApoA-I-
liposome 
(UCB) 
rProApoA-
I/sPC (1:1.25) 
 
Phase 1                                 
Single dose in patients with low HDL 
cholesterol (male, n = 4) 
IV infusion for 1hr or 10 min  
1.6 g proApoA-I 
T1/2 of ApoA-I < 24 hr No adverse events 36 
Phase 1                                 
Single dose in FH patients (n = 4)  4g by IV infusion over 20 min 
~ 40-50 mg/kg 
Plasma ApoA-I levels increased 
transiently during the first 24 hr. 
Cmax 64% and 35% above the 
baseline at 1 hr, respectively.   
No safety issues 37 
ETC-216 
(Esperion) 
rApoA-
I/POPC (1:1) 
  
Phase 1   
Single dose in healthy subjects  
(n = 32)  
 
IV infusion of doses 0-100 
mg/kg (males) and 0-50 mg/kg 
(females)  
Tmax of HDL free cholesterol level 
≈ 30 min at 15 mg/kg and higher 
Safe and well tolerated at all 
doses. 
38 
Phase 2 
Multiple doses in ACS patients  
(n = 57) 
Five doses; once per week by 
IV infusion; 
Placebo, 15 and 45 mg/kg.  
No report Minor gastrointestinal adverse 
effects in 3 groups. Two adverse 
events in high-dose group 
deemed possibly drug related. 
38-39 
CER-001 
(Cerenis) 
rApoA-
I/SM/DPPG 
(1:2.7:0.1) 
 
Phase 1 
Single dose in healthy volunteers (n = 
32)  
IV infusion of escalating doses 
of 0.25, 0.75, 2, 5, 10, 15, 30, 
45 mg/kg. 
Tmax of ApoA-IApoA ≈1-2 hr; T1/2 
≈ 10 hr; Cmax is dose-dependent 
and up to 0.9 mg/dL at 45mg/kg;  
Safe and well tolerated at all 
doses; 
 
40-41 
Phase 2 (CHI SQUARE) 
Multiple doses in patients with ACS 
(n = 507) 
6 weekly infusions of 0, 3, 6, 
and 12 mg/kg. 
No PK data 
 
Generally well tolerated 42-43 
Phase 2 
Multiple doses in patients with HoFH 
(n = 23) 
12 biweekly infusions at 8 
mg/kg.  
ApoA-I increased by 13% from 
114.8 mg/dL to 129.3 mg/dL 
during first hour after infusion. 
One serious adverse event 
reported to be drug related 
44-45 
Phase 2 
Multiple doses in patients with FPHA 
(n = 7) 
IV infusion for 1hr; 20 infusions 
at 8 mg/kg for 6 months. 
Tmax of ApoA-I ≈ 4 hr; T1/2 ≈ 12 hr No serious adverse events 
46-47 
ETC-642 
(Esperion) 
ApoA-I 
peptide/DPPC
/SM (1:1:1) 
 
Phase 1 
Single dose in patients with stable 
atherosclerosis (n = 28) 
IV infusion of placebo and 0.1, 
0.3, 1, 3 and 10 mg/kg 
Dose proportional rise in the levels 
of peptide after infusion; T1/2 = 8.3 
~ 12.8 hr.  
Safe and well tolerated 48-49 
Phase 1 
Single dose in patients with stable 
cardiovascular disease (n = 24) 
IV infusion; 
10, 20, 30 mg/kg 
Dose proportional rise in the levels 
of peptide; T1/2 of peptide = 10.2 
~13.8 hr. 
Asymptomatic elevations of 
liver function in one patient at 
30 mg/kg 
50 
Phase 1 
Multiple doses in patients with stable 
cardiovascular disease (n = 32)  
4 weekly IV infusions of 
placebo 10, 20 and 30 mg/kg 
No data reported No data reported 51 
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1.2.1 HDL Based on ApoA-I Purified from Human Plasma  
The first rHDL product tested in a clinical trial was SRC-rHDL developed by ZLB Central 
Laboratory, Switzerland. ApoA-I was isolated from human plasma and reconstituted with soybean 
phosphatidylcholine (sPC) using the cholate dialysis process described below.22 Nanjee et al. 
evaluated the effect of a single infusion of SRC-rHDL at 40 mg/kg in healthy volunteers.21 The 
dose, up to 40 mg/kg, was safe and well tolerated.23-24 Following ZLB acquisition by CSL Behring, 
Australia in 2000, SRC-rHDL was renamed as CSL-111. The product was tested in a large (183 
patients) Phase II safety and efficacy (ERASE) clinical trial in 2005.28 Patients with ACS were 
administered with four infusions of CSL-111 at 40 mg/kg or 80 mg/kg or placebo at weekly 
intervals. The high-dose CSL-111 treatment at 80 mg/kg was discontinued early due to 
abnormalities in liver functions, but CSL-111 was well tolerated at the 40 mg/kg dose. Due to the 
safety issue, CSL-111 was reformulated into CSL-112 by reducing the lipid to protein ratio, 
resulting in a homogenous particle size of 13 nm.18 Safety of CSL-112 was evaluated in healthy 
volunteers following single and multiple administrations.20 CSL-112 was found to be much safer 
than its predecessor, CSL-111, as higher doses up to 135 mg/kg were well tolerated. In addition, 
ApoA-I levels remained above the baseline for 3 days following a single infusion of CSL-111.31 
A largest-to-date clinical trial with HDL has been completed for CSL-112 in 1200 patients with 
acute myocardial infarction.33 Among patients with acute myocardial infarction, 4 weekly 
infusions of CSL112 are feasible, well tolerated, and not associated with any significant alterations 
in liver or kidney function or other safety concern. The ability of CSL112 to acutely enhance 
cholesterol efflux was confirmed. The potential benefit of CSL112 to reduce major adverse 
cardiovascular events is being assessed in an adequately powered 17,400 patient Phase 3 trial. 35 
1.2.2 HDL Based on Recombinant ApoA-I  
The first rHDL product synthesized with recombinant ApoA-I was proApoA-I-liposome 
developed by UCB (Belgium). Pro-ApoA-I, a recombinant protein produced in E. coli, has an 
additional 6 amino acid pro-sequence attached to native ApoA-I.52 Pro-ApoA-I liposomes 
administered at 1.6 and 4 g per dose were well tolerated, and ApoA-I levels remained elevated for 
over 24 hrs.  ApoA-I Milano is a naturally occurring variant of ApoA-I with Arg-173 to Cys 
substitution. ApoA-I Milano is produced by a recombinant process in E. coli.53 In 1998, Esperion 
acquired the rights to ApoA-I Milano and produced a new rHDL product, termed ETC-216, which 
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is composed of ApoA-I-Milano and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC).38 
After 5 weekly infusions at 15 mg/kg and 45 mg/kg, ETC-216 significantly reduced coronary 
plaque volume (an average of 4.2%) in treated patients measured by IVUS.39 ETC-216 was safe 
and well tolerated at all doses tested. CER-001 is another rHDL product under development by 
Cerenis. CER-001 is composed of dipalmitoylphosphatidyl-glycerol (DPPG), sphingomyelin 
(SM), and recombinant human ApoA-I, which is produced in a mammalian expression system in 
CHO cells.42 In a Phase I clinical trial in healthy volunteers, subjects were administered with 
escalating doses of CER-001 up to 45 mg/kg.41 The AUC, Cmax, and T1/2 for ApoA-I increased 
with each increased dose.41 CER-001 was also tested in a multiple-dose efficacy trial with 3, 6 and 
12 mg/kg doses given once weekly for 6 weeks.42  CER-001 was also shown to be safe and well 
tolerated at all the doses tested in these trials.  
1.2.3 HDL Based on ApoA-I Mimetic Peptide 
In addition to recombinant ApoA-I protein-based rHDL as described above, new rHDL 
systems composed of ApoA-I mimetic peptides and phospholipids have been developed. 
Utilization of ApoA-I mimetic peptides is expected to reduce the manufacturing cost and facilitate 
industrial scale-up of rHDL. ETC-642 was the first ApoA-I mimetic peptide to reach clinical 
evaluation.48, 50 A Phase I clinical study, performed in 2002, examined a single-dose infusion of 
ETC-642 in 28 patients with stable atherosclerosis.48 Study participants were monitored for 4 
weeks following a single drug administration at 0.1, 0.3, 1, 3, and 10 mg/kg. As expected, the 
pharmacokinetics parameters, such as AUC and ETC-642 elimination half-life, increased with 
higher doses.48 The second Phase I trial was conducted with stable cardiovascular patients at higher 
doses of 10, 20, and 30 mg/kg.50 At the highest dose level tested, evidence of asymptomatic 
elevations of liver functions was observed in a single patient, suggesting identification of a 
maximum tolerated dose. Overall, these two clinical trials have demonstrated the safety and 
tolerability of single infusion of ETC-642 up to 20 mg/kg dose.  A multiple dose safety study with 
ETC-642 was also conducted at 10, 15, and 20 mg/kg doses administered once weekly for four 
weeks;51 however, the results of this study have not yet been made public.  
1.2.4 Synthesis of sHDL based on ApoA-I mimetic peptide  
Apolipoprotein mimetic peptides,  which have similar Class A-type amphipathic α-helical 
structures to ApoA-I,  were initially used to investigate the structural features of the full-length 
ApoA-I protein 54. Due to their ability to recapitulate the biological functions of full-length protein 
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in vivo, they were then applied to produce mimetic HDL particles. 55-57 Several ApoA-I mimetic 
peptides have been synthesized to date and are designed based on sequences that are homologous 
to the native protein 58. These peptides are generally optimized to maximize different functional 
outputs, such as cholesterol efflux capacity and lipid binding affinity, 55, 58 and have been the focus 
of many recent clinical trials. Examples of such mimetic peptides and their applications are 
described in Table 1.2.  
Table 1.2: Mimetic peptides of ApoA-I: sequences and desired clinical applications. 
Peptide Sequence Company Optimized Functional Output Ref 
ESP24218 P-V-L-D-L-F-R-E-L-L-N-E-L-
L-E-A-L-K-Q-K-L-K 
Esperion Lipid binding 
LCAT activation 
RCT 
56 
D4F Ac-D-W-F-K-A-F-Y-D-K-V-A-
E-K-F-K-E-A-F-NH2 
Novartis Same as L4F Chemical stability  59 
L4F Ac-D-W-F-K-A-F-Y-D-K-V-A-
E-K-F-K-E-A-F-NH2 
Novartis RCT 
Lipid binding 
Inflammation reduction 
60 
Reverse 
4F 
K-L-K-Q-K-L-A-E-L-L-E-N-L-
L-E-R-F-L-D-L-V-Inp 
Ac-F-A-E-K-F-K-E-A-V-K-D-
Y-F-A-K-F-W-D-NH2 (reverse 
4F) 
Kos 
pharmaceuti
cals 
Lipid binding Cholesterol 
mobilization 
61-62 
5A D-W-L-K-A-F-Y-D-K-V-A-E-
K-L-K-E-A-F-P-D-W-A-K-A-
A-Y-D-K-A-A-E-K-A-K-E-A-A 
KineMed 
Inc. 
ABCA1 activation 
Low hemolysis 
Lipid binding 
57 
18A Ac-
EWLEAFYKKVLEKLKELF-
NH2 
N/A RCT 63 
ATI-5261 Ac-E-V-R-S-K-L-E-E-W-F-A-
A-F-R-E-F-A-E-E-F-L-A-R-L-
K-S-NH2  
Roche Anti-oxidant properties 
Promote ABCA1 dependent 
cholesterol efflux 
64 
 
There are several different methods for the preparation of HDL in vitro. The method to 
make ApoA-I reconstituted HDL is known as the sodium cholate dialysis method. This method 
involves the addition of detergents, such as cholate, followed by several days of dialysis to remove 
the detergent. The main drawbacks to use of this procedure are time consumption, incomplete 
detergent removal, endotoxin contamination of ApoA-I, and particle heterogeneity which limit the 
application of this method. Another method that utilizes sonication of peptide and lipid mixtures 
has also been employed to prepare HDL. Briefly, the lipid mixture in chloroform is dried under 
nitrogen flow to form lipid film and is then placed under vacuum oven. PBS buffer is added to the 
film, and the mixture is vortexed and sonicated under nitrogen. Apo A1 mimetic peptide in PBS 
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buffer is added to the mixture, which becomes transparent immediately. The resulting 
heterogeneous HDL needs to be filtered and purified by gel filtration chromatography to obtain 
homogeneous HDL. 65 However, this method also has similar drawbacks in that highly 
homogenous particles are difficult to make, especially in large scale. 66 Preparation of synthetic 
HDL particles by co-lyophilization, a technique developed and patented by Esperion 
Therapeutics,66 circumvents many of the issues described above. The process involves co-
dissolving peptide and lipid constituents in organic solvent, freeze-drying, and subsequent 
hydration with an isotonic, neutral buffer. The mixture is then repeatedly heated and cooled to 
form homogenous HDL particles without further purification.  
1.2.5 Lipid component play important role in sHDL RCT process.  
In most research and clinical trials, the pharmacokinetics of ApoA-I protein or mimetic 
peptides were thought to be the driving force for cholesterol efflux and mobilization, so the 
influence of lipid components was always overlooked. However, lipids play an important role in 
receptor binding and particle stability, and they can affect the biological properties of rHDL as 
evidenced by research results both in vitro and in vivo.  When ApoA-I mimetic peptide, 5A, was 
combined with either SM or POPC, 5A-SM exhibited higher ABCG1- and SR-BI-mediated 
cholesterol efflux relative to 5A-POPC. Injection of 5A-SM in rats resulted in 3-fold higher 
mobilization of plasma cholesterol than for 5A-POPC. 5A-SM exhibited more potent anti-
inflammatory properties and significant reduction of plaque area in ApoE-/- mice. 67  These findings 
extend to humans as well. Among rHDL products in clinical trials as mentioned above, CER-001 
and CSL-112 have similar compositions including ApoA-I protein and phospholipids but differ in 
lipid amount and lipid species. The lipid composition of CSL-112 is soy PC only, and CER-001 is 
sphingomyelin with only 3% DPPG 1:2.7 (wt/wt). In phase I clinical trials, these two products 
were administered at various dose level for pharmacokinetics, pharmacodynamics, and safety 
evaluation. When the pharmacokinetics of ApoA-I protein were plotted at the same dose level of 
15 mg/kg for these two rHDLs, a major difference in half-life was observed with 68 hrs for CSL-
112 versus 37 hrs for CER-001(Figure 1.1A). Additionally, the cholesterol mobilization profiles 
were significantly different as shown in Figure 1.1B and 1.1C. CER-001 achieved higher total 
HDL-cholesterol, greater HDL-cholesterol ester change, and more rapid elimination as compared 
to CSL-112 after a single infusion. We next plotted the Emax values of total or free cholesterol 
increase versus ApoA-I dose levels for the two products (Figure 1.1D and 1.1E). The plot indicates 
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that, to achieve same maximum cholesterol concentration, higher doses of CSL-112 are needed.  
The cholesterol mobilization effect plateaus at 30 mg/kg for CER-001 while Emax values keep 
increasing as dose levels escalate for CSL-112. All these dissimilarities may result from the altered 
dose levels and type of lipids in the rHDL. CER-001 appears to be more potent in activating 
cholesterol efflux but easily causes side effects due to the narrow therapeutic window. From Figure 
1.1F, CSL-112 is able to efflux more cholesterol as compared to CER-001 when subjects’ plasma 
after rHDL administration was incubated with macrophage cells. This is because SM and saturated 
fatty acid-containing lipids like DPPC have superior cholesterol binding capacity relative to 
unsaturated POPC and soyPC which is incorporated in CER-001. 67  Therefore, CSL-112 is more 
capable of accepting, or binding, cholesterol and interacting with LCAT to be esterified.     
 
Figure 1.2: Comparision of pharmacokinetic and pharmacodynamic properties of CER-001 and CSL-112 at 15mg/kg 
in clinical trials. ApoA-I concentration-time profile after IV administration of CER-001 or CSL-112 at 15mg/kg (Panel 
A); HDL-TC and HDL-CE increase after administration (Panel B and C); Relationship between maximum 
concentration of HDL-TC/HDL-FC and ApoA-I or lipid dose (Panel D and E); Ex vivo cholesterol efflux ability of 
plasma (Panel F). 
1.3 Limitations and biomimetics of sHDL 
Current sHDL products in clinics are mostly composed of lipids and ApoA-I protein either 
isolated or purified from human plasma.  The doses required to elicit clinical effect is 40 mg/kg20, 
meaning that a large amount of protein is required to meet patients’ needs, which is very expensive 
due to the complicated manufacturing process. Thus, ApoA-I mimetic peptides were introduced 
as substitutes for ApoA-I protein to form sHDL and achieve similar effects. However, the half-life 
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of sHDL composed of ApoA-I mimetic peptide is 8-12 hours, which is much shorter than 
endogenous protein with a half-life of 3.3 days. This rapid elimination necessitates more frequent 
dosing, which is inconvenient for patients using an intravenous product, or administration of high 
doses, which can lead to off-target toxicity. Thus, prolonging the circulation time of sHDL can be 
a potential strategy to improve its cholesterol efflux effects while avoiding possible side effects. 
Polyethylene glycol (PEG) has been widely used to coat or “PEGylate” nanoparticle surfaces to 
archive “stealth-like” characteristics, which can be influenced by PEG density, molecular weight, 
and structure. It can be considered a method for slowing sHDL nanoparticle elimination by the 
reticuloendothelial system. 68  
Several other investigators have developed biomimetic HDLs for not only for treatment or 
imaging of atherosclerosis but also for drug delivery purposes.69-77 For example, Marrache et al. 
reported the construction of a synthetic, biodegradable HDL-NP platform for detecting vulnerable 
plaques by targeting the collapse of the mitochondrial membrane potential that occurs during 
apoptosis.77 The particle has an average size of approximately 120 nm and contains a poly(lactide-
co-glycolide) (PLGA) polymer, cholesteryl oleate, and phospholipid with triphenylphosphonium 
(TPP) decorated with ApoA-I mimetic peptide 4F. In addition, quantum dots (QDs) were 
incorporated into the PLGA matrix for imaging purposes. In vitro evaluation of this technique 
showed a promising detection sensitivity and also therapeutic potential as well as favorable 
biodistribution and pharmacokinetics. Sanchez-Gaytan et al. developed a hybrid polymer/HDL 
nanoparticle composed of a lipid/apolipoprotein coating that encapsulated a PLGA core.75 This 
PLGA-HDL was 30-90 nm in size and displayed some characteristics of endogenous HDL, 
including preferential uptake by macrophages and an effective in vitro cholesterol efflux capacity. 
The presence of a PLGA core also enabled incorporation and sustained release of therapeutic 
agents for atheroma-targeted delivery. These PLGA-HDL nanoparticles accumulated in 
atherosclerotic plaques and co-localized with atheroma macrophages in an ApoE-/- mouse model.  
Thaxton et al. synthesized a spherical HDL nanoparticle with a gold NP core-shell structure in 
which the gold NP core served as a size- and shape-controlling scaffold for constructing an HDL-
like particle through surface attachment of phospholipids and ApoA-I. The nanoparticles were 
designed to have a similar size to endogenous HDL and to mimic the general surface composition 
of HDL to enable physical binding of cholesterol and cellular cholesterol efflux in vitro.69, 78 
Biomimetic HDL nanoparticles discussed here have demonstrated the ability to accumulate in the 
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atheroma and, in some instances, had local anti-inflammatory effects.79-80 However, to the best of 
our knowledge, the ability of these biomimetic HDL to reduce atheroma in diseased animals has 
not been confirmed, and none of these nanoparticles have been compared head-to-head with the 
sHDLs that have been tested in clinical trials. In addition, most biomimetic HDL nanoparticles 
have a larger particle size and density compared to endogenous HDL, which likely results in 
differences in biodistribution, HDL receptor interaction, and hepatic uptake of mobilized 
cholesterol. Thus, there is an urgent need to design a sHDL mimetic product that is easy to prepare 
affordably.  
1.4 HDL as drug delivery system for brain tumor therapy 
In addition to the role HDL plays in cardiovascular and liver disease, the utility of HDLs 
extends to tumor therapy as well due to the interaction between HDLs and cancer cells. 
Glioblastoma multiformes (GBM) are the most aggressive primary tumors within the central 
nervous system. Even after surgery, chemotherapy, and radiotherapy, the prognosis of patients 
with GBM remains dismal. GBMs always recur, and often result in the death of the patient. 
Therefore, the development of effective treatment strategies to control the progression and survival 
of these gliomas is in high demand. Because of the shortcomings of chemotherapy like low 
solubility, non-specificity and toxicity of drugs, nanoparticles have been used to deliver 
chemotherapeutic or immunotherapeutic molecules.  
An ideal brain tumor-targeted delivery system should at least meet the following 
requirements: efficient penetration through the BBB, efficient penetration/diffusion within tumor 
regions, and efficient intracellular delivery. HDL is a promising brain tumor-targeted delivery 
system because many of its features allow it to meet the above requirements. 
First, lipoproteins, such as HDL, are reported to circulate in the blood for an extended 
period of time,81 which can increase the possibility of HDLs penetrating the BBB and enables them 
to accumulate in the tumor regions by the enhanced permeability and retention (EPR) effect. HDL 
therapies show a long circulation time, and the half-life of ApoA-I can be up to 92.8 hours. 20, 27, 
30-31 These half-lives are comparable to some of the best-modified (PEGylated) long-circulating 
liposomes. Differing from certain other nanoparticles whose components may cause severe side 
effects, reconstituted HDLs are safe and well tolerated in the human body as a delivery system due 
to their endogenous nature, therefore they will not trigger immune reactions or be recognized by 
the reticuloendothelial system (RES). 32, 82 Second, the BBB tight junction and extracellular matrix 
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of tumors can prevent the diffusion of nanoparticles within the tumor regions due to the small 
opening space which is less than 40 nm.83 Conventional nanoparticles, such as liposomes, are 
normally larger than 60 nm, which may limit the diffusion of the nanoparticles within the tumor 
tissue. HDL has ultra-small sizes, with diameters of about 10 – 20 nm, depending on the 
composition, and therefore can penetrate deeply and diffuse efficiently with in the tumor regions.  
Third, it has been reported that natural human HDL was effective in inhibiting human glioblastoma 
cell (SNB-19 cell line) growth in a nontoxic, dose-dependent manner.84 The LD50 was 10-fold 
lower than that for normal rat astrocyte growth in vitro. One possible mechanism for this study’s 
findings was the interaction between oxidized lipids from HDL with the plasma membranes of the 
GBM cells.  
Many malignant cells have been shown to overexpress SR-BI in order to scavenge 
cholesterol-rich HDLs so that a high level of growth can be maintained. This provides a good 
marker for HDL to target due to its recognition by SR-BI.85 Among 50 human ovarian epithelial 
cancers, SR-BI is overexpressed on 96% of the tumors.86 Further, prostate cancer cells have been 
shown to take up cholesterol-rich HDLs through SR-BI for the biosynthesis of endogenous 
androgen.87 It was demonstrated that the uptake of HDL cholesterol esters is not dependent on the 
internalization and degradation of the particle, and SR-BI localized in cholesterol- and 
sphingomyelin-rich caveolae is the HDL receptor which mediates the selective uptake of 
cholesterol esters.2 Both discoidal and spherical HDLs are able to deliver drugs and interact with 
SR-BI, however, discoidal HDL has higher binding affinity than spherical HDLs.88 This evidence 
supports the idea that cancer cells have increased uptake of cargo loaded in HDLs via SR-BI. Thus, 
the caveolae domain and SR-BI expressed on both GBM and BBB endothelial cell membranes 
will be receptors for drug-loaded sHDL and achieve the selective and targeting interaction with 
HDL particles and uptake of the loaded cargo. In addition, by decorating HDL with different 
targeting ligands, such as EGF 89, RGD 90, and folate 91 92, HDL can be targeted to tumor cells that 
do not express SR-BI, which will further improve the targeting efficiency and decrease the side 
effects. Considering these advantages, sHDL can be considered as a novel therapeutic delivery 
platform for GBM to effectively deliver chemotherapeutic agents combined with immune-
stimulatory molecule.  
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1.5 Research scope and impact 
sHDL has been investigated for years as an urgent treatment to for heart attack patients to 
reduce the risk of second event.  A number of sHDL products have advanced to different stages of 
clinical trials.18 These sHDL products are intended for administration following an initial 
cardiovascular event in patients with acute coronary syndrome (ACS) to remove excess cholesterol 
from arterial plaques that may cause a secondary event. However, the ApoA-I protein component 
in most sHDL products is purified or isolated from human plasma, which is a very costly and 
complicated process. Though ApoA-I mimetic peptide with a similar structure to ApoA-I protein 
was introduced as surrogate component, the half-life of sHDL with ApoA-I mimetic peptide was 
relatively short and required frequent dosing, which may limit its future development. Thus, 
understanding the impact of ApoA-I mimetic peptide lipidation on its biological function can 
further optimize current sHDL formulations to address these concerns. By modifying the lipid 
composition of sHDL, the circulation time of sHDL can be prolonged for durable removal of 
excess cholesterol. In addition, establishing a lipid-based nanoparticle mimicking both structure 
and function of sHDL without peptide will create a novel substitute for sHDL in ACS therapy and 
other indications.  Based on evaluation of the nanoparticles, researchers are able to potentiate its 
effect with additional modifications. Because sHDL has amphipathic properties, it has been 
employed as drug delivery system for insoluble drugs.   Our formulation of the DTX-sHDL-CpG 
system provides a new, generalizable framework for using sHDL-based chemoimmunotherapy for 
glioma treatment. 
1.6 Thesis overview 
The overall goal of this thesis was to investigate the impact of lipid composition of sHDL 
on its cholesterol efflux effect and to determine whether sHDL can be modified to extend its 
circulation time and amplify cholesterol removal with sufficient safety. This can provide a possible 
approach to improve current or future sHDL products regarding their stability and efficacy. This 
idea is simple but attractive due to lower costs and easier preparation processes compared to 
conventional sHDL-like nanoparticles. Ultimately, the DTX-sHDL-CpG platform can broaden the 
application of sHDL in chemo-immunotherapy for other cancers.  
In Chapter 2 of this thesis, we studied the impact of formulation and administration route 
of ApoA-I mimetic peptide, 22A, on its biological activity in vivo including plasma peptide levels, 
cholesterol mobilization, and lipoprotein remodeling. The mean circulation half-life was longer 
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for 22A-sHDL (T1/2 = 6.27 h) than for free 22A (T1/2 = 3.81 h). The amount of 22A absorbed by 
the vascular compartment after IP dosing was ~50% for both 22A and 22A-sHDL. The strongest 
pharmacologic response was observed after IV injection of 22A-sHDL—specifically, a 5.3-fold 
transient increase in plasma free cholesterol (FC) level compared to 1.3-fold and 1.8-fold FC 
increases for 22A-IV and 22A-sHDL-IP groups. Addition of either 22A or 22A-sHDL to rat 
plasma caused lipoprotein remodeling and appearance of a lipid poor apoA-I. Using a PK-PD 
model, we found that lipid components in sHDL were  more predictive of cholesterol level changes 
in serum than were any other components. Hence, both the route of administration and the 
formulation of ApoA-I peptide significantly affected its pharmacokinetics and pharmacodynamics. 
These findings also provided the information that was applied in Chapter 3. 
In Chapter 3, sHDL surface modification with polyethylene glycol (PEG) was investigated 
for its potential to extend sHDL circulation in vivo. Various amounts (2.5, 5 and 10%) and different 
chain lengths (2 and 5 kDa) of PEG-modified lipids were incorporated in sHDL’s lipid membrane. 
In vitro characterization, cell uptake, and cholesterol efflux effects of sHDL and sHDL-PEG were 
evaluated. In vivo experiments were conducted to study impact of PEG on sHDL pharmacokinetics 
and pharmacodynamics. This work showed a comparable cholesterol efflux ability between sHDL 
and sHDL-PEG in vitro. Adding more PEG or using PEG of longer chain lengths extended the 
circulation half-life of sHDL. Addition of PEG also increased the area under the curve for the 
phospholipid component of sHDL (p < 0.05), reflecting a greater mobilization of plasma free 
cholesterol.  
Chapter 4 introduces nano-micelle (NanoMCL), a structural nano-mimetic of sHDL with 
a small particle size (12-14 nm) and a hydrophobic core and hydrophilic exterior. It shows that 
NanoMCLs are functionally similar to sHDL with the capacity to efflux cholesterol from 
macrophages and deliver cholesterol to hepatocytes for elimination. The NanoMCLs also have a 
better ability to inhibit inflammatory cytokine release in vitro compared to sHDL. More 
importantly, when administered in vivo, NanoMCLs exhibited improved cholesterol mobilization 
from peripheral tissues compared to sHDL, followed by elimination from the body within 48 
hours. When administered as a 6-week treatment in an animal model of atherosclerosis, sHDL and 
NanoMCL reduced atheroma by 21% and 40%, respectively. Based on these encouraging results, 
NanoMCL could prove to be a valuable alternative to sHDL in treatment of cardiovascular disease 
and other inflammatory diseases. 
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Chapter 5 discusses the application of sHDL as a delivery vehicle for anti-cancer drugs 
with the co-delivery of immuno-stimulatory molecule CpG for glioma treatment. After examining 
SR-BI receptor expression on different cancer cells, GL26 was selected to build tumor model. 
Chemotherapeutic agent docetaxel (DTX) was selected as model drug. DTX and immune-
stimulatory TLR-9 agonist cholesterol-CpG (cholCpG) were co-incorporated into sHDL 
nanoparticles. sHDL composition was optimized to maximize DTX retention in plasma. The 
resulting DTX-sHDL-CpG nanoparticles exhibited characteristically ultra-small ~10-12 nm size 
and discoidal shape.  Nanoparticles were uptaken successfully by tumor cells, and sHDL was able 
to penetrate through the BBB in vitro. However, systemic administration of free DTX, DTX-
sHDL, or DTX-sHDL-CpG did not make a difference in the mean survival of animals. Though, 
all three groups demonstrated longer survival than the saline-treated group. Compared to 
intravenous administration, intracranial injection of DTX-sHDL-CpG led to notable tumor growth 
inhibition, which extended the mean survival of mice from 34 days to 55 days with 20% long-term 
survivors. Thus, DTX-sHDL-CpG can be applied as a promising platform for cancer treatment.  
The conclusions of this work and implications for future studies are discussed in Chapter 
6. Chapter 2 is originally published in Journal of Lipid Research. Chapter 3 is published in 
Molecular Pharmaceutics. Chapter 4 is under review for publication in ACS Nano. Chapter 5 will 
be submitted for publication once manuscript is completed. 
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Chapter 2 : Impact of administration route and lipidation on pharmacokinetic and 
pharmacodynamics properties of sHDL 
 
This research was originally published in the Journal of Lipid Research. Tang J, Li D, 
Drake L, Yuan W, Deschaine S, Morin EE, Ackermann R, Olsen K, Smith DE, Schwendeman A. 
Influence of route of administration and lipidation of apolipoprotein A-I peptide on 
pharmacokinetics and cholesterol mobilization. J. Lipid Res. 2017 Jan;58(1):124-136.  
2.1 Abstract 
Apoliprotein A-I (apoA-I), apoA-I mimetic peptides and their lipid complexes or 
reconstituted high-density lipoprotein (HDL) have been studied as treatments for various 
pathologies. However, consensus is lacking about the best method for administration - by 
intravenous (IV) or intra-peritoneal (IP) routes, and formulation - as an HDL particle or in a lipid-
free form. The objective of this study was to systematically examine peptide plasma levels, 
cholesterol mobilization and lipoprotein remodeling in vivo following administration of lipid-free 
apoA-I peptide (22A) or phospholipid reconstituted 22A-sHDL by IV and IP routes. The mean 
circulation half-life was longer for 22A-sHDL (T1/2 = 6.27 h) than for free 22A (T1/2 = 3.81 h). The 
percent of 22A absorbed by the vascular compartment after the IP dosing was ~50% for both 22A 
and 22A-sHDL. The strongest pharmacologic response came from IV injection of 22A-sHDL - 
specifically a 5.3-fold transient increase in plasma free cholesterol (FC) level compared to 1.3 and 
1.8-fold FC increases for 22A-IV and 22A-sHDL-IP groups. Addition of either 22A or 22A-sHDL 
to rat plasma caused lipoprotein remodeling and appearance of a lipid poor apoA-I. Hence, both 
the route of administration and the formulation of apoA-I peptide significantly affect its 
pharmacokinetics and pharmacodynamics. 
2.2 Introduction 
The therapeutic use of apolipoprotein A-I (apoA-I), its mutants, and peptide mimetics for 
the treatment of atherosclerosis has been studied in a variety of animal models and clinical trials. 
93-94  However, there is a lack of consensus regarding whether the apoA-I protein or peptide should 
be administered in a lipid-free form or bound to phospholipids as a reconstituted HDL particle. 
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Early clinical trials showed that infusion of lipid-free apoA-I failed to increase circulation level of 
HDL cholesterol (HDL-C) and resulted in shorter circulation time than that for endogenous apoA-
I. 95 Consequently, the majority of clinically developed apoA-I products have been administered 
as reconstituted HDL particles: apoA-I/soybean phosphatidylcholine (CSL-111 and CSL-112), 
apoA-I-Milano/palmitoyl-oleoyl-phosphotidylcholine (ETC-216), and apoA-
I/sphingomyelin/dipalmitoyl-phosphorylglycerol (CER-001). 94, 96-97  In contrast, many preclinical 
studies have been performed using infusions of lipid-free proteins, and apoA-I peptides have been 
optimized for their pharmacological activity in lipid-free form. 98  
There is also an uncertainty concerning the mechanism(s) by which reconstituted HDL 
infusions elicit pharmacological effects and whether such mechanism(s) differ(s) from that used 
by lipid-free apoA-I. The ability of lipid-free apoA-I to efflux lipids through interaction with the 
ATP-binding cassette transporter (ABCA1) and its capacity to form de novo functional pre-β HDL 
particles are considered to be critical for cholesterol efflux in vivo. 99-100 However, infused apoA-
I peptides or proteins do not remain in the lipid-free form. Rather, they bind and remodel 
endogenous HDL, improving its functionality and thereby eliciting a pharmacological effect. 101-
102 In contrast, when apoA-I is dosed in the form of an HDL particle, the magnitude of its 
pharmacological effect, measured by the degree of cholesterol mobilization from tissues to plasma, 
depends on the HDL’s phospholipid composition. 103-104  
In a similar fashion, there is a lack of consensus surrounding the optimal route of 
administration for apoA-I and its mimetic peptides. For long term dosing in rodents, intraperitoneal 
(IP) administration is preferred for a technical reason, namely the difficulty of repeated dosing in 
the tail vein. 105 However, in many acute studies, apoA-I and HDL are administered intravenously 
(IV) specifically because these compounds act in the vascular compartment through either 
remodeling endogenous lipoproteins or direct efflux of the excess of cholesterol from foam cells 
in atheroma. 106-107  The effective dose of apoA-I or reconstituted HDL that reaches circulation is 
likely lower following IP administration in comparison to IV administration due to loss occurring 
during absorption from tissue to the vascular compartment. Yet, the fraction of apoA-I or HDL 
that is actually capable of reaching the vasculature following IP dose has not been experimentally 
determined yet.  
With growing interest around the potential therapeutic roles of administered  reconstituted 
HDL and apoA-I in the treatment of sepsis, diabetes, rheumatoid arthritis, lupus, and other diseases 
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103, 108-109, it is important to develop a basic understanding of HDL/apoA-I pharmacokinetics in 
order to select the proper dose, dosing intervals, and route of administration. In addition, the ability 
to measure basic HDL-related biomarkers of pharmacological effect in order to understand how 
these biomarkers relate to the dose, dosing interval, and administration route is important. Having 
this information at hand will allow investigators to select pharmacologically relevant doses and 
avoid obtaining false negative results. Pharmacokinetic-pharmacodynamic (PK/PD) modeling is a 
scientific tool to relate PK models (describing the relationship between dose, systemic drug 
exposure and time) to PD models (describing the mathematical relationship between exposure 
level and the pharmacological effect). 110 By establishing PK/PD modeling, the relationship 
between the PK and PD profile can be quantified, providing an assessment of effect onset/duration 
relative to the plasma PK profile. 111 
In this study, we selected a “two by two” experimental design to compare the 
administration of apoA-I peptide and apoA-I peptide reconstituted HDL following IV and IP 
administrations in normal adult male rats. We selected the synthetic peptide 22A, or ESP24218, 
as a model apoA-I mimetic peptide. This peptide was the first apoA-I mimetic peptide to reach 
clinical development, which has been administered clinically in both single and multiple-dose 
trials, and its human pharmacokinetic data is available. 112-113 We determined peptide and 
phospholipid pharmacokinetics and measured cholesterol mobilization in plasma, distribution of 
mobilized cholesterol among HDL, low-density lipoprotein (LDL), and very-low-density 
lipoprotein (VLDL) particles, plasma efflux capacity, and lipoprotein remodeling following free 
22A and 22A reconstituted HDL dosing.  
2.3 Materials and methods 
2.3.1 Materials 
 ApoA-I mimetic peptides 22A, PVLDLFRELLNELLEALKQKLK, and 5A, 
DWLKAFYDKVAEKLKEAFPDWAKAAYDKAAEKAKEAA, were synthesized by Genscript 
Inc. (Piscataway, NJ). The purities of peptides were determined to be over 95% by reserve phase 
HPLC. Phospholipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) were generously donated by Nippon Oils and 
Fats (Osaka, Japan). All other materials were obtained from commercial sources. 
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2.3.2  Preparation and characterization of 22A-sHDL particles  
Synthetic HDL particles were prepared by the thin film-hydration method. Briefly, DPPC 
and POPC were dissolved in chloroform at 20 mg/mL. 22A peptide was dissolved in methanol: 
water (1:1 volume ratio) at 10 mg/mL. DPPC, POPC, and 22A were mixed in a 4 mL glass vial at 
different weight ratios and vortexed for 5s. The mixture was dried by nitrogen gas flow and then 
placed in the vacuum oven overnight to remove residual solvent. The resulting lipid film was 
hydrated with PBS (pH 7.4) (final concentration of 22A = 15 mg/mL) and vortexed. The 
suspension was homogenized in a bath sonicator for 5 min and then with a probe sonicator 
intermittently (50 W×10 S×12 cycles) to form a clear or translucent 22A-sHDL solution. 
2.3.3 Analysis of 22A-sHDL particles  
The purity of 22A-sHDL was analyzed by gel permeation chromatography (GPC) with UV 
detection at 220 nm using Tosoh TSK gel G3000SWx 7.8mm x 30cm column (Tosoh Bioscience, 
King of Prussia, PA) on a Waters Breeze Dual Pump system. The HDL samples were diluted to 1 
mg/mL peptide concentration and an injection volume of 10 L was used. The samples were 
eluted with PBS (pH 7.4) at a flow rate of 1 mL/min. The sHDL hydrodynamic diameters were 
determined by dynamic light scattering (DLS), using a Zetasizer Nano ZSP, Malvern Instruments 
(Westborough, MA). Samples were diluted to 1.5 mg/mL peptide concentration. The volume 
intensity average values were reported.  
2.3.4 Rat pharmacokinetics and cholesterol mobilization 
Male Sprague-Dawley rats (300 ~ 350 mg) were purchased from Charles River 
Laboratories (Wilmington, MA) and acclimated for one week. The animals were maintained on a 
chow diet. Prior to dosing, the animals were fasted overnight and received either 22A peptide or 
22A-sHDL particles at 75 mg/kg by either intraperitoneal (IP) or intravenous injection (IV). Four 
groups of rats (n = 4/group) were dosed as follows: IV dose of 22A solution group; IP dose of 22A 
solution group; IV dose of 22A-sHDL group and IP dose of 22A-sHDL group. Blood (300 - 500 
μL) was drawn from the jugular vein into BD microtainer (TM) tubes (BD, Franklin Lakes, NJ) 
for capillary blood collection at pre-dose and 0.25, 0.5, 1, 2, 4, 8 and 24 after dosing. The animals 
were fed following the 8 h time-point and fasted again prior to the 24 h bleed. Serum was isolated 
immediately from the whole blood by centrifugation at 14,000 rpm for 10 min at 4 °C. Serum was 
aliquoted into multiple tubes and stored at -80°C prior to analysis. 
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2.3.5 LC-MS analysis of peptide plasma levels 
Immediately after serum separation, 10 μL of 5A peptide (3 mg/mL) was added to 10 μL 
of serum as an internal standard (IS), peptides were extracted with 100 μL of methanol containing 
0.1% acetic acid. After vortexing for 30 s, the mixture was centrifuged at 14,000 rpm for 10 min 
at 4°C. The top layer was drawn off and used for quantifying peptide levels in the serum, using 
Agilent 6520 Accurate-Mass Q-TOF LC/MS equipped with a dual electrospray ionization source 
(Dual-ESI) (Agilent Technologies, CA). The HPLC separation was performed using the Agilent 
300SB-C18 column (2.1 mm × 50 mm, 3.5 μm). The mobile phase consisted of (A) water 
containing 0.1% (v:v) formic acid and (B) methanol (pH 2.2) containing 0.1% (v:v) formic acid 
using a gradient elution of 10% to 60% B at 0-3.5 min, and 60% to 95% B at 3.5-8 min. The flow 
rate was 0.4 mL/min with an injection volume of 10 μL. Mass spectra were acquired in negative 
ion mode with the mass range set at m/z 100-3200. The conditions used for the ESI source included 
a capillary voltage of 3500 V, a drying gas temperature of 332 °C, a drying gas flow of 5 L/min, 
and a nebulizer pressure of 45 psi as well as a fragmentor voltage of 225 V. MassHunter 
Workstation software (Agilent Technologies, CA) was used for data acquisition and processing. 
The extracted ion chromatogram (EIC) of 22A was exported from the total ion chromatogram 
(TIC) by monitoring the key fragment of 22A at m/z 656.6. Analogously, the EIC of 22A (-)Lys 
metabolite and IS 5A was extracted at m/z 832.5 and m/z 844.4, respectively. The total integral 
area of 22A peak and 22A (-)Lys metabolite peak was used to calculate concentration.  
2.3.6 Measurement of plasma lipids  
The levels of serum phospholipids (PL), total cholesterol (TC), and unesterified or free 
cholesterol (FC) were determined by enzymatic analysis using commercially available kits (Wako 
Chemicals, Richmond, VA). The cholesterol ester level (CE) was calculated as the difference 
between TC and FC levels at each time point. Briefly, serum samples were diluted with PBS (pH 
7.4) 10-fold for TC detection and 3 fold for FC detection and with Milli Q water 10 times for PL 
detection. Defined amounts of standards or diluted samples were transferred into 96-well plate (50 
L, 60 L and 20 L for TC, FC and PL, respectively). Color reagents were added according to 
manufacturer instructions. The plates were gently shaken using an orbital shaker and incubated at 
37 ˚ C for 5 min The UV absorbance at 600 nm was measured by a Synergy NEO HTS Multi-Mode 
Microplate Reader (Bio-Tek).  
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2.3.7 Pharmacokinetic parameters calculation and PK-PD modeling 
Pharmacokinetic (PK) and pharmacodynamic (PD) analyses of the data were performed by 
least-squares regression analysis, weighted by the inverse of the fitted value, using Phoenix© 
WinNonlin® (Pharsight Corporation, Mountain View, CA, USA). Serum 22A and phospholipids 
(PL) PK parameters were estimated using a one-compartment disposition model for IV bolus 
administration, and a one-compartment disposition model with first order absorption and no lag 
time for IP administration. The PK parameters included time to reach maximum serum 
concentration (Tmax), maximum serum concentration (Cmax), area under the serum concentration-
time curve (AUC), first-order absorption rate constant after IP injection (k01), first-order 
elimination rate constant (k10), elimination half-life (T1/2), apparent total clearance (CL or CL/F, 
where F is bioavailabiliy) and apparent volume of distribution (Vd or Vd/F). The goodness of fit 
was determined by diagnosis plots and quantified by sum of squared residuals and model was 
selected using Akaike Information Criterion (AIC). The coefficient of variation (%CV) for each 
fitted parameter was also reported. The resulting pharmacokinetic parameters of 22A or 
phospholipids were then used as constants in the integrated PK-PD model.   
The PK-PD model was established by relating serum concentrations of either 22A or the 
phospholipid components of 22A-sHDL to FC levels as the PD endpoint using indirect 
pharmacodynamic response models (19). Fig. 2.6 shows the indirect response model described by 
Jusko et al. for PK-PD modeling in this study. 114 The pharmacologic response (free cholesterol 
mobilization) is controlled by a zero order rate constant for generation of response (kin) and a first 
order rate constant for loss of response (kout). The response compartment can be modulated by 
stimulating kin using a sigmoidal infinite model. Steepness of the sigmoidal curve (γ) and the 
serum concentration needed to achieve a 50% maximum stimulation of response of a dosed agent 
(EC50) were calculated. After the PK parameters were obtained by fitting to compartmental 
models, they were regarded as fixed values and then used to estimate PD parameters (i.e. kin, kout, 
EC50 and γ). The final models were chosen based on best fit in terms of sum of squared residuals, 
diagnosis plots and AIC values.   
2.3.8 Distribution of mobilized cholesterol in lipoproteins  
The rat sera samples were analyzed to assess cholesterol distribution between VLDL, LDL, 
and HDL lipoprotein fractions. Separation of lipoproteins was performed on Waters HPLC system 
equipped with Superose 6, 10/300 GL column (GE Healthcare, Piscataway, NJ) and on-line 
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detection of cholesterol by post-column enzymatic reactions 115. Rat sera prior to dosing, 0.25, 2 
and 24 h post-injection were analyzed. Sera aliquots (50 l) were injected and eluted with a 154 
mM sodium chloride/0.02% sodium azide solution at 0.8 ml/min. The post column reaction was 
done using a 5 mL reaction coil at 37°C and detected by UV at 490 nm.  The cholesterol detection 
enzymatic reagents were delivered at 0.2 ml/min flow rate and mix-in with separated lipoprotein 
post column. The enzymatic reagent solution was composed of 100 mM phosphate buffer (pH 
7.0), 4 M sodium chloride, 0.2% triton X-100, 10 mM sodium cholate, 2.5 mM 4-aminoantipyrine, 
7.54 mM 2-hydroxy-3,5 dichlorobenzene, 0.0625 U/ml cholesterol oxidase, 1.25 U/ml peroxidase, 
1.25 U/ml lipase and 0.1U/ml cholesterol ester hydrolase. All enzymatic reagents were purchased 
from Sigma. 
2.3.9 Remodeling of endogenous plasma lipoprotein  
Remodeling of endogenous lipoproteins in serum was assessed after incubation of 22A 
peptide or 22A-sHDL with human sera. Solutions of 22A peptide or 22A-sHDL at 0.1, 0.5, 1.5 
and 3 mg/mL peptide concentration in sera were incubated at 37°C for 1 h with shaking at 300 
rpm. The various sub-classes of HDL were separated by size and charge by one-dimensional native 
polyacrylamide gel electrophoresis (PAGE) and visualized by western blot. Samples were 
subjected to electrophoresis using 10-well Tris-Borate-EDTA gradient (3-25%) acrylamide native 
gels (Jule, Inc., Milford, CT) 116. For each well, 5 µl of human sera after incubation with PBS, 22A 
peptide or 22A-sHDL was mixed with 5 µl of 2X TBE sample buffer and 6 µl of the resulting 
mixtures were loaded per well. Gels were run at 200 V until the sample dye was 2.5 cm away from 
the bottom of the gel.  Proteins were visualized by western blot by transfer onto PVDF membrane 
and incubation overnight with anti-human apoA-I -HRP conjugated antibody (Meridian Life 
Science, Memphis, TN). Bands were visualized using SuperSignalTM West Pico 
Chemiluminescence Substrate (Thermo Fisher) and images were acquired on a FluorChem M 
Imager (Protein Simple, San Jose, CA) and Image J was used for spot densitometry. 
2.3.10 Statistical analyses 
Statistical analyses of the data were performed by Student’s t-test for comparing two 
treatment groups or by one-way ANOVA/Dunnett’s test for comparing multiple treatment groups 
with 22A-sHDL/IV serving as the control. Data are expressed as mean ± standard deviation of at 
least three independent experiments. P < 0.05 was considered to be statistically significant. 
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2.4 Results 
2.4.1 Composition optimization, assembly and characterization of 22A-sHDL particles  
HDL composition was optimized using an apoA-I mimetic peptide, 22A, and 
phospholipids to match the size of endogenous pre-  HDL particles. The 22A peptide was 
previously clinically tested in dyslipidemia patients as ETC-642. 117 The composition of ETC-642 
is approximately 1:1:1 weight ratios of 22A peptide, DPPC and sphingomyelin, combined to form 
homogeneous pre-  HDL-like discs 117. In this study we replaced sphingomyelin with POPC in 
order to increase sHDL interaction with lecithin-cholesteryl acyltransferase (LCAT). Unsaturated 
phospholipids like POPC are preferred substrates for LCAT, while sphingomyelin is not a 
substrate of the enzyme. 118 In order to optimize 22A-sHDL particle size and purity, we varied the 
weight ratio of 22A to total phospholipids varied between 1:0.5 to 1:4 (Table 2.1). Gel permeation 
chromatography was used to examine the purity and the size distributions of newly generated 22A-
sHDL particles. As shown in Fig. 2.1A, the retention times of different 22A-sHDL particles were 
between 7 and 10 min, the peak of unbound or lipid-free peptide appeared at around 11.5 min. The 
amount of lipid-free peptide was less than 0.48% for all formulations.  The retention time of sHDL 
decreased with the increase of lipid to peptide ratio, indicating formation of larger sHDL particles. 
.  
Figure 2.1: Characterization of 22A reconstituted sHDL particles. Gel permeation chromatography (A), dynamic 
light scattering (B). 
 
Dynamic light scattering (DLS) analysis confirmed the increase of particle size from 5.5 
nm to 12.5 nm with the increase of lipid:peptide ratio (Fig. 2.1B), which was consistent with the 
GPC results. The particle polydispersity index (PDI) for 0.5:1, 1:1 and 4:1 formulations were high, 
indicating heterogeneity of particle size (Table 2.1). Large PDI and small size for 0.5:1 and 1:1 
formulation indicates insufficient amount of lipids for complete peptide binding and perhaps 
presence of peptide aggregates in the solution. 119 Increasing the ratio to 4:1 resulted in larger PDI 
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as well, indicating the presence of large lipid vehicles due to phospholipid excess. The optimal 
lipid to peptide weight ratio for 22A peptide appears to be between 2:1 and 3:1. The 1:1:1 weight 
ratio of 22A: DPPC: POPC was selected for future examination. These 22A-sHDL particles had 
almost no impurities and a homogeneous size of 9.0 ± 0.1 nm.  Many other studies verified that 
the size of natural human HDL ranges from 8.5 - 12.0 nm. 120 To further confirm similarity of size 
for selected 22A-sHDL with endogenous HDL, purified human HDL was analyzed by GPC 
(supplemental Fig. 2.8). The retention time for endogenous human HDL was 7.35 min, 
demonstrating a size similarity to the selected 22A-sHDL.  
Table 2.1: The characterization summary of different 22A-sHDL particles. 
sHDL formulations 
(wt/wt/wt ratio) 
Retention 
time (min) 
Particle 
size (nm) 
Polydispersity 
index 
DPPC:POPC:22A (2:2:1) 7.02 12.5 ± 0.1 0.29 ± 0.07 
DPPC:POPC:22A (1.5:1.5:1) 7.32 10.5 ± 0.1 0.17 ± 0.06 
DPPC:POPC:22A (1:1:1) 7.80 9.0 ± 0.1 0.16 ± 0.03 
DPPC:POPC:22A (0.5: 0.5:1) 8.83 7.4 ± 0.1 0.23 ± 0.04 
DPPC:POPC:22A (0.25:0.25:1) 9.16 5.5 ± 0.1 0.56 ± 0.09 
 
2.4.2 Validation of LC-MS method for peptide quantification in serum 
A new LC-MS method capable of accurate and sensitive detection of 22A and its main 
metabolite was developed. For this, we used a different apoA-I-mimetic peptide, 5A, as an internal 
standard. We have compared solid-state extraction of peptide from serum using Oasis® HLB 
extraction cartridges (Waters, Miford, MA) and organic solvent precipitation methods for sample 
preparation prior to LC-MS analysis. Product recovery using the solid-state extraction method was 
less than 30% (data was not shown). Using methanol to precipitate proteins, the peptide recovery 
was greater than 90%. 121 The LC-MS analysis indicated a rapid decrease in 22A peak area in 
serum and the appearance of a terminal lysine-truncated metabolite (22A(-)Lys). The 22A(-)Lys 
metabolite was stable in plasma for up to 48 h. For the pharmacokinetic evaluation, a sum of serum 
concentrations of 22A and 22A (-)Lys was plotted as a function of time.  
A limited validation was performed for serum extraction of peptide and LC-MS analysis. 
Linearity of the LC-MS analysis was observed for the peptide concentration range of 5 and 200 
μg/mL, with r2 = 0.995 (supplemental Fig. 2.9). The limit of quantification was determined to be 
5 μg/mL. The extraction recovery of 22A ranged between 92 - 112 %. The accuracy of 
28 
 
concentration determination for serum samples spiked with 22A at 6, 50, 160 μg/mL ranged from 
7.8 to 12.0% of the target concentrations with precision (n = 6) ranging between 2.3% and 1.5%. 
The inter-assay precision (n = 3) was between 3.8 - 4.3% (shown in supplemental Table 2.6). 
Based on the analysis of percentage of 22A Lys (-) peptide in serum for the first four time points, 
metabolism appears to occur in a similar rapid manner for all four groups (as shown in 
supplemental Fig. 2.10).  
2.4.3 Pharmacokinetic evaluation of apoA-I peptide 
This experiment evaluated the dependence of apoA-I peptide’s pharmacokinetics on its 
formulation and administration route. We found that following IV administration of either 22A 
solution of 22A-sHDL, peptide elimination followed first-order kinetics (Fig. 2.2A and B). As 
shown in Table 2.2, after IV dosing the clearance (CL) of 22A was more rapid when administered 
as free peptide than as 22A-sHDL particles (CL = 0.025 vs. 0.014 dL/h). Given the same volume 
of distribution between IV formulations (Vd = 0.13-14 dL), a similar increase was observed for 
the 22A elimination rate constant (K10 = 0.18 vs. 0.112 h
-1) with a concomitant decrease in the 
elimination half-life of 22A (T1/2 = 3.81 vs. 6.27 h).  As a result of the slower clearance, area under 
the 22A serum concentration-time curve (AUC) was 1.79-fold higher for 22A-sHDL than for the 
22A peptide. This PK difference is significant and it is possibly due to peptide proteolysis in vivo 
or potentially different organs responsible for elimination of lipid-free peptide – kidney and sHDL 
particles – liver 122-123.  Following IP administration of 22A and 22A-sHDL, a first order absorption 
was observed from the injection site into the systemic circulation. The plasma peptide levels 
following IP administration were lower compared with IV administration and peaked at 4 h. The 
AUC of 22A, after IP dosing of 22A and 22A-sHDL, were only 52.0% and 54.1% of the IV 
administration, respectively. Since the vascular compartment is a target organ for most HDL 
therapeutics, dose adjustment appears to be critical since only about half of dose reaches the 
systemic circulation following IP administration.  
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Figure 2.2: Pharmacokinetics of 22A peptide and phospholipids after administration of lipid-free 22A peptide or 22A-
sHDL.Pharmacokinetics of 22A peptide after administration of lipid-free 22A peptide (panel A) or 22A-sHDL (panel 
B). The kinetics of phospholipid mobilization and elimination following administration of lipid-free 22A peptide (panel 
C and insert D) or 22A-sHDL (panel E and insert F). Sprague-Dawley rats received 75 mg/kg of 22A or 22A-sHDL 
by either IV or IP injection. For 22A-sHDL a dose of 75 mg/kg of peptide corresponded to a 150 mg/kg dose of 
phospholipids. Serum peptide concentrations were determined by LC-MS and total choline containing phospholipids 
was measured by a commercial choline oxidase assay.  
  
No difference was observed when comparing the volume of distribution (Vd) of 22A after 
IV and IP administrations of 22A (i.e., 0.14 for IV and 0.16 dL [Vd/F × F or 0.30 × 0.52] for IP).  
Likewise, the clearance (CL) of 22A did not change between these two dosing routes (i.e., 0.025 
for IV and 0.025 dL [CL/F × F or 0.048 × 0.52] for IP).  As a result, the elimination rate constants 
(K) and half-lives (T1/2) of 22A were very similar following IV and IP administrations. In contrast, 
the Vd of 22A was about 40% lower when administered as 22A-sHDL/IP (0.081 dL [Vd/F × F or 
0.15 × 0.54]) as compared to 22A-sHDL/IV (0.13 dL). The reason for this difference is unclear 
but may be related to partial dissociation of 22A and phospholipid during absorption into systemic 
circulation following IP administration and peptide degradation/tissue binding during absorption.  
Since there was no difference in the CL of 22A after IV and IP treatments of 22A-sHDL (i.e., 
0.014 for IV and 0.014 dL/h [CL/F × F or 0.026 × 0.54] for IP), the 22A elimination rate constant 
30 
 
(K) was higher (0.17 vs. 0.11 h-1) and the 22A half-life (T1/2) lower (4.14 vs. 6.27 h) following IP 
administration as compared to IV dosing.   
Table 2.2: Pharmacokinetic parameters (% CV) of 22A peptide after 75 mg/kg doses of 22A by four different 
treatments. 
Parameters 
Groups 
22A/IV 22A/IP 22A-sHDL/IV 22A-sHDL/IP 
Tmax (h) – 4.27 (15.3) – 4.04 (21.5) 
Cmax (mg/dL) 152.16 (5.0)ns 34.83 (14.0)**** 165.23 (7.6) 68.87 (19.9)**** 
AUC 
(mg*h/dL) 
836.3 (7.8)*** 434.5 (17.3) **** 1495.5(13.9) 809.4 (24.6)*** 
K01 (h-1) – 0.33 (34.3) – 0.35 (47.7) 
K10 (h-1) 0.18 (9.6)** 0.16 (10.9)* 0.11 (16.6)  0.17 (14.4)* 
T1/2 (h) 3.81 (9.6)*** 4.43 (10.9)** 6.27 (16.6)  4.14 (14.4)** 
CL (dL/h) 0.025 (7.8)ns 0.048 (17.4)**** 0.014 (13.9) 0.026 (24.6)* 
Vd (dL) 0.14 (5.0)ns 0.30 (26.1)** 0.13 (7.6) 0.15 (36.16)ns 
AIC 15.48 12.35 23.36 7.00 
Mean ± S.D. (n = 3), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns: no significant difference compared with 22A-
sHDL/IV treatment. Tmax: Time at which the Cmax is observed; Cmax: the maximum plasma concentration of 22A; AUC: 
the area under the curve in plot of concentration of 22A against time; k01: the first-order absorption rate constant; k10: 
the first order elimination rate constant; T1/2: the half-life of elimination; CL: apparent total clearance for 22A (CL for 
IV and CL/F for IP, where F is bioavailability); Vd: apparent volume of distribution for 22A (Vd for IV and Vd/F for 
IP, where F is bioavailability); AIC: Akaike Information Criterion.  
 
2.4.4 Phospholipid kinetics 
Monitoring lipid plasma kinetics provides indirect information not only about the 
formation of HDL following administration of naked apoA-I peptide, but also about the in vivo 
stability of administered sHDL and elimination of its lipid component. Administration of apoA-I 
peptide in sHDL formulation at a dose of 75 mg/kg peptide dose corresponds to administration of 
150 mg/kg of phospholipids (PL). The plasma levels of both endogenous and 22A-sHDL 
administered lipids were measured by choline oxidase assay. The elimination kinetics of total PL 
following 22A-sHDL injection are shown in Fig. 2.2C-F. After subtracting the pre-dose plasma 
PL levels, the pharmacokinetic parameters were determined and summarized in Table 2.3. The 
maximum PL level after IV injection of sHDL reached 483.0 mg/dL and constituted a 2.7-fold 
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increase over the baseline PL level of 132.2 mg/dL (Fig. 2.2E). The AUC of PL after IV dosing of 
22A-sHDL was 1559.6 mg*hr/dL. The AUC after IP administration of 22A-sHDL was 416.2 
mg*hr/dL, indicating the bioavailability of lipids into the systemic circulation for IP injection was 
only 26.7%.  Following IP administration of sHDL, the bioavailability of lipids is lower than that 
of 22A peptide (26.7% versus 54.1%), indicating some degree of dissociation of peptide from 
sHDL lipids during absorption. Although no exogenous PL was given in the case of peptide 
injection, it is believed that apoA-I mimetic peptides administered in vivo are capable of forming 
new HDL particles by lipid and cholesterol efflux via ATP-binding cassette transporter ABCA1 
or by mobilizing phospholipid directly from cellular membranes 100, 124. Hence, the slight increase 
in plasma lipid levels is suggestive of de novo HDL formation. As shown in Fig. 2.2C and D, a 
small increase in circulating lipids was observed for IV administration of 22A. In contrast, for IP 
administration of 22A, there was no obvious increase in plasma PL, likely due to tissue binding of 
peptide and decreased bioavailability to systemic circulation compared to IV dosing of peptide.  
Table 2.3: Pharmacokinetic parameters (% CV) of phospholipids after 150 mg/kg doses of phospholipids by two 
different treatments. 
Parameters 
Groups 
22A-sHDL/IV 22A-sHDL/IP 
Tmax (h) – 2.33 (14.6) 
Cmax (mg/dL) 420.9 (2.9) 58.3 (10.1) 
AUC (mg*h/dL) 1559.6 (3.9)  416.2 (14.2)**** 
K01 (h-1) – 0.67 (46.9) 
K10 (h-1) 0.27 (4.9) 0.25 (40.2) 
T1/2 (h) 2.57 (4.9) 2.74 (40.2)ns 
CL (dL/h) 0.027 (3.9) 0.10 (14.2)** 
Vd (dL) 0.10 (2.9) 0.40 (35.1)* 
AIC 13.51 19.34 
Mean ± S.D. (n = 3), *p<0.05, **p<0.01, ****p<0.0001, ns: no significant difference compared with 22A-sHDL/IV 
treatment. Tmax: Time at which the Cmax is observed; Cmax: the maximum plasma concentration of phospholipid; AUC: 
the area under the curve in plot of concentration of phospholipid against time; k01: the first-order absorption rate 
constant; k10: the first order elimination rate constant; T1/2: the half-life of elimination; CL: apparent clearance for 
phospholipid (CL for IV and CL/F for IP, where F is bioavailability); Vd: apparent volume of distribution for 
phospholipid (Vd for IV and Vd/F for IP, where F is bioavailability); AIC: Akaike Information Criterion. 
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2.4.5 Cholesterol mobilization and esterification  
To investigate the impact of lipidation and route of administration on apoA-I peptide ability 
to elicit pharmacological response, we examined the kinetics of plasma cholesterol biomarkers. 
Both free apoA-I peptide and sHDL infusions are capable of facilitating reverse cholesterol 
transport (RCT) by enhancing cholesterol efflux. Therefore, transient increases in plasma levels of 
cholesterol following treatment are expected. The kinetic changes in plasma total and unesterified 
cholesterol levels were measured directly by plate assays and the cholesterol ester levels were 
calculated (Fig. 2.3). Administration of 22A-sHDL by IV resulted in a rapid two-fold increase in 
total cholesterol (TC) within 0.5-1 h post-dose (Fig. 2.3A and B). The TC levels also increased 
slightly following IV administration of lipid-free 22A peptide (p<0.05 0.25-2 h post-dose). In 
contrast, no statistically significant increase in TC was observed for administration of both lipid-
free 22A and 22A-sHDL by IP route (Fig. 2.3A and B).  
The mobilized cholesterol for 22A-sHDL infusions was predominantly unesterified or free 
cholesterol (Fig. 2.3C and D). Normal pre-dose levels of rat plasma free cholesterol (FC) were 
approximately 11.7 mg/dL, and increased to 91.0 mg/dL within 1 h for IV dosing.  The IP dosing 
of 22A-sHDL or IV dosing of lipid-free 22A also generated an increase in FC, but the effect was 
much smaller than that caused by IV injection of 22A-sHDL. There was no FC increase detected 
after IP peptide solution administration (Fig. 2.3C and D). For 22A-sHDL IV administration, 
limited conversion of mobilized free cholesterol into cholesterol ester (CE) was observed (Fig. 
2.3E). It is possible that mobilized free cholesterol overwhelmed the esterification capacity of 
circulating LCAT, or that 22A-sHDL was not a good activator of rat lecithin cholesterol 
acyltransferase. Cholesterol seemed to be predominantly eliminated from plasma in its unesterified 
form following mobilization, and returned to the baseline levels 24 h post-dose. Hence, the 
pharmacological effect of apoA-I peptide was remarkably affected by the formulation and 
administration route, in which the IV dose of 22A-sHDL generated the strongest cholesterol 
transfer and mobilization efficacy.  
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Figure 2.3: Pharmacodynamic assessment of sHDL therapeutics after IV or IP administration of lipid-free 22A 
peptide or 22A-sHDL.Mobilization of total TC (A and B), FC (C and D) and CE (E and F) after injection of 75 mg/kg 
of 22A peptide solution (A, C and E) and 22A-sHDL (B, D and F). (*) denotes statistical significant differences of TC, 
FC or EC changes compared with their pre-dose levels with p-values of at least < 0.05.  
 
2.4.6 Lipoprotein Distribution of Mobilized Cholesterol 
In order investigate in greater detail the mechanism of cholesterol mobilization and 
elimination following apoA-I peptide or sHDL administrations, we determined the relative 
distribution of mobilized cholesterol in the HLD, LDL and VLDL fractions. Serum lipoproteins 
were separated by gel permeation chromatography and total cholesterol was detected following 
post-column enzymatic reaction (Fig. 2.4). Again, for the 22A-sHDL IV group, drastic but 
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transient changes in lipoprotein profiles were observed over 24 h. Cholesterol was mobilized by 
injected HDL-sized particles, causing a rapid increase in particle size upon free cholesterol uptake. 
Since sHDL are prepared with a short, single-helical peptide, the size of the nanoparticle is not 
constrained by the length and structure of lipid bound full-length apoA-I, a major protein 
component of endogenous HDL. Therefore, we saw a rapid transition of cholesterol-carrying 
particles from HDL to LDL size (15 min post-dose, with the maximum increase in cholesterol 
levels associated with LDL-sized particles detected by 2 h post-dose). While mobilization of FC 
was significant, the increase in levels of CE was disproportionally lower, indicating that 
cholesterol is likely to be taken up by the liver in its unesterified form (Fig. 2.3D and F). At 2 h 
post-dose we also observed a significant increase in cholesterol levels in VLDL-sized lipoproteins. 
The VLDL-C increase could be due to saturation of liver receptors and enzymes that internalize, 
metabolize and secrete large amount of mobilized FC. However, the cholesterol changes were 
transient and lipoprotein-cholesterol distribution returned to a pre-dose profile 24 h post-dose. In 
contrast to 22A-sHDL IV group, only limited lipoprotein changes were observed for all other 
groups. A small transient increase in LDL-cholesterol level was observed for the 22A peptide 
group at 0.25 and 2 h post-dose, returning to baseline by 24 h post-dose. Due to limited cholesterol 
mobilization for all groups except for 22A-sHDL, it was difficult to assess differences in in vivo 
mechanisms of cholesterol efflux, mobilization, lipoprotein transfer and elimination for both lipid-
fee peptide administrations and IP dosing of sHDL.  
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Figure 2.4: The cholesterol distribution between VLDL, LDL and HDL lipoprotein fractions following IV (A) or IP 
administration (B) of 22A peptide solution or IV (C) or IP administration (D) 22A-sHDL.   
 
2.4.7 Plasma Remodeling 
Potential differences in how apoA-I peptide or sHDL induce remodeling of endogenous 
lipoproteins were examined following in vitro incubation of both formulations with human serum. 
22A and 22A-sHDL were added at 0, 0.15, 0.5, 1 and 3 mg/ml peptide concentrations, incubated 
for 30 min and separated by either 1-D native page electrophoresis (Fig. 2.5). The 1-D gels were 
visualized by western blot, staining for human apoA-I. The incubations were performed with a 
broad concentration range of 22A peptide, corresponding to in vivo concentration ranges of 0-1.5 
mg/mL 22A, as measured by LC-MS. Compared to control serum (lane 1), all incubations showed 
reduction in the apoA-I content of α-HDL, seen by decreased stain intensity between 720 and 200 
kDa. Along with this decrease, a 22A-peptide concentration dependent appearance of lipid-free or 
lipid-poor apoA-I protein was observed. The band of lipid-poor ApoA-I ran around 25-30 kDa and 
it had slightly higher intensity for 22A-serum incubations, but slightly larger size for 22A-sHDL-
serum incubation. Hence, both naked and lipid-bound 22A were capable of associating with 
endogenous HDL and displacing endogenous apoA-I on HDL particles. Lipoprotein remodeling 
and release of lipid free apoA-I could potentially be responsible for the therapeutic effect, 
independent of cholesterol mobilization and RCT. 
 
Figure 2.5: Free apoA-I and various subclasses of HDL were separated by 1-D native page electrophoresis and 
visualized by western blot using anti-apoA-I antibody. Lane 1 was the control serum, lane 2, 3, 4, 5 represented 0.15, 
0.5, 1 and 3 mg/ml of 22A and lane 6, 7, 8, 9 represented 0.15, 0.5, 1 and 3 mg/ml 22A-sHDL, respectively. Labels a, 
b and c refer to the approximate positions of lipid-poor apoA-I, small pre-β HDL particles and large α-HDL particles.  
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2.4.8 Pharmacokinetics and pharmacodynamics correlation  
Based on experimental pharmacokinetic (PK) and free cholesterol mobilization 
pharmacodynamic (PD) data, the indirect response PK-PD models were developed for 22A and 
phospholipids (Fig. 2.6). The parameters obtained from PK-PD modeling allow for the prediction 
of timing and magnitude of FC increase, such that the dosing regimens can be further optimized. 
The best fit for the PK data was obtained using a one-compartment disposition model, with lowest 
Akaike Information Criterion (AIC) values for both IV and IP injections without lag time. PD 
parameters obtained from 22A-FC or phospholipids-FC PK-PD models are listed in Table 2.4. For 
IP injection of the 22A group, the model failed to fit the data because FC mobilization was limited 
for this group. 
 
Figure 2.6: Scheme of the pharmacokinetic-pharmacodynamic (PK-PD) model based on a one-compartment PK 
model. k01: the first-order absorption rate constant for IP groups only; k10: the first order elimination rate constant; 
kin: the zero-order constant for production of response; kout: the first-order constant for loss of the response; EC50: 
the serum concentration needed to achieve a 50% of maximum stimulation achieved at the effect site of a dosed agent; 
γ: steepness of the sigmoidal curve.  
 
Figure 2.7: Plot of the relationship between 22A serum concentration and FC increase at individual time points 
following IV (A) or IP (B) administration of 22A peptide solution or 22A-sHDL at dose of 75 mg/kg. 
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In all four groups, a plot of the relationship between 22A serum concentration and FC 
levels showed an anticlockwise hysteresis, indicating a significant delay in peak levels of free 
cholesterol relative to the Cmax of 22A or phospholipids (Fig. 2.7). This relationship was described 
by an indirect response model in which serum concentrations of 22A or PL had a stimulatory effect 
on the production of FC. Under normal physiological condition without HDL injection the 
endogenous free cholesterol level change can be described by a basic turnover model, which 
includes a zero-order turnover or synthesis rate constant (kin) and a first-order rate constant for 
cholesterol elimination (kout). 22A or 22A-sHDL worked as stimulatory factors having an effect 
on production of the response (Fig. 2.6). Among all stimulation functions, the infinite stimulation 
model fits the data best, giving the lowest sum of squared residual value.  The parameters kin and 
kout are independent of drug concentration, thus estimated values for all three groups were similar.  
The free cholesterol baseline level R0, which is assumed to be constant, can be calculated by R0 = 
kin/kout for the three modeled groups. Similar baseline values were observed to be approximately 
12 mg/dL, meeting the values detected for pre-dose.   
Table 2.4: Estimated pharmacodynamic parameters (with % CV of the estimate) for 22A peptide. 
Parameters 
Groups 
22A/IV 22A/IP 22A-sHDL/IV 22A-sHDL/IP 
kin (mg/(dL*h)) 30.38 (53.7) – 30.48 (18.3) 30.60 (70.4) 
kout (h-1) 2.65 (61.6) – 2.61 (10.5) 3.46 (60.1) 
EC50 (mg /dL) 142.81 (8.6) *** – 53.77 (21.2) 47.63 (247.8) ns 
gamma 2.08 (71.9) ns – 1.92 (10.6) 0.36 (90.6) *** 
LogLik -9.96 – -15.97 -11.94 
Mean ± S.D. (n = 3), ***p<0.001, ns: no significant difference versus 22A-sHDL/IV group. kin: the zero-order constant 
for production of response; kout: the first-order constant for loss of the response; EC50: the plasma concentration needed 
to achieve a 50% of maximum stimulation achieved at the effect site of a dosed agent; gamma: steepness of the 
sigmoidal curve. LogLik: Log-likelihood of best-fitted model.  
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Table 2.5: Estimated pharmacodynamic parameters (with % CV of the estimate) for phospholipids. 
Parameters 
Groups 
22A-sHDL/IV 22A-sHDL/IP 
kin (mg/(dL*hr)) 30.48 (18.2) 22.26 (27.2) 
kout (hr-1) 2.61 (10.5) 1.85 (27.3) 
EC50 (mg /dL) 27.11 (51.6)  74.02 (9.93) * 
gamma 0.78 (10.6) 1.25 (25.2) ns 
LogLik -15.97 -7.34  
Mean ± S.D. (n = 3), *p<0.05, ns: no significant difference versus 22A-sHDL/IV group. kin: the zero-order constant 
for production of response; kout: the first-order constant for loss of the response; EC50: the plasma concentration needed 
to achieve a 50% of maximum stimulation achieved at the effect site of a dosed agent; gamma: steepness of the 
sigmoidal curve. LogLik: Log-likelihood of best-fitted model.  
 
There was no significant difference between the sigmoidicity factor gamma (γ), except in 
the case of the 22A-PD model for the 22A-sHDL IP group, whose value was much lower than IV 
group. The EC50 represents the plasma concentration needed to achieve a 50% of maximum 
stimulation achieved at the effect site of a dosed agent. From Table 2.4, 22A peptide had a 
significantly lower EC50 value after IV dosing of 22A-sHDL than after IV dosing of free peptide 
(53.8 mg/dL versus 142.8 mg/dL), indicating that the sHDL formulation had a more potent effect 
on cholesterol efflux than did the free peptide. There was no significant difference between the 
22A-sHDL IV and IP groups. Combining EC50 and γ values, lipidation of 22A increases the 
potency of peptide whereas altering the administration route can increase the sensitivity of 
cholesterol efflux towards any 22A concentration change at the effect site. However, the smaller 
value of phospholipids EC50 value for phospholipids in the 22A-sHDL IV group compared to IP 
groups (27.1 mg/dL versus 74.0 mg/dL) showed that the phospholipids in sHDL triggered higher 
cholesterol efflux after IV injection compared to IP injection at the same dose, which may result 
from sHDL particle dis-assembly during the absorption process (Table 2.5).   
The log-likelihood value reflects the quality of the fitted model. In the 22A-sHDL IP group, 
the phospholipid-FC PK/PD model appears to provide a better fit for the data compared to the 
22A-FC PK/PD models, as highlighted by the larger LogLik values (Tables 2.4 and Table 2.5). 
This better fit underscores the notion that FC mobilization is likely elicited by the presence of 
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cholesterol-free lipid membranes of sHDL in the plasma and to a lesser degree by peptide-mediated 
cholesterol efflux.   
2.5 Discussion and conclusion  
We found that both the physical state of the apoA-I peptide (i.e. naked or lipid-bound 
sHDL) and the route of administration (IV versus IP) profoundly affected its pharmacokinetics 
and the mechanism of eliciting pharmacological response. Only lipidated 22A-sHDL administered 
by IV resulted in rapid and massive mobilization of free cholesterol. Additionally, only a partial 
conversion of FC to CE was observed, and all mobilized cholesterol was subsequently eliminated 
within 24 h. The difference in plasma-mobilized cholesterol levels did not directly correlate with 
differences in the pharmacokinetics of apoA-I peptide administered in a lipid-free form or in the 
bioavailability of apoA-I peptide to systemic circulation following IP dosing. The half-life of 
peptide administered in lipid-free form was only 0.61-fold shorter relative to 22A-sHDL. 
However, 1-2 h post-dose the maximum levels of mobilized FC reached 22 mg/dL for 22A and 91 
mg/dL for 22A-sHDL (Fig. 2.3C, D, Table 2.2), constituting a 1.3 and 5.3 increase from pre-dose 
level, respectively. This significant difference in the magnitude of plasma cholesterol mobilization 
indicated a potential mechanistic difference in how cholesterol efflux is elicited for lipid-free 
peptide and sHDL in vivo. The rapid cholesterol mobilization following IV administration of 
sHDL was likely caused in part by a physical partitioning of FC from cellular membranes to 
cholesterol-free lipid bilayers of sHDL. For administration of lipid-free 22A peptide, cholesterol 
mobilization possibly occurs in a receptor-mediated manner following interaction with peptide or 
de novo formed HDL following of plasma remodeling of lipoprotein by 22A peptide. Extensive 
mobilization of FC in serum led to rapid conversion of the injected sHDL particles to LDL-sized, 
cholesterol-loaded particles, causing a spike in LDL-C levels between 2-8 hours post-dose. These 
transient increases in LDL-C and triglyceride levels have been observed previously for both free 
ApoA-I and HDL infusions, and has been attributed to saturating the liver’s capacity to excrete 
free cholesterol and inhibiting hepatic and lipoprotein lipases 125. While the changes in lipoproteins 
appeared to be very dramatic following 22A-sHDL IV infusion, they were also transient, as all 
lipoprotein levels returned to baseline 24-hours post-dose. Similar transient changes in lipoproteins 
have been observed in clinical settings for infusions of other HDL products, such as CER-001 126 
and ETC-216. 127  
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When either lipid-free or lipidated peptide was mixed with serum, each was capable of 
remodeling of endogenous lipoproteins, leading to the appearance of a lipid-poor apoA-I fraction. 
The appearance of lipid-poor apoA-I indicates that, upon administration, 22A peptide binds to 
endogenous HDL particles and causes endogenous apoA-I displacement from HDL. It is unclear 
how this phenomenon impacts the anti-atherosclerotic activity of apoA-I mimetic peptide as well 
as how the sequences of various peptides influence endogenous lipoprotein binding. The PK-PD 
modeling that correlated 22A with an increase in FC, a plasma biomarker of cholesterol efflux, 
revealed EC50 values to be much lower for 22A-sHDL-IV compared with lipid-free-22A-IV (Table 
2.4).  
The initial decision to use reconstituted HDL particles rather than lipid-free apoA-I in 
clinical development occurred in the 1990s following the first clinical evaluation by Miller et al. 
95, 107 In these studies, prolonged IV infusion and bolus administration of lipid-free apoA-I up to 
50 mg/kg dose failed to increase plasma levels of HDL-C. Instead, transient increases in LDL 
particles were noted and attributed to inhibition of lipoprotein and hepatic lipases. In contrast, 
infusions of reconstituted HDL particles at 25 and 40 mg/kg of apoA-I resulted in transient 
increases in HDL unesterified cholesterol levels, followed by cholesterol esterification and 
elimination. Since these first clinical trials, the elevation of HDL-C levels has become a primary 
biomarker of sHDL’s pharmacological effect. The clinical dose selection and preclinical 
optimization for many follow-on HDL products (ETC-642, CER-001) were performed based on 
the HDL-C increase as biomarker. 94, 97 However, it is becoming clear that there are mechanistic 
differences in how sHDL and free apoA-I elicit cholesterol efflux. Lipid-free apoA-I interacts with 
ABCA-1 receptors to efflux, forms de novo HDL and remodel existing lipoproteins. In contrast, 
the cholesterol-free lipid bilayers of sHDL particles are strong acceptors of cholesterol from 
ABCG1, SR-BI, and via passive efflux from cellular membranes. Indeed, recent studies have 
shown that SR-BI receptors are largely responsible for free cholesterol elevation following rHDL 
infusion, and that phospholipids, not ApoA-I, dictate FC efflux. 128-129 Because of these factors, 
CSL-112 pharmacological efficacy in early clinical trials was monitored by increases in ABCA1 
cholesterol efflux capacity of patient plasma following drug administration. 130  
Several studies have directly compared the anti-inflammatory effects of apoA-I and HDL 
administered by IV infusion in animal models of arthritis and a carotid peri-arterial collar model. 
104 When lipid-free apoA-I and reconstituted HDL were administered at a low dose of 8 mg/kg, 
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they exhibited similar measurable anti-inflammatory activity. This indicates that some of 
protective mechanisms of apoA-I and sHDL infusions could not be characterized simply by 
monitoring cholesterol mobilization, and additional biomarkers are needed to establish the PK-PD 
relationship.   
Direct comparisons of the anti-atherosclerotic potency of IP injections of 30 mg/kg of 
either ATI-5261 peptide or reconstituted HDL were performed in a high-fat diet fed ApoE-/- mouse 
model of atherosclerosis. 64 While no increase in plasma cholesterol levels was detected, sHDL 
injections showed slightly better atheroma reduction, however the difference was not statistically 
significant. In our study, IP administrations resulted in only limited plasma cholesterol 
mobilization, with slightly higher mobilization for sHDL infusions compared to those using lipid-
free peptide. Following IP dosing 52% of lipid-free apoA-I peptide, 54% of lipidated apoA-I 
peptide and 27% of sHDL phospholipids reached the systemic circulation. In addition, the values 
for absorption (K01) and elimination (K10) constants differed for PL and 22A following IP 
administration of 22A-sHDL (Tables 2.2 and 2.3), indicating that some of 22A-sHDL was 
dissociated prior to absorption. Peptide tissue-binding, proteolysis and disassembly of 22A-sHDL 
particles are potential reasons for the reduced and different bioavailabilities. Peptide tissue-binding 
and proteolysis depend on the primary sequence of peptide and, thus, differ for various peptides 
and full-length apoA-I. Stability of sHDL in vivo and extent of endogenous HDL remodeling 
depend on the lipid binding affinity of amphipathic helixes toward lipid used in sHDL formulation, 
endogenous lipoproteins and plasma lipid membrane as well as the peptide's tendency to self-
associate. 96, 131 Furthermore, lipid formulation of sHDL (peptide-lipid ratio, lipid type and sHDL 
particle size) affects particle stability, cholesterol affinity and interaction with LCAT. 132 Thus, in 
vivo behavior of apoA-I peptide and sHDL formulation could be distinctly different for various 
peptide sequences and lipid formulations.  
    The magnitude of cholesterol mobilization and pharmacokinetic parameters depend on 
the dose of administered apoA-I peptide. The dose used in this study, 75 mg/kg, was selected to 
assure the detection of peptide in plasma following IP administration. The selected dose is slightly 
higher than doses used in animal pharmacology studies for apoA-I and HDL, which range between 
1 and 50 mg/kg. 133-134 However, in phase I clinical dosing the infusions were given up to 45 mg/kg 
for CER-001, 135 mg/kg for CSL-112 and 50 mg/kg for lipid free apoA-I. 94-96 Hence, 75 mg/kg 
was a reasonable dose for the current study. In addition, our study was conducted in healthy rats 
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to allow for the multiple blood draws required to determine for PK and PD parameters. However, 
the cholesterol pool mobilized in healthy rats is likely to be different from that present in human 
atheromas and, thus it would be beneficial to evaluate how apoA-I lipidation affects cholesterol 
mobilization in hyperlipidemic disease models.  
   The results of this study emphasize the criticality of considerations for formulation, route 
of administration, and dose used in pharmacological studies of apoA-I peptide and sHDL particles. 
Historic drug development considerations for the selection of HDL dose and formulation were 
based on measurements of plasma cholesterol level increase, which were primarily observed upon 
IV administration of sHDL particles. Yet, the increase in plasma cholesterol primarily depends on 
sHDL lipid composition and particle stability in vivo, and is seen upon administration of relatively 
high doses of sHDL. Thus, endogenous lipoporotein remodeling, anti-inflammatory effects and 
apoA-I protein mediated ABCA-1 efflux that are exhibited at lower doses are often 
underemphasized. Consequently, a mechanistic understanding of which therapeutics effects of 
sHDL are mediated by lipoprotein particles and which are mediated by their apoA-I component, 
as well as correlating elicited pharmacologic effect in vivo with the actual systemic concentrations, 
AUC and pharmacokinetic parameters for administered apoA-I peptide, will significantly improve 
clarity around the development of HDL mimetics. Identification of in vivo biomarkers indicative 
of HDL mimetic potency in addition to HDL-C plasma increase and rapid assessment of in vivo 
of PK and biomarker response for novel apoA-I mimetic peptides could improve their development 
outcomes, as extensive in vitro optimization does not account for peptide proteolysis and excessive 
tissue binding in vivo.  
2.6 Supplementary information 
 
Figure 2.8: The retention time of isolated human HDL analyzed by gel permeation chromatography. 
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Figure 2.9: Linearity of calibration curve for the determination of 22A concentrations in rat serum (r2 = 0.995).  
 
Figure 2.10: The percent of 22A (-) Lys peptide in serum at the first four time points after injection. 
 
Table 2.6: Precision, accuracy and recovery for the determination of 22A in rat serum (n=6). 
Concentration (µg/ml) RSD (%) 
RE (%) Recovery (%) 
Added measured (mean) intra-assay inter-assay 
6 6.7 2.29 4.30 12.00 112.0 ± 2.6 
50 55.9 2.41 3.92 11.80 111.8 ± 2.7 
160 147.5 1.54 3.80 -7.84 92.2 ± 1.4 
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Chapter 3 : Effect of synthetic high-density lipoproteins modification with polyethylene 
glycol on pharmacokinetics and pharmacodynamics 
 
This research was originally published in the Molecular Pharmaceutics. Li D, Fawaz MV, 
Morin EE, Ming R, Sviridov D1, Tang J, Ackermann R, Olsen K, Remaley AT, Schwendeman A. 
Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on 
Pharmacokinetics and Pharmacodynamics. Mol Pharm. 2018 Jan 2;15(1):83-96.  
3.1 Abstract 
Synthetic high density lipoprotein nanoparticles (sHDL) capable of mobilizing excess 
cholesterol from atherosclerotic arteries and delivering it to the liver for elimination have been 
shown to reduce plaque burden in patients. Unfortunately, sHDLs have a narrow therapeutic index 
and relative to the endogenous HDL shorter circulation half-life. Surface modification with 
polyethylene glycol (PEG) was investigated for its potential to extend sHDL circulation in vivo. 
Various amounts (2.5, 5 and 10%) and different chain lengths (2 and 5 kDa) of PEG-modified 
lipids were incorporated in sHDL’s lipid membrane. Incorporating PEG did not reduce the ability 
of sHDL to facilitate cholesterol efflux, nor did it inhibit cholesterol uptake by the liver cells. By 
either adding more PEG or using PEG of longer chain lengths the circulation half-life was 
extended. Addition of PEG also increased the area under the curve for the phospholipid component 
of sHDL (p < 0.05), but not for the apolipoprotein A-I peptide component of sHDL — suggesting 
sHDL is remodeled by endogenous lipoproteins in vivo. The extended phospholipid circulation led 
to a higher mobilization of plasma free cholesterol, a biomarker for facilitation of reverse 
cholesterol transport. The area under the cholesterol mobilization increased about 2 to 4-fold (p < 
0.05), with greater increases observed for longer PEG chains and higher molar percentages of 
incorporated pegylated lipids. Mobilized cholesterol was associated primarily with the HDL 
fraction, led to a transient increase in VLDL cholesterol, and returned to baseline 24 h post-dose. 
Overall, pegylation of sHDL leads to beneficial changes in sHDL particle pharmacokinetic and 
pharmacodynamic behaviors. 
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Figure 3.1: Table of Contents/Abstract Graphic. 
 
3.2 Introduction 
Cardiovascular disease (CVD) is the leading cause of death in the United States, 
responsible for 17% of national health expenditures.135 High-density lipoprotein cholesterol 
(HDL-C) levels are known to inversely correlate with the risk of CVD.136 HDL is natural 
nanoparticle composed primarily of apolipoprotein A-I (ApoA-I) and lipids. One of the key 
functions of HDL is to maintain cholesterol homeostasis through reverse cholesterol transport 
(RCT), whereby HDL effluxes free cholesterol from peripheral tissues through ATP-binding 
cassette transporters (ABCA1 and ABCG1) and then delivers it to liver for excretion by the 
scavenger receptor B type I (SR-BI) receptor.137 Thus, the idea of administrating synthetic HDL 
(sHDL) to facilitate RCT and promote the regression of atherosclerotic plaque has gained 
significant interest.18, 138-140  Several sHDL therapeutic products have been developed that consist 
of either ApoA-I protein purified from human plasma, recombinant ApoA-I, or ApoA-I mimetic 
peptides.112, 141 The protein component is usually combined with phospholipids to form sHDL 
nanoparticles, which are administered intravenously following a cardiovascular event. It was 
hypothesized that the acute administration of several sHDL infusions could lead to a rapid 
reduction in plaque volume and prevent the likelihood of subsequent cardiovascular events.12, 140  
A number of sHDL products have been tested in Phase I and II clinical trials and were able to 
increase HDL-C levels, reduce inflammation and decrease atherosclerotic plaque volume.141   
Despite initial clinical success, the translation of sHDL nanomedicine into an FDA 
approved therapy has been difficult. This class of drugs has a unique pharmacokinetic-
pharmacodynamic relationship. Administration of sHDL causes rapid mobilization of cholesterol, 
which is subsequently delivered to the liver for elimination.11 The amount of mobilized cholesterol 
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is often several folds higher than pre-dose plasma cholesterol levels, leading to saturation of 
hepatic receptors and pathways for cholesterol metabolism.142 Thus, administration of sHDL often 
results in drug-related toxicity exhibited by transient elevation of liver transaminases (ALT and 
AST), triglycerides, low and very low-density lipoprotein cholesterol levels (LDL-C and VLDL-
C). In addition, the half-life of endogenous ApoA-I protein in humans is only 3.3 days.143 It is 
believed that the protein participates in multiple cycles of RCT by forming HDL, effluxing 
cholesterol, delivering it to the liver, and returning to the peripheral tissues to efflux more 
cholesterol.11 In contrast, administration of sHDL results in a protein or peptide half-life of only 
8-12 hours.33, 144  
Due to the rapid elimination of sHDL, the duration of time following administration when 
sHDL plasma levels remain above the level required to obtain therapeutic effect is quite short. 
This rapid elimination necessitates either frequent dosing, which is inconvenient for patients 
especially for an intravenous product, or administration of relatively high doses, which can lead to 
off-target toxicity. In addition, following administration in vivo, sHDL nanoparticles rapidly 
interact with endogenous lipoproteins by exchanging lipid and protein components. This is a 
natural phenomenon in lipoprotein metabolism, known as remodeling, that leads to the 
disassembly of administered sHDL particles, and results in differences in elimination kinetics of 
ApoA-I and lipid components of sHDL.31 This remodeling, in turn, affects both the efficacy and 
safety of administered sHDL. The main hypothesis of this study is that by modifying the sHDL 
surface with polyethylene glycol, it may be possible to slow down sHDL remodeling by 
endogenous lipoproteins, thereby reducing sHDL nanoparticle elimination by reticuloendothelial 
system, increasing its circulation half-life in vivo and altering its antiatherogenic properties. 
Polyethylene glycol (PEG) has been widely used to coat or pegylate nanoparticle surfaces 
to archive “stealth-like” characteristics.68 Pegylated drug delivery systems have been shown to be 
more physically stable in vitro and have longer circulation half-lives in vivo, resulting from the 
ability of PEG to escape uptake by the reticuloendothelial system.145 Pegylation has been shown 
to be clinically safe and currently used in several products approved by the Food and Drug 
Administration.146 It has been reported that by conjugating PEG to ApoA-I protein, protein in vivo 
circulation was prolonged and anti-inflammatory activity in a murine model of atherosclerosis was 
improved147. The PEG density on the nanoparticle surfaces, PEG molecular weight, and branch 
structure are all known to affect nanoparticle circulation and efficacy148, but this has not been 
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systematically investigated for sHDL. Thus, to test our hypothesis, we incorporated PEG-modified 
phospholipids in sHDL nanoparticles and examined how the degree of surface modification and 
PEG chain length affected sHDL pharmacokinetics and pharmacodynamics in vivo.  
The model sHDL used in this study is a peptide-based sHDL, ETC-642. ETC-642 was 
previously examined in single- and multiple-dose clinical studies in dyslipidemic patients.144, 149 It 
was shown that infusion of ETC-642 increased HDL-C levels at doses as low as 3 mg/kg and was 
well tolerated by patients at doses up to 30 mg/kg.149 However, the plasma circulation half-life of 
22A-peptide in humans was only ~12 h, which is significantly shorter than the reported half-life 
of endogenous ApoA-I protein, 68 h.27, 150 In this study, the abilities of pegylated sHDL to promote 
cellular cholesterol efflux and facilitate cholesterol uptake in vitro were examined. The remodeling 
of pegylated sHDL by endogenous lipoproteins was also examined in vitro, following incubation 
with human serum, as well as in vivo following administration to Sprague-Dawley (SD) rats. 
Biodistribution of unmodified and pegylated sHDL nanoparticles was examined in mice. The 
pharmacokinetic properties of both unmodified and pegylated sHDL nanoparticles in addition to 
their abilities to mobilize, esterify and eliminate cholesterol were also examined in SD rats.  
3.3 Materials and methods 
3.3.1 Materials 
ApoA-I mimetic peptides 22A (PVLDLFRELLNELLEALKQKLK) and 5A 
(DWLKAFYDKVAEKLKEAFPDWAKAAYDKAAEKAKEAA) were synthesized by Genscript 
(Piscataway, NJ). The peptide purities were determined to be over 95% by reserve phase HPLC. 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), N-(Carbonyl-methoxypolyethyleneglycol 
2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG-2k) and N-(Carbonyl-
methoxypolyethyleneglycol 5000) -1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-
PEG-5k) were purchased from NOF Corporation (White Plains, NY). DSPE-PEG-FITC amd 
Bodipy-labeled cholesterol were purchased from Avanti Polar Lipids, Inc (Alabaster, AL). All 
other materials were obtained from commercial sources.  
3.3.2 Preparation of sHDL particles 
All investigated particles were prepared using a lyophilization method. Briefly, 22A 
peptide, DPPC, DSPE-PEG2000 (PEG-2k) or DPSE-PEG5000 (PEG-5k) were dissolved in acetic 
acid at a molar ratio of 1:7.15 for peptide to total lipids. The molar percentage of DSPE-PEG2000 
in total lipids was 0, 2.5%, 5% and 10% for sHDL, sHDL-PEG-2k (2.5%), sHDL-PEG-2k (5%), 
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and sHDL-PEG-2k (10%), respectively. Similarly, HDL-PEG-5k (5%) contained DSPE-PEG5000 
at 5% of total lipids. After freeze-drying for over 24 hours, PBS (pH = 7.4) was added to hydrate 
to a final 22A peptide concentration of 10 mg/mL. The mixture was vortexed briefly, heated to 
50°C for 10 min and cooled to 25°C for 10 min, and this cycle repeated three times. sHDL particle 
concentrations are expressed in terms of 22A peptide concentration.  
sHDL and sHDL-PEG particles loaded with DiD fluorescent dye or bodipy-labeled 
cholesterol were prepared by a freeze-drying method that dissolved DiD or labelled cholesterol in 
glacial acetic acid together with all other components. The final concentration of bodipy-
cholesterol after hydration of lyophilized powder was 30 μg/mL and 20 μg/mL for DiD.  
3.3.3 Characterization of HDL and HDL-PEG particles 
The purity and particle size of sHDL and sHDL-PEG was analyzed by gel permeation 
chromatography (GPC), with UV detection wavelength of 220 nm, using a Tosoh TSK gel 
G3000SWx 7.8mm x 30cm column (Tosoh Bioscience, King of Prussia, PA) on Waters Breeze 
Dual Pump system.  Samples were diluted to 1 mg/ml and 50 µL injection volume was used. The 
samples were eluted with PBS (pH 7.4). Particle size distribution was also determined by dynamic 
light scattering (DLS), using a Zetasizer Nano ZSP, Malvern Instruments (Westborough, MA). 
The samples were diluted to 1 mg/ml prior to analysis.  
3.3.4 Cholesterol efflux evaluation  
Baby hamster kidney (BHK)-mock and BHK cells transfected with ABCA1 or SR-BI 
receptors were grown in Dulbecco’s modified eagle medium with 10% FBS and 1% pen strep 
glutamine. 105 cells were then seeded into 24-well plates and grown for 24 hours. Cells were 
washed with PBS (pH 7.4) once at room temperature and labeled with cholesterol for 24 hours in 
DMEM/BSA/antibiotic media (0.5 mL) containing 1 µCi of [3H] cholesterol/mL of media. 
Subsequently, labeled cells were washed with PBS (pH 7.4) twice to remove [3H] cholesterol that 
was not taken up by cells. Tritium-labeled cholesterol was effluxed from cells for 18 hours, using 
various lipid complex acceptors (5 µM) in duplicate. Finally, all cell media (0.5 mL) was removed 
into separate Eppendorf tubes and centrifuged at 10,000 rpm for 5 min. Remaining cells were lysed 
with 0.1%SDS/0.1M NaOH solution for 2 hours. Radioactive counts of media and cell fractions 
were measured separately, using a Perkin Elmer liquid scintillation counter. Percent cholesterol 
effluxed from cells was calculated by dividing media counts by the total sum of media and cell 
counts and then multiplying this number by 100%.      
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3.3.5 Liver cell uptake of sHDL particles and sHDL cholesterol  
HepG2 cell uptake of sHDL and sHDL-PEG loaded either with DiD fluorescent dye or 
with bodipy-labeled cholesterol was visualized by confocal laser scanning microscopy and 
quantified by flow cytometry. Briefly, liver hepatocellular carcinoma (HepG2) cells were cultured 
in Dulbecco’s Modified Eagle Medium with 10% FBS and 1% Pen Strep Glutamine and 
maintained in an incubator at 37℃ and 5% CO2. On day 0, 104-105 cells were seeded in a MatTek 
35 mm petri dish in DMEM. The next day, media was aspirated and cells were washed with PBS. 
Fresh media containing sHDL and sHDL-PEG loaded with DiD or bodipy-labeled cholesterol 
were added at a final 22A concentration of 100 μg/ml. After incubation at 37 °C for 5, 15, 30, 60, 
and 120 min, cells were washed twice with PBS followed by fixation with 4% paraformaldehyde 
in PBS for 15 min at room temperature. 1% Triton-X solution was then added to the dish for 15 
min and washed with PBS twice. Finally, the cell nuclei were stained with DAPI. The nuclei and 
bodipy fluorescence images were acquired on a Nikon A-1 Spectral Confocal microscope system 
(Nikon Corporation, Tokyo), with an excitation wavelength of 644 nm for DiD and 495 nm for 
bodipy. Quantification of cellular fluorescent signal was performed using a cell sorter (Beckman 
Coulter FC500 5-colour analyzer). 
To understand the effect of sHDL concentration on cholesterol uptake, a similar experiment 
was conducted in which the bodipy-labelled cholesterol concentration was held constant while the 
sHDL concentration varied. Briefly, cells were incubated with sHDL or sHDL-PEG2k (10%) 
particles loaded with bodipy-cholesterol at a concentration of 0.3 μg/mL for 1 hour at 37 °C. The 
final sHDL concentration was 1 mg /mL, 0.5 mg/mL or 0.1 mg/mL in terms of 22A peptide 
concentration. Cells were washed twice with PBS and analyzed by flow cytometry.  
3.3.6 Particle remodeling in serum  
To study the remodeling of sHDL by endogenous lipoproteins, sHDL or sHDL-PEG-2K 
(5%) particles were incubated with human serum at 1 mg/mL 22A concentration at 37 °C for 1 h 
with shaking at 300 rpm. To track the exchange of DSPE-PEG 2000 between sHDL and 
endogenous lipoproteins, sHDL particles were prepared with fluorescent FITC-DSPE-PEG-2K, 
which has excitation and emission spectrum peak wavelengths of approximately 495 nm and 519 
nm respectively. The cholesterol distribution among different lipoproteins in samples after 
incubation was analyzed using Waters HPLC system equipped with a Superose 6, 10/300 GL 
column (GE Healthcare, Piscataway, NJ) and on-line detection of cholesterol was achieved via 
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post-column enzymatic reactions151. The post column reaction was done using a 5 mL reaction 
coil at 37°C by mixing separated lipoprotein and enzymatic reagent whose flow rate was 0.2 
mL/min. The UV absorbance of the product was detected at 490 nm.  The enzymatic reagent 
solution was composed of 100 mM phosphate buffer (pH 7.0), 4 M sodium chloride, 0.2% triton 
X-100, 10 mM sodium cholate, 2.5 mM 4-aminoantipyrine, 7.5 mM 2-hydroxy-3,5 
dichlorobenzene, 0.0625 U/ml cholesterol oxidase, 1.25 U/ml peroxidase, 1.25 U/ml lipase and 
0.1 U/ml cholesterol ester hydrolase. To examine the distribution of FITC-DSPE-PEG-2K among 
endogenous lipoproteins, the HPLC fractions of HDL, LDL and VLDL were collected after 
separation, and fluorescence for each fraction was determined, using a Synergy NEO HTS Multi-
Mode Microplate Reader (Bio-Tek). 
To determine the effect of sHDL induced remodeling of endogenous HDL subclasses, 
lipoproteins after incubation were separated by one-dimensional native polyacrylamide gel 
electrophoresis (PAGE) based on particle size and visualized by western blot for ApoA-I protein. 
Samples were subject to electrophoresis in 10-well Tris-Borate-EDTA gradient (3-25%) 
acrylamide native gels (Jule, Inc., Milford, CT). For each line, 5 µl of human serum after 
incubation with PBS, 22A peptide or 22A-sHDL was mixed with 5 µl of 2X TBE sample buffer 
and 6 µl of the resulting mixtures were loaded per line. Gels were run at 200 V until the sample 
dye was 2.5 cm away from the bottom of the gel.  Proteins were visualized by western blot by 
transfer onto PVDF membrane and incubation overnight with anti-human apoA-I-HRP conjugated 
antibody (Meridian Life Science, Memphis, TN). Bands were visualized using SuperSignalTM 
West Pico Chemiluminescence Substrate (Thermo Fisher) and images were acquired on a 
FluorChem M Imager (Protein Simple, San Jose, CA). Image J was used for spot densitometry. 
3.3.7 Pharmacokinetic and pharmacodynamic study in rats 
The sHDL and sHDL-PEG formulations were prepared at a final 22A concentration of 20 
mg/mL in PBS. Sixteen male Sprague-Dawley rats were randomly assigned to four groups: sHDL, 
sHDL-PEG-2k (5%), sHDL-PEG-2k (10%) and sHDL-PEG-5k (5%), containing four rats each. 
All rats were fasted overnight before dosing and received different sHDL formulations at the dose 
of 50 mg/kg based on 22A peptide concentration via tail vein injection. Blood samples of 
approximately 0.3 mL were collected from the jugular vein in heparinized BD centrifuge tubes 
(BD, Franklin Lakes, NJ) at pre-dose and 0.25, 0.5, 1, 2, 4, 8, 24 and 48 hours after dosing. Serum 
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samples were separated immediately by centrifugation at 10,000 rpm for 10 minutes at 4°C and 
stored at -20°C until further analysis.  
3.3.8 Measurement of peptide serum concentration and pharmacokinetic analysis 
To determine 22A peptide concentration in serum, 10 μL of 5A peptide (3 mg/mL) was 
added to 10 μL of each serum sample as an internal standard (IS). The sample was then mixed 
with 100 μL of methanol containing 0.1% acetic acid and vortexed for 30 seconds. The mixture 
was centrifuged at 10,000 rpm for 10 minutes at 4°C and supernatant was collected for LC-MS 
analysis. Samples were injected into the Agilent 6520 Accurate-Mass Q-TOF LC/MS system 
equipped with a dual electrospray ionization source (Dual-ESI) (Agilent Technologies, CA). An 
Agilent 300SB-C18 column (2.1 mm × 50 mm, 3.5 μm) was used for separation and the UV 
detector was set to a wavelength of 220 nm. The flow rate was 0.3 mL per minute, with the initial 
mobile phase composed of 90% solvent A (water containing 0.1% v/v formic acid) and 10% 
solvent B (methanol containing 0.1% v/v formic acid). A linear gradient to 40% solvent A and 
60% solvent B at 3.5 min, followed by an additional linear gradient to 5% solvent A and 95% 
solvent B at 8 min was used. Mass spectra were acquired in negative ion mode with the mass range 
set at m/z 100-3200. The conditions used for the ESI source included a capillary voltage of 3500 
V, a drying gas temperature of 332°C, a drying gas flow of 5 L/min, and a nebulizer pressure of 
45 psi as well as a fragmentor voltage of 225 V. MassHunter Workstation software (Agilent 
Technologies, CA) was used for data acquisition and processing. The extracted ion chromatogram 
(EIC) of 22A was exported from the total ion chromatogram (TIC) by monitoring the key fragment 
of 22A at m/z 656.6. Since 22A(-)Lys (21A) is the main metabolite of 22A peptide after 
administration, we also determined 22A(-)Lys levels. The EIC of 22A(-)Lys metabolite and IS 5A 
was extracted at m/z 832.5 and m/z 844.4, respectively. The total integral area of 22A peak and 
22A(-)Lys metabolite peak was used to calculate concentration of 22A. A pharmacokinetic non-
compartmental analysis (NCA) was also performed to derive basic pharmacokinetic parameters of 
peptide using Phoenix© WinNonlin® Version 7.3 (Pharsight Corporation, Mountain View, CA, 
USA), including maximum serum concentration (Cmax), area under the serum concentration-time 
curve (AUC), elimination rate constant (K10), elimination half-life (T1/2), total clearance (CL) and 
volume of distribution (Vss) for each rat using Phoenix© WinNonlin® Version 6.3 (Pharsight 
Corporation, Mountain View, CA, USA). Coefficient of variation was calculated for each 
parameter. 
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3.3.9 Quantification of serum phospholipids and cholesterol  
The levels of serum phospholipids (PL), total cholesterol (TC), and unesterified or free 
cholesterol (FC) were determined by enzymatic analysis, using commercially available kits (Wako 
Chemicals, Richmond, VA). Cholesterol ester levels (CE) were calculated as the difference 
between TC and FC levels at each time point. Briefly, serum samples were diluted with PBS (pH 
7.4) for TC and FC detection, or with Milli Q water for PL detection. Defined amounts of standards 
or diluted samples were transferred to 96-well plates (50 μL, 60 μL and 20 μL for TC, FC and PL 
analyses, respectively), and assay reagents were added per manufacturer’s instructions. The plates 
were gently shaken using an orbital shaker and incubated at 37 ˚C for 5 min. The UV absorbance 
at 600 nm was measured by a Synergy NEO HTS Multi-Mode Microplate Reader (Bio-Tek).  A 
pharmacokinetic non-compartmental analysis (NCA) was also performed to derive basic 
pharmacokinetic parameters of phospholipids using Phoenix© WinNonlin® Version 7.3 
(Pharsight Corporation, Mountain View, CA, USA). The pharmacodynamic effect in each mouse 
was determined as the area under the total effect curve (AUEC) from dosing time point to 48 hours 
after dosing, which were calculated by trapezoidal rule. Secondary pharmacodynamic endpoints 
(maximal effect [Emax] and time to Emax [Tmax, E]) were also analyzed to compare pharmacodynamic 
effects. The coefficient of variation was calculated for each parameter. 
3.3.10 Cholesterol distribution among lipoproteins 
To study the effect of sHDL or sHDL-PEG on lipoprotein profiles in vivo, cholesterol 
distribution between lipoprotein fractions was determined for rat serum collected at various post-
dose time intervals. Briefly, serum lipoproteins were separated by size using a Waters HPLC 
system equipped with a Superose 6, 10/300 GL column (GE Healthcare, Piscataway, NJ) and 
cholesterol distribution between VLDL, LDL, and HDL lipoprotein fractions was determined by 
post-column enzymatic reactions. Rat serum prior to dosing and 2, 4, 12 and 24 h post-injection 
was analyzed. Serum aliquots (50 μl) were injected and eluted with 154 mM sodium 
chloride/0.02% sodium azide solution at 0.8 ml/min. The post column reaction was used to 
determine cholesterol concentration as described in section 2.6.  
3.3.11 In vivo fluorescence imaging 
sHDL, sHDL-PEG2k (5%), sHDL-PEG2k (10%) and sHDL-PEG5k (10%) were labelled 
with fluorescent dye DiR using the same preparation method described in Section 2.2, with the 
addition of DiR in acetic acid. The final DiR concentration was 20 μg/ml.  Twelve 7-week old 
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male C57BL/6 mice (Harlan Sprague Dawley, Inc. Indianapolis, IN) were randomly divided into 
four groups of three mice per group. DiR-labelled nanoparticles were intravenously administered 
at a dose of 100 μg/kg DiR. Whole body optical images were obtained using an IVIS Spectrum 
Imaging System (Caliper, Fullerton, CA) at 1, 2, 4, 8 and 24 h post-injection. Immediately after 
the last time point, mice were perfused with PBS and their main organs, including hearts, livers, 
spleens, lungs, kidneys and brains, were collected and imaged.  The average fluorescence 
intensities were quantified as total photons per centimeter squared per steradian (p s-1 cm-2 sr-1) 
using the Living image® software package (Caliper Life Science, Hopkinton, MA). 
3.3.12 Statistical Analysis 
The significance of difference between data points, calculated Km and Vmax of cholesterol 
efflux, pharmacokinetic (Cmax, AUC, T1/2, K10, CL, Vss) and pharmacodynamic parameters (Emax, 
AUEC) were determined by one-way ANOVA analysis, with sHDL group as the control. Data are 
expressed as mean value with CV% of independent experiments. Statistical significance was 
established at p < 0.05, p < 0.01, p < 0.001 and p < 0.0001. 
3.4 Results 
3.4.1 Preparation and Characterization of PEG Modified sHDL Nanoparticles 
The sHDL selected for PEG modification was composed of 22A ApoA-I mimetic peptide 
and DPPC at 1:2 w/w (1:7.15 mol/mol) ratio of peptide:lipid. This composition was very similar 
to the composition of ETC-642, a peptide-based sHDL that has been tested in both single- and 
multiple-dose Phase I clinical trials in dyslipidemic patients144, 149. The molar ratio between peptide 
and phospholipid components of sHDL dictates both the size and purity of the resulting sHDL. 
For our study, a 1:2 weight ratio resulted in formation of homogeneous pre-like HDL nanodiscs 
with average diameter of 8 - 10 nm152. Therefore, the ratio between peptide and lipid was kept 
constant while a portion of DPPC was substituted for DPSE-PEG to achieve surface pegylation of 
sHDL. Two different molecular weights of PEG were used (2 kDa and 5 kDa) and DSPE-PEG 
were substituted for DPPC at either 2.5, 5 or 10 molar percent. One unmodified and four pegylated 
sHDL nanoparticle formulations were prepared and their compositions are summarized in Table 
3.1.  
The size distributions of sHDL and sHDL-PEG particles were determined by dynamic light 
scattering (DLS) (Table 3.1, Fig. 3.1A). The average diameter of non-pegylated sHDL was 9.2 ± 
0.3 nm, similar to other reported sHDL sizes152. The average particle size of sHDL increased 
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gradually with increasing amounts of surface modifications, from 10.4 ± 0.2, 11.4 ± 0.2 to 13.1 ± 
0.1 nm with addition of 2.5, 5 and 10% of PEG-2K, respectively. The size further increased to 14.9 
± 0.1 nm upon surface modification with the longer PEG-5K polymer. The homogeneity of particle 
size distribution was preserved, as evidenced by the low polydispersity index. Further 
characterization of sHDL nanoparticle size and purity was performed by gel permeation 
chromatography (GPC) (Fig. 3.2B). In agreement with our DLS findings, the GPC retention time 
decreased from 7.89 min to 6.45 min with pegylation, indicating the formation of larger particles.  
Table 3.1: The characterization summary of different 22A-sHDL particles. 
sHDL Formulations (molar ratio) RTa (min) Particle size (nm) PDIb 
22A: DPPC (1:7.15) 7.89 9.21 ± 0.29 0.36 ± 0.09 
22A: DPPC: DSPE-PEG2k (1:6.97:0.18) 7.78 10.44 ± 0.16 0.15 ± 0.06 
22A: DPPC: DSPE-PEG2k (1:6.79:0.36) 7.44 11.38 ± 0.22 0.24 ± 0.06 
22A: DPPC: DSPE-PEG2k (1:6.43:0.72) 6.92 13.06 ± 0.03 0.23 ± 0.06 
22A: DPPC: DSPE-PEG5k (1:6.79:0.36) 6.45 14.91 ± 0.02 0.26 ± 0.02 
aRT: retention time, bPDI: polydispersity index. 
 
 
Figure 3.2: Particle size distribution of different 22A-sHDL particles determined by dynamic light scattering (Panel 
A) and gel permeation chromatography (Panel B). 
 
3.4.2 Impact of PEG modification of sHDL surface on cholesterol efflux capacity  
The ability of PEG modified sHDL to facilitate cholesterol efflux was evaluated, using 
BHK cells stably transfected with either human ABCA1, ABCG1 or SR-BI transporters. Efflux 
from non-transfected or mock-transfected cells was measured for comparison. The cells were first 
loaded with 3H- cholesterol and then incubated with sHDL, sHDL-PEG2k (5%), sHDL-PEG2k 
(10%) or sHDL-PEG5k (5%) for 18 hours at concentrations of 0, 1.25, 2.5, 5, 10 or 20 μM 22A to 
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obtain dose-response curves (Fig. 3.3). The percent of cholesterol effluxed into the medium by 
sHDL was determined by counting the radioactivity in the medium and combined radioactivity of 
medium and lysed cells.  
The ABCA1 transporter is one of the major efflux mechanism for removing cholesterol 
from macrophages in the atheroma, and primarily interacts with the lipid-free and or lipid-poor 
forms of ApoA-I protein. In contrast, the ABCG1 transporter interacts with larger, more mature 
HDL to efflux cholesterol. The SR-BI transporter is found in the calveolar regions of macrophage 
and endothelial cell membranes and is responsible for mediating bi-directional cholesterol efflux 
and anti-inflammatory signaling induced by HDL. All four formulations showed significant ability 
to efflux cholesterol passively from the cellular membrane of BHK mock cells (Fig. 3.3D). 
Induction of ABCA1, ABCG1 and SR-BI transporters slightly increased cholesterol efflux. The 
amount of effluxed cholesterol reached saturation at 5-10 M of sHDL in all four cell types and 
for all sHDL formulations. In summary, pegylation of sHDL does not appear to shield the 
functional interaction between sHDL and cholesterol transporters.    
 
Figure 3.3: Cholesterol Efflux of cholesterol from BHK cells transfected with ABCA1 (Panel A), ABCG1 (Panel B), 
SR-BI (Panel C) and BHK-mock cell (Panel D) by sHDL particles. 
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3.4.3 Impact sHDL pegylation on cholesterol uptake by liver cells 
After cholesterol is effluxed from peripheral tissues by sHDL, it is taken up by hepatocytes, 
metabolized and excreted into the bile12. To evaluate the effect of sHDL pelygaltion on cholesterol 
and nanoparticle uptake by hepatic cells, sHDL particles were loaded with bodipy-labeled 
cholesterol as well as insoluble DiD dye and incubated with HepG2 cells.  Following various 
periods of incubation, cellular uptake of bodipy-cholesterol from both unmodified and pegylated 
sHDL was visualized by confocal imaging and quantified by flow cytometry (Fig. 3.4A and B). 
The bottom row shows the channel overlay, with nuclei in blue and bodipy-cholesterol in green. 
The fluorescence of bodipy appears to distribute throughout cellular membranes and cytosol for 
all groups and increase with longer uptake time. When bodipy uptake by HepG2 cells was 
quantified by flow cytometry no statistically significant differences were observed between 
different sHDL formulations. Thus, HDL nanoparticle pegylation at up to 10% with PEG-2k and 
up to 5 % with PEG-5K does not prevent cellular uptake of cholesterol by hepatocytes. This lack 
of cellular uptake difference could be due in part to the mobility of bodipy-cholesterol label. It is 
possible that bodipy-cholesterol diffused out of sHDL particles and was taken up by the cell as 
free bodipy-cholesterol leading to a similar apparent cell uptake. To access indirectly the 
contribution of sHDL-mediated cellular uptake of bodipy-cholesterol, we loaded different amount 
of bopipy-cholesterol per sHDL particle and performed cell uptake experiment at a constant 
bodipy-cholesterol concentration (Supplemental Fig. 3.10). At higher sHDL or sHDL-PEG 
concentrations when less bodipy-cholesterol is loaded per each sHDL particle, lower cellular 
uptake was observed indicating that at least some cholesterol uptake is mediated by sHDL-receptor 
interaction.  
When sHDL or sHDL-PEG particles were labelled with DiD fluorescent dye within the 
lipid bilayer, faster accumulation of DiD in HepG2 cells was observed in sHDL groups compared 
to pegylated sHDL groups (Fig. 3.4C and D). As more PEG was added to sHDL, the uptake of 
DiD became slower. However, after 2 hours of incubation, the sHDL-PEG2k (5%) group had the 
same fluorescence intensity as sHDL group, indicating the saturation of DiD uptake. This slower 
uptake could be caused by PEG shielding the interaction between sHDL particles and cell receptors 
and the lack of mobility of insoluble DiD label relative to bodipy-cholesterol. The slower HepG2 
uptake of pegylated sHDL could result in the increased sHDL circulation in vivo.  
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Figure 3.4: Cell uptake of bodipy-labelled cholesterol and DiD fluorescence dye by HepG2 cells  at various time 
points after incubation of sHDL particles containg bodipy-cholesterol (Panel A and B) and DiD (Panel C and D). The 
fluorescent intensity was quantified by flow cytometry (Panel B and Panel D). (*) denotes statistical significant 
differences of fluorescence intensities for each group compared with sHDL group with p < 0.05. 
 
3.4.4 Effect of sHDL pegylalion on lipoprotein remodeling in vitro  
Following in vivo administration, sHDL are known to undergo significant remodeling in 
blood, a process in which both lipid and protein components of sHDL nanoparticle exchange with 
lipid and protein components of endogenous lipoproteins153. The rate of this exchange and how 
composition of sHDL affects this rate is not well characterized. To examine if pegylation of lipid 
component of sHDL affects particle remodeling, the sHDL nanoparticles were incubated in serum 
for 1 h at 37C. By incorporation of fluorescently labelled DSPE-PEG2k-FITC in sHDL and 
monitoring fluorescence, we confirmed that pegylated lipid eluted with the HDL fraction before 
and after incubation with serum (Fig. 3.5B). We used post-column reaction to measure levels of 
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cholesterol in VLDL, LDL and HDL fractions before and after serum incubations with various 
sHDLs (Fig. 3.5A). After one hour incubation with non-pegylated sHDL, VLDL cholesterol levels 
appear to decrease and cholesterol distributes to smaller HDL particles likely due to partitioning 
to cholesterol-free sHDL. When sHDL-PEG-2K (5%) was mixed with serum, cholesterol 
redistribution toward HDL appears to be reduced.   
Potential differences in how serum incubations with pegylated and non-pegylated sHDL 
affect re-distribution of endogenous apoA-I between various HDL sub-classes were also examined 
by 1-D native page electrophoresis. Different free 22A peptide and various sHDLs formulation 
were added at either 0, 0.3, and 1.0 mg/ml peptide, incubated for 30 min, separated by 1-D native 
page electrophoresis and visualized by western blot for human ApoA-I (Fig. 3.5C). Compared to 
control serum (lane 1), addition of all sHDL formulations resulted in the appearance of a lipid-free 
band of ApoA-I (30 kDa) and in some instances a small pre- HDL particle or ApoA-I dimer 
around 60 kDa. For serum incubations with pegylated HDL, increase of ApoA-I signal in larger 
α-HDL was seen by the decreased intensity between 250 and 720 kDa. The increase in pre- HDL 
levels are considered to be a beneficial effect of sHDL infusions as this sub-class of smaller HDL 
is thought to be responsible for cholesterol efflux from macrophages by the ABCA1 transporter.154 
Thus, serum incubation with non-pegylated sHDL leads to more favorable endogenous HDL 
remodeling. However, formation of larger alpha-HDL, in case of pegylated sHDL incubations, 
could be just an artifact of increased hydrodynamic diameter of lipoprotein due to presence of PEG 
on the surface.   
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Figure 3.5: The cholesterol distribution between VLDL, LDL and HDL lipoprotein fractions  before and at 1 hour 
after incubation of sHDL and FITC labelled sHDL-PEG2k (5%) with human serum at 37 ⁰C (Panel A). The 
distribution of FITC-labelled PEG2k component in sHDL-PEG2k (5%) among lipoproteins after incubation was 
shown in Panel B. The ApoA-I distribution between various subclasses of HDL after 1 hr incubation was determined 
by 1-D native page electrophoresis and visualized by western blot using anti-apoA-I antibody (Panel C). Lane 1 was 
the control serum, lane 2, 3, 4, 5 ,6 represented free 22A, sHDL, sHDL-PEG 2k (5%), sHDL-PEG2k (10%), sHDL-
PEG5k (5%) at peptide concentration of 0.3 mg/ml. Lane 7, 8, 9 represented sHDL, sHDL-PEG 2k (5%), sHDL-
PEG2k (10%) at peptide concentration of 1.0 mg/ml.  
 
3.4.5 Pharmacokinetics of 22A peptide and phospholipids 
The pharmacokinetics of the peptide and phospholipid components of sHDL nanoparticles 
were examined following IV bolus administration in SD rats (Fig. 3.6). Nanoparticles with 
different degrees of pegylation were injected at 50 mg/kg dose of 22A peptide. The peptide 
concentration in serum was detected by LC-MS analysis. The total choline containing 
phospholipids in serum were measured by plate assay and the pre-dose levels of lipids were 
subtracted. The serum concentration kinetics data for peptide and lipid components of sHDL were 
fitted using a non-compartment analysis (NCA) by WinNonlin software (Version 7.3).  
Pharmacokinetic parameters derived included maximum serum concentration (Cmax), area under 
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the serum concentration-time curve (AUC), elimination rate constant (K10), elimination half-life 
(T1/2), total clearance (CL) and volume of distribution at steady state (Vss). 
 
Figure 3.6: Pharmacokinetics of 22A peptide and phospholipids after intravenous bolus of various sHDL to Sprague-
Dawley rats at 22A peptide dose of 50 mg/kg corresponding to 100 mg/kg dose of phospholipids. Serum peptide 
concentrations were determined by LC-MS and total choline containing phospholipids was measured by a commercial 
choline oxidase assay. (*) denotes statistical significant differences for each PEG-sHDL group compared with sHDL 
group with p < 0.0001. 
 
Similar 22A peptide PK profiles were observed among all treatment groups (Fig. 3.6), 
indicating that PEG modification had no effect on peptide elimination following sHDL 
administration in vivo. The elimination rate constants obtained from NCA analysis showed no 
significant difference among all groups and small inter-subject variability for each group. The 
calculated area under the curve (AUC) values were comparable in all groups as well (Table 3.2). 
Different from 22A peptide, the PK behavior of sHDL’s phospholipids was significantly altered 
by PEG addition. Phospholipids in sHDL-PEG5k (5%) had a higher peak concentration Cmax (578 
mg/dL) relative to the Cmax of unmodified sHDL (384 mg/dL) (p < 0.05). Higher surface density 
of PEG-2000 led to a longer lipid serum half-life in vivo and a higher AUC (Fig. 3.6 and Table 
3.3). The AUC increased gradually as more PEG was added, from 2071 mg*h/dL for non-
pegylated sHDL to 3042 and 4473 mg*h/dL for 5 and 10 mol% PEG-2k, respectively. Similarly, 
the addition of longer PEG chains at the same surface density of polymer led to a longer half-life 
and a larger AUC, with half-lives of 8.6 h for sHDL-PEG2k (5%) and 12.5 h for sHDL-PEG5k 
(5%) (NS) and AUC of 4473 mg*h/dL for sHDL-PEG2k (5%) and 6108 mg*h/dL for sHDL-
PEG5k (5%) (p < 0.01). 
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Table 3.2: Pharmacokinetic parameters (% CV) of 22A peptide after 50 mg/kg doses of sHDL, sHDL-PEG2k (5%), 
sHDL-PEG2k (10%) and sHDL-PEG5k (5%) treatments.  
Parameters 
Groups 
sHDL sHDL-PEG2k (5%) sHDL-PEG2k (10%) sHDL-PEG5k (5%) 
Cmax a (mg/dL) 633.5 (22.4) 677.1 (15.2)ns 612.3 (27.5)ns 712.0 (15.2)ns 
AUC b (mg*h/dL) 4185 (19.4) 4150 (22.6)ns 5885 (8.50)* 5163 (10.4)ns 
K10c (h-1) 0.1521 (7.94) 0.1693 (21.4)ns 0.1071 (33.7)ns 0.1377 (6.46)ns 
T1/2 d (h) 4.588 (8.58) 4.25 (17.4)ns 7.14 (28.8)ns 5.05 (6.34)ns 
CL e (dL/h) 0.0034 (21.4) 0.0032 (19.9)ns 0.0022 (8.40)* 0.0025 (9.18)ns 
Vssf (dL) 0.0221 (21.1) 0.0188 (9.84)ns 0.0216 (9.6)ns 0.0179 (13.3)ns 
aCmax: the maximum plasma concentration of peptide; bAUC: the area under the curve in plot of concentration of 
peptide against time; cK10: elimination rate constant; dT1/2: the half-life of elimination; eCL: total clearance for peptide; 
fVss: volume of distribution for peptide at steady state. Data was shown as mean with CV%. Significance: *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, ns: no significant difference compared with sHDL group. 
 
Table 3.3: Pharmacokinetic parameters (% CV) of total phospholipids after 50 mg/kg doses of sHDL, sHDL-PEG2k 
(5%), sHDL-PEG2k (10%) and sHDL-PEG5k (5%) treatments.  
Parameters 
Groups 
sHDL sHDL-PEG2k (5%) sHDL-PEG2k (10%) sHDL-PEG5k (5%) 
Cmaxa (mg/dL) 383.9 (28.0) 438.1 (9.5)ns 477.0 (27.3)ns 578.0 (4.8)* 
Tmaxb (h) 0.38 (38.5) 0.88 (28.6)* 1.6 (46.2)* 1.0 (0)*** 
AUCc (mg*h/dL) 2071 (21.7) 3042 (26.2)ns 4473 (11.8)*** 6108 (18.5)*** 
K10d (h-1) 0.17 (34.5) 0.11 (54.9)ns 0.072 (19.7)* 0.065 (37.9)* 
T1/2e (h) 4.59 (43.3) 8.62 (46.9)ns 9.96 (18.2)** 12.5 (38.2)* 
CLf (dL/h) 0.014 (23.6) 0.0088 (20.5)* 0.0057 (10.7)** 0.0044 (30.4)** 
VSSg (dL) 0.083 (19.7) 0.10 (37.2)ns 0.084 (28.0)ns 0.074 (27.4)ns 
aCmax: the maximum plasma concentration of phospholipids; bTmax: the time to observe Cmax; cAUC: the area under the 
curve in plot of concentration of phospholipids against time; dK10: elimination rate constant; eT1/2: the half-life of 
elimination; fCL: total clearance for phospholipids; gVSS: volume of distribution for phospholipids. Data was shown as 
mean with CV%. Significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns: no significant difference 
compared with sHDL group. 
 
The dichotomy of how pegylation did not affect pharmacokinetics of ApoA-I peptide 
component of sHDL but significantly altered elimination of phospholipid component was 
surprising. It became clear that pegylation of sHDL by insertion of pegylated lipid does not provide 
stealth properties to the entire nanoparticle, but rather just to the phospholipid bilayer component. 
This also points to the fact that following in vivo administration, sHDL undergoes extensive 
remodeling. The cholesterol-free lipid bilayers readily accept cholesterol; the ApoA-I peptide 
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components exchange with endogenous apolipoproteins; and the phospholipid themselves likely 
exchange with endogenous lipoprotein lipids.  
3.4.6 The impact of sHDL pegylation on in vivo pharmacodynamics 
To examine the potential therapeutic effect of sHDL pegylation on cholesterol metabolism 
in vivo, the pharmacodynamics biomarkers were measured following administration of 
nanoparticles to normal SD rats by IV infusion at a dose of 50 mg/kg 22A peptide. sHDL has been 
reported to facilitate cholesterol efflux from peripheral tissues through RCT, and the level of 
cholesterol in serum can be used to reflect the transient efflux of cholesterol induced by 
administration of sHDL. The levels of plasma total cholesterol (TC, Fig. 3.7A) and free cholesterol 
(FC, Fig. 3.7B) were determined directly, while esterified cholesterol level was calculated by 
subtracting free cholesterol level from total cholesterol level at each time point (CE, Fig. 3.7C). 
Pharmacodynamics parameters were calculated and summarized in Table 3.4. The typical 
pharmacological response following sHDL infusion is a rapid mobilization of free cholesterol into 
the plasma compartment, followed by a rise in cholesterol ester due to esterification by lecithin-
cholesterol acyltransferase (LCAT) and subsequent elimination of cholesterol by the liver. These 
expected effects were observed for sHDL infusions, with a maximum FC mobilization of 75 mg/dL 
at 0.5 h followed by a peak in CE (46 mg/dL) at 4 h, and elimination of all mobilized cholesterol 
by 24 h post-dose. In line with the improvements in phospholipid PK, the pegylated sHDL 
exhibited greater cholesterol mobilization and longer pharmacodynamic effect relative to non-
pegylated sHDLs.  Both the higher degree of surface modification by PEG and longer PEG chain 
lengths resulted in higher maximum effect levels for TC, FC, and CE increases. For example, the 
maximum mobilized FC levels increased from 75 mg/dL for non-pegylated sHDL, to 110, 125 and 
137 mg/dL for sHDL-PEG-2K (5%), sHDL-PEG-2K (10%) and sHDL-PEG-5K (5%). The area 
under the effect curve also increased for all pegylated formulations: from 422 mg*h/dL (sHDL) to 
1241 mg*h/dL (a 1.9-fold increase) for sHDL-PEG-2K (10%) and to 1588 mg*h/dL (a 2.8-fold 
increase) for sHDL-PEG-5K (5%). Hence, the longer lipid circulation time for pegylated sHDL 
resulted in greater levels of mobilized cholesterol and a longer duration of the effect.  
Table 3.4: Pharmacodynamic parameters (% CV) of total cholesterol (TC), free cholesterol (FC) and cholesterol ester 
(CE) after 50 mg/kg doses of sHDL, sHDL-PEG2k (5%), sHDL-PEG2k (10%) and sHDL-PEG5k (5%) treatments.  
 Parameters sHDL sHDL-PEG2k (5%) sHDL-PEG2k (10%) sHDL-PEG5k (5%) 
Tmax,Ea (h) 0.94 (82.6) 2.0 (70.7)ns 2.0 (0)* 3.3 (46.2)* 
Emaxb(mg/dL) 114.9 (25.4) 177.8 (8.1)** 181.4 (17.4)* 212.5 (7.7)** 
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T
TC 
AUECc (mg*h/dL) 562.8 (25.9) 1660 (37.2)* 2031 (13.1)**** 3171 (25.8)*** 
F
FC 
Tmax,E (h) 0.56 (55.9) 0.88 (28.6)ns 2.0 (0)**** 1.5 (38.5)* 
Emax (mg/dL) 74.6 (26.8) 109.6 (7.0)* 125.1 (31.6)ns 136.9 (12.0)** 
AUEC (mg*h/dL) 421.7 (36.5) 740.7 (31.5)ns 1241 (35.6)* 1588 (26.1)** 
C
CE 
Tmax,E (h) 1.2 (79.5) 4.3 (67.6)ns 5.0 (40.0)* 7.0 (28.6)** 
Emax (mg/dL) 46.4 (43.0) 76.2 (14.6)* 73.5 (39.8)ns 89.9 (33.5)ns 
AUEC (mg*h/dL) 372.9 (21.4) 869.6 (51.8)ns 1034 (41.3)* 1562 (32.1)** 
aTmax: time at which the Emax is observed. bEmax: the maximum plasma concentration of different cholesterol species. 
cAUEC: the area under the effect curve. Data was shown as mean with CV%. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001, ns: no significant difference compared with sHDL group. 
 
 
Figure 3.7: Pharmacodynamic assessment after IV administration of sHDL particles from the pharmacokinetic study. 
The level of total cholesterol (Panel A), free cholesterol (Panel B) and cholesterol ester (Panel C) in rat serum were 
determined by commercially available kits. (*) denotes statistical significant differences of TC, FC or EC changes for 
each group compared with sHDL group with p < 0.0001. 
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3.4.7 Distribution of mobilized cholesterol and lipoprotein remodeling in vivo  
In order investigate in greater detail the mechanism of cholesterol mobilization and 
elimination following administration of pegylated and non-pegylated sHDL particles, we 
determined the relative distribution of mobilized cholesterol in the HDL, LDL and VLDL fractions 
by HPLC. The positions of HDL, LDL and VLDL sized particles containing cholesterol are labeled 
on Fig. 3.8. The infusion of sHDL caused a rapid mobilization of cholesterol in the HDL fraction, 
with the maximum increase at 0.5 h post-dose (blue line, Fig 3.8A). The increase in HDL-C was 
accompanied by small increase in VLDL-C, and cholesterol returned to baseline levels by 24 h 
post-dose. The cholesterol profile changes were different when pegylated sHDLs were 
administered. Because pegylated sHDLs are slightly larger in size, the mobilized cholesterol 
appears to elute between HDL and LDL fractions at 0.5, 2 and 4 h post administration (Fig. 3.8B-
D). The increase in VLDL-C appears to be higher for all pegylated sHDLs relative to sHDL, 
especially for sHDL-PEG-2K (10%). It is possible that DSPE-PEG caused inhibition of lipoprotein 
lipase or stimulation of liver lipogenesis, which both lead to the transient increase in VLDL-C. 
However, for all formulations cholesterol increases were transient. The cholesterol level and its 
relative lipoprotein distribution returned to pre-dose levels, indicating completion of the RCT 
process triggered by administered sHDL. This type of increase in lipoproteins, including 
VLDL/HDL, has been observed in clinical trials, and the levels returned back to baseline at 24-72 
hours post dose.139, 145, 155-157.   
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Figure 3.8: The cholesterol distribution between VLDL, LDL and HDL lipoprotein fractions at different time points 
after IV injection of sHDL (Panel A), sHDL-PEG2k (5%) (Panel B), sHDL-PEG2k (10%) (Panel C) and sHDL-PEG5k 
(5%) (Panel D) to SD rats.  
 
3.4.8 In vivo distribution of sHDL and sHDL-PEG nanoparticles 
A bio-distribution study of sHDL or sHDL-PEG nanoparticles in mice was conducted by 
labelling particles with DiR. Results are summarized in the supplemental material (Supplemental 
Fig. 3.9). IThe whole-body mages were obtained at 1, 2, 4, 8, and 24 hours after intravenous 
injection of nanoparticles and tissues including heart, liver, spleen, lung, kidney and brain were 
harvested at 24 hours post-dose and imaged. From the whole-body imaging, sHDL-PEG groups 
have stronger signal than sHDL group at all time points later that 4 hours, and the fluorescence 
dye DiR mainly accumulated in liver. From the tissue distribution at 24 hours, both sHDL and 
sHDL-PEG formulations were found to accumulate in the liver and sHDL-PEG groups had much 
higher fluorescence intensity than sHDL group, indicating that longer circulation of pegylated 
sHDL results in increased accumulation in major organs.  
In this study, we successfully prepared pegylated sHDL with varying PEG surface densities 
of 5 and 10 mol%, as well as two different molecular weights of PEG, 2 kDa and 5 kDa. 
Incorporation of PEG resulted in a small increase in the sHDL hydrodynamic diameter, but the 
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overall size homogeneity was preserved. Owing to the relatively low degree of PEG surface 
modifications, pegylated sHDL retained their ability to efflux cholesterol by passive uptake and 
through ABCA1, ABCG1 and SR-BI transporters and facilitate uptake of cholesterol by HepG2 
cells. However, when insoluble DiO dye was incorporated in sHDL bilayer, pegylation reduced 
cellular uptake of sHDL. The differences in HepG2 uptake of bodipy-cholesterol and DiO could 
be attributed to difference in mobility of two dyes, and, hence different contribution of passive 
cellular uptake of the dye. The reduced uptake of bodipy-cholesterol with decreased of its loading 
in sHDL indicated that some of cholesterol uptake is receptor mediated.  
Despite high similarity in vitro, the performance of pegylated sHDL differed when 
nanoparticles were examined normal rats. Administration of pegylated sHDL led to greater extent 
of cholesterol mobilization and longer duration cholesterol elevation relative to non-pegylated 
sHDL (Fig. 3.7). Administration of pegylated and non-pegylated sHDL led to transient increases 
in HDL-cholesterol levels, following by increased LDL and VLDL-cholesterol levels and 
lipoprotein cholesterol profile returned to normal 24-hours post-dose (Fig. 3.8). The transient 
increase in VLDL cholesterol lasted longer for pegylated sHDLs relative to unpegylated one 
possibly due to higher levels of cholesterol mobilized by pegylated sHDL.  This type of increase 
in plasma HDL cholesterol levels following by transient increase in LDL and VLDL cholesterol 
levels has been observed in both pre-clinical and clinical studies for sHDL products (CSL-111, 
ETC-216, ETC-642, CER-001, CSL-112) and it has been used as biomarker of cholesterol efflux 
in vivo during product development.19, 149-150, 158-160. This is based on the fundamental mechanism 
of the reverse cholesterol transport (RCT) process, where a transient increase in plasma cholesterol 
should be detected as it is effluxed from peripheral tissues and transported to the liver for 
elimination. Interestingly, in vivo the pharmacokinetic effect appeared to be different from 
cholesterol mobilization. While some increases phospholipid circulation times and AUCs were 
observed after administration of pegylated sHDL, the ApoA-I peptide PK parameters remained 
unchanged (Fig. 3.6). Overall, 22A peptide appears to be eliminated more rapidly than sHDL’s 
lipid components. This indicates that peptide and lipid components of administered sHDL 
exchange in vivo with contents of endogenous lipoproteins and are eliminated independently. 
Some degree of remodeling was observed in vitro following incubation of serum with sHDL, with 
22A peptide displacing endogenous ApoA-I proteins from various sub-fractions of HDL (Fig. 3.5).  
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3.4 Discussion and conclusion 
Our intention was to improve the duration of sHDL pharmacologic effect by increasing 
stability of the entire sHDL nanoparticle in blood and, thus, increasing circulation time. Recent 
failures of CETP inhibitors brought into question the utility of systemically increasing HDL-C 
levels.161-165 CETP inhibition leads to the accumulation of cholesterol-rich HDL particles, while 
infusion of sHDL provides increased levels of cholesterol-poor HDL which are capable of 
additional cholesterol efflux from the atheroma.166-167 It has been reported that naked ApoA-I 
mimetics have anti-atherogenic activity.168 However, by administering naked peptide or naked 
ApoA-I intravenously or orally, lipoprotein changes were not observed.152, 169-170 Because of this 
finding ApoA-I and peptides were formulated with phospholipids to form sHDL nanoparticles for 
clinical trials. There is an emerging evidence that anti-atherogenic effect of ApoA-I mimetic 
peptides is due to their ability to sequester oxidized lipids in intestine.171-173 The mechanism is 
intriguing and we have not investigated the impact of pegylation on this mechanism since in this 
paper we focus on investigating the impact of pegylation on RCT. Another possible mechanism of 
ApoA-I peptide or sHDL activity is remodeling of LDL particles and reduction of their 
accumulation in the arteries.174-175 This potential mechanism was not examined in detailed in this 
study, although transient changes in LDL-C were observed (Fig. 3.8).  
While extensive pegylation of nanoparticles (20% of lipid) is known to improve their 
stealth properties176, we were concerned that 20% pegylation would interfere with sHDL’s ability 
to interact with cholesterol efflux transporters and liver scavenger receptors, leading us to choose 
modest pegylation levels for our sHDL preparations (5 and 10%). We have previously shown a 
modest reduction in sHDL internalization by SR-BI receptors expressed by colon carcinoma cells 
using fluorescently labelled sHDL containing only 5 mol% DSPE-PEG-2K relative to non-
pegylated sHDL177. When in vivo circulation times of fluorescently non-pegylated sHDL and peg-
modified sHDL (5 mol% DPPG-PEG2K) were compared by measuring fluorescence intensity by 
Zhang et al., no differences were observed178. Careful examination of how the degree of 
nanoparticle pegylation influence PK was performed by Liu et al176. When lipid-calcium 
phosphate nanoparticles of 30 nm in diameter were modified with DPPE-PEG2K at 5 mol%, no 
changes in PK or biodistribution were observed. In contrast, modification with 20 mol% lead to a 
significant improvement in plasma nanoparticle stability and a longer circulation time. Hence, 
using a higher molar content of PEG on the sHDL surface may lead to a more significant reduction 
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in sHDL remodeling by lipoproteins in vivo and further improvement in PK/PD profiles relative 
to those observed in the current study.   
In this study, the PK parameters of lipid component of sHDL were improved by pegylation, 
but the half-life of 22A peptide remained unchanged. This result confirms that sHDL particle is 
not eliminated in vivo in its intact form. It is likely that elimination rates of sHDL’s protein and 
lipid components depend on their exchange with endogenous lipoproteins. The signs of this 
remodeling were confirmed by ex-vivo incubation of sHDL with human plasma (Fig. 3.5), with 
22A peptide displacing ApoA-I protein on endogenous HDL, as is evident by the appearance of 
lipid-free ApoA-I band in western blot (Fig. 3.5). Previously, we observed longer circulation times 
for sHDL lipid components relative to 22A peptide, as well as extensive displacement of ApoA-I 
protein from endogenous HDL by 22A peptide.152 Some differences in elimination rates of protein 
and phospholipid components were also noticed in clinical studies of sHDL products. Indeed, 
faster elimination of ApoA-I (T1/2 ~ 10 h) was observed relative to phospholipid (T1/2 ~ 46 h) 
following administration of 45 mg/kg of CER-001, ApoA-I-sphingomyelin nanoparticles.179 The 
elimination of ApoA-I and lipid components of CSL-112, ApoA-I-soybean phosphatidylcholine 
nanoparticles, followed an opposite trend to CER-001 with a longer protein half-life of 36.4 h 
relative to phospholipid half-life of 18.0 h31. There are known differences in in vivo metabolism 
of DPPC used in this study to prepare sHDL, soybeanPC (CSL-112) and sphingomyelin (CER-
001).180 In addition, full-length ApoA-I has about 10 amphipathic -helical segments, resulting in 
stronger binding to phospholipid relative to the much smaller 22A peptide. Thus, it is possible that 
ApoA-I-based sHDLs are more stable and less susceptible to the remodeling in vivo relative to 
ApoA-I-peptide-based sHDL.  
Various strategies have been used to increase in vivo half-life of the ApoA-I component of 
sHDL. In one study, a trimer of the ApoA-1 protein was produced by recombinant expression181. 
An improvement in residence PK profiles was observed156, 182, but clinical development of trimeric 
ApoA-I was halted likely due to high manufacturing cost and immunogenicity concerns. Using a 
similar concept, crosslinked dimers, trimers and star-like multimers of ApoA-I mimetic peptides 
were synthesized to improve the in vivo stability, circulation time and efficacy of peptide-based 
sHDL.183 Having multiple -helixes to bind phospholipids resulted in longer in vivo circulation 
time and lower plasma cholesterol levels in murine model of atherosclerosis, but a reduction in 
atheroma volume was not reported.182 A different chemical approach, termed hydrocarbon 
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stapling, was employed by Sviridov et al. to stabilize peptide α-helices and improve cholesterol 
efflux, but the impact of stapling on RCT was not fully characterized.184 Finally, the ApoA-I 
protein of sHDL was selectively pegylated by attaching a single 20K PEG chain to protein N-
terminal by Murphy et al.147 Pegylation of ApoA-I did not reduce its ability to efflux cholesterol, 
but did improve protein circulation in vivo and led to the suppression of bone marrow myeloid 
progenitor cell proliferation in hypercholesterolemic mice. Pegylation also appeared to improve 
anti-atherosclerotic properties of HDL as observed by the reduction in atheroma necrotic core area 
and lipid content of the aortic arch relative to placebo. However, differences between pegylated 
and unmodified HDL were not significant. This indicates that the composition of pegylated sHDL 
needs to be further optimized for their plasma stability and pharmacokinetic properties prior to 
formal efficacy studies.  
The focus of this study was to understand how pegylation affects the RCT pathway 
facilitated by HDL. The impact of pegylation on cholesterol efflux in vitro and elevation of 
cholesterol levels in vivo were examined as biomarkers of RCT. However, the impact of pegylation 
on the anti-inflammatory and anti-thrombotic properties of sHDL has not yet been examined. In 
addition, the reduction in atheroma volume following HDL administration in animal models of 
atherosclerosis is the ultimate measure of sHDL’s efficacy in vivo. In addition, the mechanism by 
which ApoA-I peptide, sHDL We plan to perform these studies following development of a 
complete understanding of the impact of pegylation on the pharmacokinetics and in vivo stability 
of sHDL, in addition to selecting the optimal surface-modified sHDL formulation. 
The results of our study have broader impact of the field of sHDL design and nanoparticle 
drug delivery. This study underlines the importance of sHDL remodeling by endogenous 
lipoproteins in vivo in regards to sHDL’s PK and pharmacological effect. Hence, strategies for 
minimizing sHDL in vivo remodeling, such as crosslinking ApoA-I or lipid components, could 
potentially improve sHDL PK properties and efficacy. Similarly, HDL-like nanoparticles used for 
imaging and drug delivery purposes are likely to remodel in vivo, which could lead to rapid cargo 
release.141, 155, 157, 178 In the recent years, the formation of protein corona on the surface of 
nanoparticles used for drug delivery and imaging had emerged as a critical issue for in vivo efficacy 
of nanomedicines.185-187 Endogenous lipoprotein components were found to be major components 
of the protein corona.188 It has been reported that endogenous lipoproteins also rapidly remodel 
liposomal and micellar nanocarriers and alter cargo release.189-190 Thus, understanding the forces 
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driving lipoprotein remodeling in vivo and developing strategies to minimize it could lead to the 
design of more stable and efficacious sHDL based nanomedicines.  
3.5 Supplementary information 
 
Figure 3.9: The in vivo imaging of C57BL/6 mice after administration of sHDL, sHDL-PEG2k (5%), sHDL-PEG2k 
(10%) and sHDL-PEG5k (10%) at 1h, 2h, 4h, 8h, and 24h together with the ex vivo fluorescence images of isolated 
organs collected at 24 h post-injection  (Panel A). The average fluorescence intensities of tissues were analyzed using 
Living image® software (Panel B).  Data represent mean ± SEM (n=3). *: P<0.05 relative to sHDL group. 
 
Figure 3.10: Cell uptake of bodipy-labelled cholesterol loaded in sHDL or sHDL-PEG (10%) by HepG2 cells after 1 
h incubation. The particle concentrations are 1 mg/mL, 0.5 mg/mL and 0.1 mg/mL (Panel A). The fluorescent intensity 
was quantified by flow cytometry. 
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Chapter 4 : Nano-micelles mimicking high-density lipoproteins reverse atherosclerosis and 
prevent inflammatory response in animals 
 
4.1 Abstract  
Administration of high doses of synthetic high-density lipoproteins or “DrainoTM for the 
arteries” has led to atheroma volume reductions in patients with acute coronary syndrome (ACS). 
Because there is a high prevalence of cardiovascular disease, commercialization of synthetic high-
density lipoprotein (sHDL) treatment will require the manufacturing of metric tons of recombinant 
apolipoprotein A-I and lipoprotein nanoparticles, which is both technically difficult and costly. 
Here we introduce nano-micelle (NanoMCL), a structural nano-mimetic of sHDL with a small 
particle size (12-14 nm) and a hydrophobic core and hydrophilic exterior. We show that 
NanoMCLs are functionally similar to sHDL with the capacity to efflux cholesterol from 
macrophages and deliver the cholesterol molecules to hepatocytes for elimination. The NanoMCLs 
also have a 4-14-fold better ability to inhibit inflammatory cytokine release in vitro compared to 
sHDL. More importantly, when administered in vivo, NanoMCLs exhibit 2-fold improved 
cholesterol mobilization from peripheral tissues compared to sHDL, followed by elimination from 
the body within 48 hours. When tested in an endotoxemia model, NanoMCL exhibits similar to 
sHDL ability to inhibit inflammatory cytokine release both in prevention and in treatment settings. 
When administered as a 6-week treatment to a commonly used animal model of atherosclerosis—
ApoE k/o mice fed a high-fat diet, sHDL and NanoMCL induced reduction of atheroma by 21% 
and 40%, respectively. Further demonstrating superior anti-atherosclerotic efficacy to sHDL, 
NanoMCL treatment in the mouse model resulted in a reduced area of atheroma macrophages, a 
landmark of cardiovascular disease. Furthermore, treatments with either sHDL or NanoMCL were 
well tolerated as neither elevation of plasma toxicity biomarkers nor histological changes in liver 
tissues were detected. Taken together, we found that NanoMCL a structural and functional mimetic 
of the sHDL nanoparticle, was effective in relevant animal models. Owing to its simplistic 
composition and ease of preparation, we propose that NanoMCL could prove to be a valuable 
alternative to sHDL in treatment of ACS and other inflammatory diseases. 
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4.2 Introduction  
Cardiovascular disease (CVD) is the leading cause of death in the United States, 
responsible for approximately 17% of national health expenditures.135 Lipid metabolism 
imbalance and vascular inflammation lead to an accumulation of macrophages loaded with 
cholesterol in the sub-intimal space and  formation of lipid-rich vulnerable plaques in the arteries 
that could subsequently rapture and cause cardiovascular infarct which might lead to death.191-193  
While many approved cardiovascular therapeutics inhibit cholesterol synthesis and absorption, 
thus halting the development of new plaques, there are currently no available therapies that 
facilitate a reduction in an existing atheroma burden.194-195 Following a first heart attack, CVD 
patients are at a significant risk of having a secondary event within 6 to 12 months due to the 
presence of additional vulnerable plaques.196-197 Thus, administration of a therapeutic that 
functions like a “DrainoTM for the arteries” by rapidly removing excess lipids from the atheroma 
might prevent the occurrence of secondary events.  
Endogenous high-density lipoproteins (HDLs) facilitate the efflux of excess cholesterol 
from atheroma macrophages, mobilization of effluxed cholesterol into blood circulation and 
subsequent delivery of cholesterol to the liver for elimination via the reverse cholesterol transport 
(RCT) pathway.198 Endogenous HDLs are 8 to 12 nm nanoparticles with a hydrophilic exterior to 
promote plasma circulation and a hydrophobic interior to facilitate cholesterol capture.11  This 
HDL structure is supported by the helical protein apolipoprotein A-I (apoA-I) that wraps around a 
bilayer of phospholipids to form a small nanoparticle with a hydrophilic exterior and a 
hydrophobic core.141  The small particle size allows HDL to penetrate the endothelial layer into 
the core of the atheroma and interact with several extracellular receptors on macrophages to efflux 
cholesterol.199 However, in individuals with CVD, the number of functional HDL particles capable 
of cholesterol efflux is reduced.200 Thus, several synthetic HDL (sHDL) products have been 
designed and clinically tested for their abilities to reduce patients’ atheroma burden. For these 
sHDLs, apoA-I protein is either produced by a recombinant process or by purification from human 
plasma. The apoA-I protein is then combined with lipids to form the HDL nanoparticle. In CVD 
patients, 5 to 6 weekly doses of sHDL are capable of reducing plaques.201-202 The ability of the 
sHDL product, CSL-112, to reduce the rate of death, myocardial infraction or stroke is currently 
being tested in a large 17,400 patient phase III clinical trial.203-204 However, the doses required to 
produce a clinical effect are 40 mg/kg.20 Thus, a course of therapy will require approximately 20 
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grams of protein and treatment for a million of patients—a conservative estimate of the number of 
patients needing annual treatment—requires 20 tons of protein annually. The recombinant 
manufacturing process for apoA-I is very expensive due to the hydrophobic nature of this protein, 
relatively low expression levels and multiple purification steps required to remove protein-bound 
hydrophobic impurities. The current alternative, a plasma purified version of apoA-I, will likely 
result in shortages of plasma supply due to high market needs.  
Nanomaterials have been shown to mimic the structures and functions of human 
proteins.205 Nanoparticles and globular proteins are similar in overall size, charge, and shape, and 
the exterior surfaces of nanoparticles can be coated with organic functional groups similar to 
proteins, indicating that nanoparticles could function as protein mimics. Thus, to resolve the cost 
and scalability dilemma of producing apoA-I, several innovative nanotechnology-based functional 
mimetics of sHDL have been proposed.69, 71, 75-76  One such approach describes a HDL biomimetic 
that is built on a gold nanoparticle core with a functionalized surface via attachment of 
phospholipids and apoA-I proteins.69-70 Another approach describes a poly(lactic-co-glycolic) acid 
(PLGA) core functionalized with lipids and apoA-I mimetic peptides.75, 77 These HDL 
nanomimetics accumulate in atherosclerosis plaques and achieve the similar cholesterol efflux 
capacity as HDL.78 However, it has not been shown that these HDL nanomimetics are capable of 
reducing the atheroma area in the standard atherosclerosis animal models.  
In this study, we aimed to create a synthetic nanoparticle that mimics the structural and 
functional properties of sHDL. The main design criteria were: a) nanoparticles of a small HDL-
like 10 to 12 nm size to allow endothelial layer penetration and efflux of cholesterol from 
macrophages through cellular transporters; b) nanoparticles that mimic the amphipathic nature of 
HDL with a hydrophilic exterior for long circulation time in vivo and a hydrophobic interior with 
the ability to expand in size to allow for cholesterol sequestration in the nanoparticle core. To 
accomplish this goal, we combined phosphotidylcholine (PC) with polyethylene-glycol modified 
PC (PEG-PC) to obtain nanoparticles with fatty acids tails in the hydrophobic interior and 
hydrophilic phosphate head groups and PEG on the exterior at the target particle size of 10 to 15 
nm. Two selected HDL mimicking nanostructures of different sizes (NanoMCL-12 and 
NanoMCL-14) were compared with traditional sHDL composed of PC and apoA-I mimetic 
peptides. This particular sHDL had previously been tested in single and multiple dose clinical 
studies as ETC-642, and was found to be safe and capable of cholesterol efflux in patients.112, 206-
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207 Compared to sHDL, we found that our NanoMCLs have a similar ability to efflux cholesterol, 
had a 4-14-fold improved ability to inhibit LPS-induced inflammatory response, a 2-fold higher 
cholesterol mobilization capacity in vivo, and a 2-fold superior anti-atherogenic effect in ApoE-/- 
murine model of the disease.  
4.3 Materials and methods 
4.3.1 Materials 
ApoA-I mimetic peptides 22A (PVLDLFRELLNELLEALKQKLK) and 5A 
(DWLKAFYDKVAEKLKEAFPDWAKAAYDKAAEKAKEAA) were synthesized by Genscript 
(Piscataway, NJ). The peptide purities were determined to be over 95% by reserve phase HPLC. 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and N-(Carbonyl-
methoxypolyethyleneglycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-
PEG2k) were purchased from NOF Corporation (White Plains, NY). Bodipy-labeled cholesterol 
was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Lipopolysaccharide (LPS) (E. coli 
O111:B4) was purchased from Sigma Aldrich (St. Louis, MO). All other materials were obtained 
from commercial sources.  
4.3.2 Preparation of sHDL and NanoMCL nanoparticles 
All investigated particles were prepared using a co-lyophilization method. Briefly, to 
prepare sHDs, 22A peptide and DPPC were dissolved in glacial acetic acid at a molar ratio of 
0.14:1. Micellar nanoparticles (NanoMCLs) were prepared by dissolving DPPC and DSPE-
PEG2000 in glacial acetic acid at the molar ratios of 1:0.065, 1:0.131, 1:0.262, 1:0.523, 1:1.05 and 
1:2.09. After freeze-drying for over 24 hours, PBS (pH = 7.4) was added to hydrate the powders 
to a final lipid concentration of 27.24 mM. The mixture was vortexed briefly, heated to 50°C for 
10 min. and cooled to 25°C for 10 min. This cycle was repeated three times. sHDL particle and 
Nano-MCL concentrations are expressed in terms of total lipid concentration throughout this work.  
sHDL and micelle particles loaded with DiR fluorescent dye or bodipy-labeled cholesterol 
were prepared by a freeze-drying method and by dissolving DiR or labelled cholesterol in glacial 
acidic acid together with all other components. The final concentration of bodipy-cholesterol after 
hydration of the lyophilized powder was 30 μg/mL.  
4.3.3 Characterization of sHDL and Nano-MCL 
Particle size distribution of sHDLs and Nano-MCLs was determined by dynamic light 
scattering (DLS) using a Zetasizer Nano ZSP, Malvern Instruments (Westborough, MA) at 
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concentration of 2.7 μM. The average size and polydispersity index with standard deviation was 
reported. The particle morphology was assessed by transmission electron microscopy (TEM). The 
diluted sample solution was deposited on a carbon film-coated 400 mesh copper grid and dried for 
1 minute. Samples were then negatively stained with 1% (w/v) uranyl formate, and the grid was 
dried before TEM observation. All specimens were imaged on a 100kV Morgagni TEM equipped 
with a Gatan Orius CCD. 
4.3.4 Cholesterol efflux evaluation  
RAW 264.7 cells were grown in DMEM medium supplemented with 10% FBS, penicillin 
(100 units/ml) and streptomycin sulfate (100 mg/ml) in a humidified 5% CO2 atmosphere. 10
5 
cells were then seeded into 24-well plates and grown for 24 hours. Cells were washed with PBS 
(pH 7.4) once at room temperature and labeled with cholesterol for 24 hours in 
DMEM/BSA/antibiotic media (0.5 mL) containing 1 µCi of [3H] cholesterol/mL of media. 
Subsequently, labeled cells were washed twice with PBS (pH 7.4) to remove [3H] cholesterol that 
was not taken up by cells. Tritium-labeled cholesterol was effluxed from cells for 18 hours, using 
various lipid complexes at different concentrations in duplicate. Finally, all cell media (0.5 mL) 
was removed into separate Eppendorf tubes and centrifuged at 10,000 rpm for 5 min. The remained 
cells were lysed with a 0.1% SDS / 0.1M NaOH solution for 2 hours. Radioactive counts of media 
and cell fractions were measured separately using a Perkin Elmer liquid scintillation counter. 
Percent cholesterol effluxed from cells was calculated by dividing media counts by the total sum 
of media and cell counts and then multiplying this number by 100%.   
4.3.5 Liver cell uptake of cholesterol form sHDLs and NanoMCLs 
The uptake of bodipy-labeled cholesterol loaded in either sHDLs or NanoMCLs by HepG2 
cells was visualized by confocal laser scanning microscopy and quantified by flow cytometry. 
Briefly, liver hepatocellular carcinoma (HepG2) cells were cultured in Dulbecco’s Modified Eagle 
Medium with 10% FBS and 1% Pen Strep Glutamine and maintained in an incubator at 37°C and 
5% CO2. On day 0, 10
4 to 105 cells were seeded in a MatTek 35 mm petri dish in DMEM. The 
next day, media was aspirated and cells were washed with PBS (pH 7.4). Fresh media containing 
sHDLs or micelles loaded with bodipy-labeled cholesterol was added at a final lipid concentration 
of 272.4 µM. After incubation at 37 °C for 2 hours, cells were washed twice with PBS (pH 7.4) 
followed by fixation with 4% paraformaldehyde in PBS for 15 min at room temperature. 1% 
Triton-X solution was then added to the dish for 15 min and washed twice with PBS (pH 7.4). 
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Finally, the cell nuclei were stained with DAPI. The nuclei and bodipy fluorescence images were 
acquired on a Nikon A-1 Spectral Confocal microscope system (Nikon Corporation, Tokyo), with 
an excitation wavelength of 495 nm for bodipy. Quantification of the cellular fluorescent signal 
was performed using a cell sorter (Beckman Coulter FC500 5-colour analyzer) at an excitation 
wavelength of 495 nm. 
4.3.6 Anti-inflammation effect of sHDLs and NanoMCLs in vitro 
To evaluate the anti-inflammatory effect of sHDLs and NanoMCLs, RAW 264.7 
macrophage cells were seeded in 96-well plate on the first day. After a 24-hour incubation, 
cytokine release from macrophage cells was stimulated by addition of 2 ng/mL 
lipopolysaccharides (LPS). Subsequently, nanoparticles were added to the media immediately 
after the LPS at a 27.2 uM lipid concentration and incubated for 16 hours. The level of pro-
inflammatory cytokines, TNF-α and IL-6, in the media were measured with an ELISA kit (Thermo 
Fisher Scientific, Waltham, MA). HEK-Blue cells purchased from InvivoGen (San Diego, CA) 
were cultured in DMEM containing 10% low endotoxin FBS and selective antibiotics according 
to the manufacturer’s instructions. Growth medium was discarded, and cells were resuspended in 
HEK-Blue Detection medium. Cells were seeded at 25,000 cells per well. The cells were treated 
with sHDLs or NanoMCLs at 0.082 mM in a presence or an absence of 2 ng/ml of LPS and 
incubated for 18 hours. LPS binding to TLR4 results in activation of NF-κB reporter gene 
expression, causing the HEK-Blue detection medium to turn blue. The blue color was quantified 
by measuring absorption at 650 nm using a SpectraMax M3 plate reader from Molecular Devices 
(San Jose, CA). 
4.3.7 Pharmacokinetics and pharmacodynamics evaluation in rats 
The sHDL and NanoMCL nanoparticles were prepared at a final lipid concentration of 
54.48 μM in PBS (pH 7.4). Eight male Sprague-Dawley rats were randomly assigned to two groups 
of four rats each, sHDL and NanoMCL-12 (DPPC: DSPE2k = 1:2.09). All rats were fasted 
overnight before dosing and received different formulations at a dose of 136 µmol/kg based on 
lipids concentration via tail vein injection. Blood samples of approximately 0.3 mL were collected 
from the jugular vein in heparinized BD centrifuge tubes (BD, Franklin Lakes, NJ) at pre-dose and 
0.25, 0.5, 1, 2, 4, 8, 24 and 48 hours after dosing. Serum samples were separated immediately by 
centrifugation at 10,000 rpm for 10 minutes at 4°C and stored at -20°C until further analysis.  
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4.3.8  Quantification of serum lipids  
The levels of serum phospholipids (PL), total cholesterol (TC), and unesterified or free 
cholesterol (FC) were determined by enzymatic analyses using commercially available kits (Wako 
Chemicals, Richmond, VA). Cholesterol ester levels (CE) were calculated as the difference 
between TC and FC levels at each time point. Briefly, serum samples were diluted with PBS (pH 
7.4) for TC and FC detection, or with Milli Q water for PL detection. Defined amounts of standards 
or diluted samples were transferred to 96-well plates (50 μL, 60 μL and 20 μL for TC, FC and PL 
analyses, respectively), and assay reagents were added per manufacturer’s instructions. The UV 
absorbance at 600 nm was measured using a Synergy NEO HTS Multi-Mode Microplate Reader 
(Bio-Tek).  
4.3.9 Pharmacokinetics and pharmacodynamic analyses  
A non-compartmental analysis (NCA) was performed to derive basic pharmacokinetic 
parameters for phospholipids serum concentration versus time profile using Phoenix© 
WinNonlin® Version 7.3 (Pharsight Corporation, Mountain View, CA). Serum concentration of 
phospholipids, total cholesterol, free cholesterol and cholesterol ester versus time were plotted. 
The pharmacokinetics parameters of phospholipids was calculated and the pharmacodynamic 
effect in each rat was determined as the area under the total effect curve (AUEC) from dosing time 
point to 48 hours after dosing. Secondary pharmacodynamic endpoints (maximal effect [Emax] and 
time to Emax [Tmax, E]) were also analyzed to compare pharmacodynamic effects. The coefficient of 
variation was calculated for each parameter. 
4.3.10  Cholesterol distribution among lipoproteins 
Distribution of mobilized cholesterol between VLDL, LDL and HDL lipoprotein fractions 
following nanoparticle administration and exchange of cholesterol between lipoprotein throughout 
the 48-hour elimination process was monitored via lipoprotein analysis. Briefly, rat serum 
lipoproteins were separated by size using a Waters HPLC system equipped with a Superose 6, 
10/300 GL column (GE Healthcare, Piscataway, NJ). Cholesterol distribution among VLDL, LDL, 
and HDL lipoprotein fractions was determined by post-column enzymatic reactions. Rat serum 
collected prior to nanoparticle dosing and 0.5, 4, 24 and 48 hours post-injection was analyzed. 
Serum aliquots (50 μL) were injected and eluted with 154 mM sodium chloride/0.02% sodium 
azide solution at 0.8 mL/min. The post-column reaction was used to determine cholesterol 
concentration as described in our previous published work.208  
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4.3.11 Anti-inflammation effect of sHDLs and NanoMCLs in vivo 
The anti-inflammatory effects of sHDLs and NanoMCLs were compared in the murine 
endotoxemia model. 7 to 8 weeks old male C57BL/6 mice were purchased from Jackson 
Laboratories and randomly divided into four groups , containing 5 mice each: a) PBS, b) LPS, c) 
LPS and sHDL, and d) LPS and NanoMCL-12. In the first study, 0.05 mg/kg of LPS was mixed 
with either sHDL or NanoMCL-12 and dosed to mice by intraperitoneal (IP) injection. LPS alone 
and PBS injections were used as controls. In the second study, 0.05 mg/kg of LPS was dosed 
initially by intraperitoneal injection. Subsequently, different formulations were dosed at 27.2 
µmol/kg (based on the phospholipids concentration) by tail vein injection. All blood samples were 
collected from the jugular vein in heparinized BD centrifuge tubes (Franklin Lakes, NJ) at 2 hours 
after LPS dosing. Serum samples were separated immediately by centrifugation at 14,000 rpm for 
10 minutes at 4°C and stored at -80°C until further analysis. The concentrations of inflammatory 
cytokines of TNF-α in the serum were quantified using ELISA (Thermo Fisher Scientific, 
Waltham, MA) per manufacturer’s instruction.  
4.3.12 Bio-distribution and accumulation of particles in plaque area in mice 
To monitor if sHDL and NanoMCL particles could accumulate in the atheroma, ApoE-/- 
(knockout) mice were fed a high-fat high-cholesterol diet (21% fat, 34% sucrose, and 0.2% 
cholesterol; Harlan, T.D. 88137) for 6 weeks to develop atherosclerotic lesions. DiR fluorescent 
dye was incorporated into sHDLs and NanoMCLs for tracking. The final DiR concentration was 
20 μg/ml.   The accumulation of sHDLs or micelles in plaque were evaluated by intravenous 
administration of DiR-labelled particles at a DiR level of 100 μg/kg after 12-weeks of feeding. 
Aorta were isolated for imaging purpose at 72 hours after dosing using an IVIS Spectrum Imaging 
System (Caliper, Fullerton, CA).  
4.3.13 Anti-atherosclerotic efficacy study  
Eight-week-old male ApoE knockout mice purchased from the Jackson Laboratories were 
fed a high-fat high-cholesterol diet (21% fat, 34% sucrose, and 0.2% cholesterol; Harlan, T.D. 
88137) for 6 weeks to develop atherosclerotic lesions. Mice were then randomized into three 
groups and received an intravenous injection twice a week (Tuesday and Friday) of either sHDLs 
or NanoMCLs at a lipid dose of 136 µmol/kg or an equivalent volume (200 µl) of PBS as a control 
for another 6 weeks under the same feeding diet. At 72 hours after the last treatment, whole blood 
of mice were collected for serum clinical chemistry analysis, and the left ventricle of the heart was 
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perfused with PBS, followed by a fixative solution (4% paraformaldehyde in PBS). Liver was 
collected and kept in formalin for histological evaluation. To quantify the extent of the 
atherosclerotic lesions in the aortic root, the atherosclerotic lesions in the aortic sinus region were 
examined at three locations, each separated by 80 µm. The largest plaque of the three valve leaflets 
was used for morphological analysis. The lipid-burden plaque areas at the aortic sinus were 
determined by Verhoeff's staining.  The macrophage cells in plaques were stained using a galectin-
3 antibody (Mac-2; SANTA CRUZ Biotechnology, Santa Cruz, CA). To compare the effect of 
different groups, the area of stained lipid and macrophage were calculated using Image J. 
4.3.14 Analysis of serum clinical chemistry and liver histology  
As described in section 2.13, whole blood of ApoE knockout mice were collected at 72 
hours after the last treatment and serum was separated by centrifuge at 14.000 rpm for 10 min. 
Serum triglyceride, alanine aminotransferase (ALT) activity and aspartate aminotransferase (AST) 
activity were measured using kits (TR0100, MAK052, MAK055, Sigma-Aldrich, St. Louis, MO). 
Liver tissue was collected and fixed in 4% formalin after perfusion of the animals. Then the liver 
tissue was routinely processed and embedded in paraffin. 8 µm thick sections were cut and stained 
with hematoxylin and eosin (H&E) for histopathological examination. All sections were 
investigated using a light microscope.  
4.3.15 Lipogenesis study in mice 
Normal C57BL/6 mice were divided into three groups (5 animals per group) including a 
PBS control, sHDL and NanoMCL-12. sHDL or NanoMCL-12 was given at the lipid dose level 
of 136 µmol/kg through intravenous administration. At 24 hours post-injection, mice were 
euthanized by CO2 inhalation. After perfusion using PBS, liver tissues were collected and kept at 
-80 °C. Total RNA was purified from the liver tissues with TRIzol Reagent (Life technologies. 
Corp.), followed by reverse transcription with a SuperScript III kit (Invitrogen). qPCR was carried 
out with iQ SYBR Green Supermix (Bio-Rad). Cholesterol biogenesis related gene expression 
including Srebp2 and Hmgcr was determined. 
4.3.16 Statistical Analysis 
For comparisons and analyses between two groups, the significance of differences between 
data points, calculated pharmacokinetic and pharmacodynamic parameters were determined by the 
two-tailed unpaired Student's t-test. For comparisons among three groups or more, one-way 
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ANOVA analysis was performed followed by the Tukey’s test. Data are presented as mean ± SEM.  
A p-value < 0.05 was considered statistically significant. 
4.4 Results 
4.4.1 Preparation and characterization of nanoparticles 
We prepared the model sHDL nanoparticles using 22A apoA-I mimetic peptides and 
phospholipids (DPPC) combined at a 1:2 w/w (1:7.15 mol/mol) ratio of peptide to lipid. This 
composition was based on the composition of ETC-642, a peptide-based sHDL that has been 
previously tested in clinical trials in dyslipidemic patients.144, 149 The average diameter of sHDLs 
was determined by dynamic light scattering (DLS) to be 9.2 ± 0.3 nm (Table 4.1, Fig. 4.1A), 
similar to the reported sHDL size.152 To match the size of the nano-micelles (NanoMCL) with 
sHDLs, we combined increasing amounts of pegylated phospholipid (DPSE-PEG2000) with 
DPPC. We then prepared six NanoMCLs and their compositions and sizes are summarized in 
Table 4.1. The average particle size of micelles decreased gradually with the increase in DSPE-
PEG-2000 to DPPC ratio. We selected two micelles had similar size to sHDL, 14 and 12 nm, and 
low polydisperse for further investigation and named them NanoMCL-14 and NanoMCL-12, 
respectively. We further characterized the nanoparticle morphology using transmission electron 
microscopy (TEM) (Fig. 4.1B). In agreement with our DLS findings, the TEM images showed 
homogeneous size distribution for all three nanoparticles.  
Table 4.1: Characterization of sHDL and NanoMCL particles. 
Formulation (molar ratio) Particle size (nm) PDI 
22A: DPPC (0.14:1)  9.2 ± 0.3 0.16 ± 0.09 
DPPC: DSPE-PEG2k (1:0.0654) 699 ± 51  0.40 ± 0.01  
DPPC: DSPE-PEG2k (1:0.131) 403 ± 4.4 0.34 ± 0.03 
DPPC: DSPE-PEG2k (1:0.262) 30.9 ± 1.0  0.13 ± 0.01 
DPPC: DSPE-PEG2k (1:0.523) 27.8 ± 2.3 0.18 ± 0.01 
DPPC: DSPE-PEG2k (1:1.05) 14.2 ± 0.4 0.20 ± 0.01 
DPPC: DSPE-PEG2k (1:2.09) 12.2 ± 0.2 0.12 ± 0.01 
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Figure 4.1: Characterization of NanoMCLs and sHDLs. Particle size distribution determined by dynamic light 
scattering (Panel A) and TEM  (Panel B). 
 
4.4.2 Cholesterol efflux capacity of sHDLs and micelles 
Cholesterol filled macrophage-derived foam cells in the arterial wall are the hallmark of 
atherosclerosis. The removal of excess cholesterol from macrophage cells is important for reverse 
cholesterol transport process and reduction of plaque area.200 We evaluated the ability of sHDLs 
and NanoMCLs to facilitate cholesterol efflux using RAW 264.7 macrophages. The cells were 
loaded with 3H-cholesterol and treated with different concentrations of NanoMCLs and sHDLs to 
determine cholesterol efflux capacity of the nanoparticles. We determined the percent of 
cholesterol effluxed into the medium by nanoparticles by counting the radioactivity in the medium 
relative to combined radioactivity of the medium and lysed cells. All nanoparticles showed a 
significant ability to efflux cholesterol from the cellular membrane of macrophages (Fig. 4.2A). 
As the concentration of nanoparticles increased, the amount of effluxed cholesterol also increased 
and reached saturation at 70 to 80 M lipid concentrations for all nanoparticles. At low 
concentration, the sHDLs group had slightly higher cholesterol efflux capacity relative to 
NanoMCLs groups, while all three groups achieved a similar plateau at high concentrations. Taken 
together, NanoMCLs have similar cholesterol efflux ability in vitro compared to sHDLs.  
4.4.3 In vitro anti-inflammation effect of sHDLs and NanoMCLs 
The anti-inflammatory properties of sHDLs and NanoMCLs were evaluated in RAW 264.7 
macrophages. We induced an inflammatory response by addition of endotoxin (LPS) to stimulate 
the release of pro-inflammation cytokines such as TNF-α and IL-6.209 Nanoparticles sHDLs or 
NanoMCLs were added to cell culture media and we determined cytokine levels by ELISA to 
assess abilities of the nanoparticles to inhibit the inflammatory response (Fig. 4.2D and E). Both 
82 
 
sHDLs and micelles showed a significant inhibitory effect on the secretion of TNF-α likely due to 
their abilities to physically bind and neutralize LPS and possibly disrupt toll-like receptor 4 (TLR-
4) signaling by altering lipid raft microenvironment through cholesterol efflux.210 Compared to 
sHDLs, NanoMCLs had a 4 to 14-fold higher cytokine release inhibitory effect. The difference 
between the effects of sHDLs and NanoMCLs are potentially due to differences in their LPS 
binding capacity.  The HEK293-derived TLR-4 reporter cells were used to analyze neutralization 
of the LPS-induced inflammatory response by sHDLs and NanoMCLs. When activated by LPS, 
TLR4 receptor initiates a downstream signaling cascade resulting in activation of the NF-κB 
transcription factor, which we monitored in this assay. As shown in Fig. 4.2F, both sHDLs and 
NanoMCLs interfered with LPS interaction with TLR-4 resulting in the reduced activation of NF-
κB. The NanoMCL-12 group exhibited similar activity to sHDLs and appeared to be superior to 
NanoMCl-14 as measured by this assay. 
4.4.4 Cholesterol uptake by liver cells in sHDLs and NanoMCLs 
After cholesterol is effluxed from peripheral tissues by sHDLs, it is taken up by scavenger 
receptors on hepatocytes, metabolized and excreted into the bile.12 To evaluate cholesterol uptake 
by hepatocytes, sHDLs and NanoMCL particles were loaded with bodipy-labeled cholesterol and 
incubated with HepG2 cells for various time intervals. The kinetics of cellular uptake of bodipy-
cholesterol was visualized using confocal imaging and quantified by flow cytometry (Fig. 4.2B 
and 2C). The fluorescence of bodipy appears to distribute throughout the cellular membranes and 
cytosol for all groups. When bodipy-cholesterol uptake by HepG2 cells was quantified using flow 
cytometry and compared among different formulations, there were no significant differences 
observed between the sHDLs and NanoMCLs groups. Thus, we conclude that, similar to delivery 
of cholesterol by sHDLs, cholesterol can be taken up by hepatocytes when delivered by 
NanoMCLs.  
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Figure 4.2: Comparison of in vitro potency of NanoMCLs and sHDL. Cholesterol efflux from RAW 264.7 
macrophages (Panel A). Cholesterol uptake kinetics by HepG2 cells following incubation with bodipy-labeled 
cholesterol-loaded sHDL or NanoMCL nanoparticles imaged with confocal microscopy (Panel B) and quantified by 
flow cytometry (Panel C). Panel B shows the channel overlay, with nuclei in blue and bodipy-cholesterol in green. 
Release of inflammatory cytokines TNF-α (Panel D) and IL-6 (Panel E) after incubation of sHDLs or NanoMCLs with 
RAW 264.7 macrophages for 16 hours with pre-treatment of LPS. LPS-induced NF-kB activation in HEK-blue cells 
expressing TLR4-NF-kB reporters is reduced by addition of sHDLs and NanoMCLs (Panel F). *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, ns: no significant difference. 
 
4.4.5 Pharmacokinetic characterization of sHDLs and NanoMCLs 
We selected NanoMCL-12 for further evaluation in vivo based on our in vitro results 
showing NanoMCL-12 exhibited higher anti-inflammation efficacy and smaller particle size 
compared to other micelles analyzed. We compared the pharmacokinetics of sHDLs and 
NanoMCL-12 and the nanoparticles’ abilities to efflux cholesterol from the peripheral cells into 
blood compartment in the Sprague Dawley (SD) rat.  Both nanoparticles were administered at 136 
µM of phospholipids/kg dose by an intravenous bolus administration. This phospholipid dose was 
equivalent to 50 mg/kg dose of apoA-I peptide, the typical dose used in preclinical models.67, 208 
We measured the serum concentrations of the phospholipid components of sHDL and NanoMCL-
12 using a plate assay and subtracted the pre-dose levels of lipids (Fig. 4.3A). The 
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pharmacokinetics data were fitted using a non-compartment analysis (NCA) and pharmacokinetic 
parameters such as maximum serum concentration (Cmax), area under the serum concentration-
time curve (AUC), elimination rate constant (K10), elimination half-life (T1/2), total clearance (CL) 
and volume of distribution at steady state (Vss) were derived (Table 4.2). 
The PK behavior of sHDL phospholipids was significantly different from that of 
NanoMCL-12. Though there was no significant difference between the peak concentration Cmax of 
phospholipids in sHDL and NanoMCL-12, the peak time of NanoMCL-12 appeared much later 
than that of sHDL, at 8 hours after administration. The later Cmax for NanoMCL relative to sHDL 
may be due to  differences in biodistribution of the two nanoparticles.211 In addition, NanoMCL-
12 had a longer lipid serum half-life in vivo with value of 16 hours compared to 1.7 hours for 
sHDL. The AUC increased nearly 10-fold from 1063 mg*h/dL for sHDL to 10620 mg*h/dL for 
NanoMCL-12 resulting from the slower clearance. Thus, packaged in Nano-MCLs, phospholipid 
appear to have longer residence time in vivo, which might result in the ability to efflux and 
eliminate more cholesterol per injected dose.  
Table 4.2: Pharmacokinetic parameters (% CV) of phospholipids after admistration of sHDL and NanoMCL-12 at 
136 µmol/kg.  
Parameter 
Groups 
sHDL NanoMCL-12 
Cmax a (mg/dL) 383.9 (24.3) 481.8 (36.4) 
Tmaxb (h) 0.38 (33.3) 8.0 (0.00) **** 
AUCc (mg*h/dL) 1603 (26.0) 10620 (31.3) ** 
K10d (h-1) 0.4776 (41.8) 0.04885 (37.6) ** 
T1/2e (h) 1.686 (34.7) 16.07 (32.1) ** 
CLf (dL/h) 0.018 (26.9) 0.0027 (30.0) *** 
VSSg (dL) 0.0404 (26.1) 0.0649 (51.8) 
aCmax: the maximum plasma concentration of peptide; bAUC: the area under the curve in plot of concentration of 
peptide against time; cK10: elimination rate constant; dT1/2: the half-life of elimination; eCL: total clearance for peptide; 
fVss: volume of distribution for peptide at steady state. Data was shown as mean with CV%. Significance:*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, ns: no significant difference compared with sHDL group. 
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4.4.6 In vivo pharmacodynamics of sHDLs and NanoMCLs 
To examine the impact of increased circulation time of NanoMCLs relative to sHDLs on 
pharmacological response, we determined the changes in cholesterol metabolism biomarkers 
following administration of nanoparticles to normal SD rats by IV infusion. sHDLs has been 
reported to facilitate cholesterol removal from peripheral tissues through RCT, thus, transient 
increase in serum cholesterol levels reflects cholesterol efflux induced by administration of 
nanoparticles followed by its elimination by the liver. The levels of plasma total cholesterol (TC) 
and free cholesterol (FC) were determined directly, while esterified cholesterol level was 
calculated by subtracting free cholesterol level from total cholesterol level at each time point (CE) 
(Fig. 4.3D, E and F). Pharmacodynamics parameters were calculated and summarized in Table 2.3. 
The typical pharmacological response following sHDL infusion is a rapid mobilization of free 
cholesterol into the plasma compartment, followed by a rise in cholesterol ester due to 
esterification by lecithin-cholesterol acyltransferase (LCAT) and subsequent elimination of 
cholesterol by the liver. These expected effects were observed for sHDL infusions with a 
maximum FC mobilization of 75 mg/dL at 0.5 hours followed by a peak in CE (46 mg/dL) at 4 
hours, and elimination of all mobilized cholesterol by 24 hours post-dosing. In line with the 
improvements in PK, NanoMCL-12 exhibited greater cholesterol mobilization and longer 
pharmacodynamic effect relative to sHDL with peak time of 7 hours after infusion and maximum 
free cholesterol increase of 166 mg/dL. The area under the effect curve increased over 10-fold 
from 422 mg*h/dL (sHDL) to 4387 mg*h/dL (for NanoMCL-12). We observed a similar trend for 
the total cholesterol and cholesterol ester levels with significantly higher Emax and AUEC values 
for NanoMCL-12. However, cholesterol increase in both groups was transient, and the cholesterol 
level returned back to baseline after 24 hours for sHDLs and 48 h for NanoMCL-12 along with 
the elimination of particles. Hence, the longer lipid circulation time for NanoMCL-12 resulted in 
greater levels of mobilized cholesterol and a longer duration of the effect, which, in turn, should 
lead to a higher amount of cholesterol eliminated from the body and superior anti-atherosclerotic 
effect of NanoMCLs relative to sHDLs.  
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Table 4.3: Pharmacodynamic parameters (% CV) of total cholesterol (TC), free cholesterol (FC) and cholesterol ester 
(CE) after admistration of sHDL and NanoMCL-12 at 136 µmol/kg.  
 Parameter sHDL NanoMCL-12 
TC 
Tmax,Ea (h) 0.75 (33.3) 6.0 (33.3)** 
Emaxb(mg/dL) 114.9 (22.0) 237.9 (16.4)** 
AUECc (mg*h/dL) 562.8 (22.4) 6607 (24.1)*** 
FC 
Tmax,E (h) 0.56 (48.4) 7.0 (24.7)*** 
Emax (mg/dL) 74.6 (23.2) 165.9 (20.5) ** 
AUEC (mg*h/dL) 421.7 (31.6) 4387 (28.9)*** 
CE 
Tmax,E (h) 1.2 (68.8) 15 (60.7)* 
Emax (mg/dL) 46.4 (37.2) 84.7 (17.8)* 
AUEC (mg*h/dL) 372.9 (18.6) 2220 (14.7)**** 
aTmax: time at which the Emax is observed. bEmax: the maximum plasma concentration of different cholesterol species. 
cAUEC: the area under the effect curve. Data was shown as mean CV%. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
 
4.4.7 Distribution of mobilized cholesterol and lipoprotein remodeling in vivo  
To investigate in greater detail the mechanism of cholesterol mobilization and elimination 
following administration of sHDLs and NanoMCLs, we determined the relative distribution of 
mobilized cholesterol in the HDL, LDL, and VLDL fractions by HPLC. The positions of HDL, 
LDL, and VLDL sized particles containing cholesterol are labeled on Fig. 4.3B and C. The infusion 
of sHDL caused a rapid mobilization of cholesterol in the HDL fraction, with the maximum 
increase at 0.5 h postdose (blue line). The increase in HDL-C was accompanied by small increase 
in VLDL-C, and cholesterol returned to baseline levels by 24 hours post-dosing. The cholesterol 
profile changes were different when NanoMCL-12 were administered. Because NanoMCL-12s 
are slightly larger in size than sHDLs, the mobilized cholesterol appeared to elute between the 
HDL and LDL fractions at 0.5 and 4 hours post-administration. The increase in VLDL-C appeared 
to be higher for NanoMCL-12s relative to sHDLs. It is possible that DSPE-PEG caused inhibition 
of lipoprotein lipase or stimulation of liver lipogenesis, which both lead to the transient increase 
in VLDL-C. However, for both formulations, cholesterol increases were transient. The cholesterol 
level and its relative lipoprotein distribution returned to pre-dose levels, indicating completion of 
the RCT process triggered by administered sHDLs and NanoMCL-12s. 
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Figure 4.3: Comparison of sHDL and NanoMCL-12 pharmacokinetics and pharmacodynamics in the rat. 
Pharmacokinetics of phospholipids after IV bolus administration of 136 µmol/kg of sHDLs or NanoMCL-12s in the 
Sprague Dawley rat. Change in plasma lipids was measured by choline oxidase assay (Panel A); Distribution of 
mobilized cholesterol among VLDL, LDL and HDL lipoprotein fractions following administration of sHDLs (Panel 
B) and NanoMCL-12s (Panel C). Mobilization of cholesterol from prerripheral tissues into blood compartment. The 
change in levels of total cholesterol (TC, Panel D), free cholesterol (FC, Panel E) and cholesterol ester (CE, Panel 
F) in rat serum was determined using commercially available kits. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 
ns: no significant difference.  
 
4.4.8 In vivo anti-inflammation effect of sHDLs and NanoMCLs  
To further examine functional similarities of NanoMCLs and sHDLs, we examined their 
abilities to inhibit inflammatory cytokine release in a mouse endotoxemia model. In clinical trials, 
co-administration of endotoxin mixed with sHDLs in health subjects resulted in reduced 
inflammatory cytokine release, control of blood pressure and a marked decrease of the severity of 
clinical symptoms relative to administration of endotoxin alone.79 To simulate this study, we dosed 
normal C57BL/6 mice with either LPS alone (0.05 mg/kg mixed with PBS) or co-administered 
either with sHDLs or NanoMCL-12s. When LPS alone was administered to the mice, release of 
TNF-α was observed at 2 hours post-dosing. In contrast, co-administration of LPS with sHDLs or 
NanoMCL-12s significantly reduced TNF-α release by 10.7 and 3.7-fold (p<0.01, Fig. 4.4A).  
To simulate a more realistic scenario of infection-induced sepsis and nanoparticle treatment, 
we next dosed C57BL/6 mice with LPS by intraperitoneal injection, while sHDLs and NanoMCL-
12s were administered subsequently by IV bolus at a 27.2 µmol/kg dose as a rescue treatment. 
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Two hours later, we collected whole blood and isolated serum to quantify cytokines levels. Both 
sHDL and NanoMCL-12 groups exhibited notable inhibition of TNF-α release 2 hours post 
endotoxin challenge (Fig. 4.4B). TNF-a is known a rapid response cytokine elevated shortly after 
endotoxin challenge, thus, it is logical that we saw functional changes in TNF-a at this time point. 
Taken together, NanoMCL exhibits both cholesterol efflux and anti-inflammatory functions of 
sHDL in vivo.  
4.4.9 Accumulation of sHDLs and NanoMCLs in atherosclerotic plaque 
We examined the ability of NanoMCLs and sHDLs to accumulate in atheroma in ApoE-/- 
mice that were fed a high-fat diet for 12 weeks to develop atherosclerosis. NanoMCL-12s and 
sHDLs were fluorescently labelled by incorporation of DiR dye and dosed by intravenous 
administration at a 100 μg/kg DiR dose corresponding to 136 µmole/kg lipid dose. At 72 hours 
after dosing, the entire aorta was isolated for IVIS imaging (Fig. 4.4C). From the images, both 
sHDLs and NanoMCL-12s successfully accumulated in the heart and plaque area enabling the 
potential interaction between sHDLs and micelles with macrophages for cholesterol efflux. The 
accumulation of both particles can last at least three days after administration due to the 
hydrophobicity of the particles and the specific distribution can potentially reduce the side effect 
caused by systemic treatment.  
4.4.10 Anti-atherosclerosis efficacy of sHDLs and NanoMCLs 
The ability of sHDLs and NanoMCLs to reduce the atherosclerotic burden was evaluated 
in ApoE-/- mice. ApoE-/- mice were placed on high fat diet for 6 weeks to develop atherosclerosis 
and were randomly divided into three groups for treatment with either PBS, sHDL or NanoMCL-
12s for 6 weeks. We dosed the mice intravenously twice weekly at the dose level of 136 µmol/kg. 
Following the conclusion of treatment regimens, animals were euthanized and aortic root were 
excised for plaque area analysis by Verhoeff's staining (Fig. 4.4D) and Mac-2 macrophage staining 
(Fig. 4.4E).  
Compared to PBS control groups, the atheroma area was reduced significantly following 
the 6-week treatment of either sHDLs or NanoMCL-12s.  There was a 21% reduction in plaque 
area following sHDLs administration and 40% reduction (p <0.01) for NanoMCL-12s compared 
to the non-treatment group (Fig. 4.4D) suggesting that consistent with a higher efflux capacity in 
vivo, NanMCL-12 sexhibit greater anti-atherosclerotic potency in the ApoE-/- murine model.  The 
Mac-2 staining signal represents the macrophages infiltration in aorta root area, which is a 
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biomarker for inflammation and plaque formation.212-213 Compared to the PBS control group, 
sHDL treatment did not significantly influence the Mac-2 positive macrophage area, while 
NanoMCL-12 group showed a 36% reduction of macrophage positive plaque burden relative to 
placebo (p <0.05). By inhibiting the macrophage infiltration into the arterial wall, the induction of 
an early atherosclerotic lesion development can be prevented.214 Taken together NanoMCL 
exhibits superior to sHDL ability to reduce atherosclerotic burden and prevent atherogenesis in 
murine model of the disease.  
 
Figure 4.4: Pharmacological effects of NanoMCL and sHDL in murine models of inflammation and atherosclerosis. 
Serum concentration of TNF-α in C57BL/6 mice at 2 h after co-administration of sHDLs or NanoMCL-12s (27.2 
µmol/kg) with LPS (0.05 mg/kg) by IP route (Panel A) and administration of LPS by IP followed by administration of 
sHDLs or NanoMLC-12s by IV at the same doses (Panel B). (n=5/group; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001, ns: no significant difference)  Accumulation of DiR-labelled sHDL or NanoMCL-12 particles in 
plaque in ApoE-/- mice fed a high fat diet for 12 weeks (Panel C). Effect of sHDLs and NanoMCL-12s on 
atherosclerosis regression in ApoE-/- mice. Mice were fed for 6 weeks, and dosed at 136 µmol/kg on every Tuesday 
and Friday for 6 weeks. Aortas were dissected and plaque areas were visualized by Verhoeff's staining (Panel D) and 
macrophage s in aortas sections were visualized by Mac-2 stain (Panet E). Representative lesion images and 
corresponding quantitative analyses of the aortic root cross-sections are shown. (n=12/group; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, ns: no significant difference). 
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4.4.11 Safety evaluation after treatment with sHDLs and micelles 
We next studied the potential side effects and liver toxicity caused by sHDL or NanoMCL 
administration in ApoE-/- mice. H&E staining of liver tissues indicated no obvious damage to liver 
tissues when either sHDLs or NanoMCL-12s were administered (Fig. 4.5A). Plasma AST or ALT 
levels determined 72 hours following the last dose were similar for all groups indicating no 
reduction in liver function (Fig. 4.5C and D). In addition, plasma triglycerides level, were identical 
among the nanoparticle groups (Fig. 4.5E). Then we assessed the effect of sHDL or NanoMCL in 
C57BL/6 mice at dose level of 136 µmol/kg (Fig. 4.5B). At 24 hours after intravenous 
administration of nanoparticles cholesterol biosynthesis related genes expression were examined. 
Srebp2 expression were not changed while Hmgcr expression in the liver was slightly down-
regulated in NanoMCL-12 group. The elevation of plasma AST, ALT and triglyceride levels are 
hallmarks of sHDL nanoparticles toxicity resulting from the need for the liver to metabolize large 
quantities of mobilized cholesterol. The sHDL nanoparticles used in this ApoE-/- study were found 
to be safe in dyslipidemic patients at a similar dose level (~ 11.4 µmol/kg peptide) and safe in non-
human primates at 2-fold higher doses.112, 215 Since no significant liver enzymes and triglyceride 
elevation had been observed for sHDL or NanoMCL at therapeutic doses, we expect that 
NanoMCL will have comparable safety to that of sHDL in humans.  
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Figure 4.5: Safety comparasion between sHDL and NanoMCL-12. H&E staining of liver tissues after 6-week 
treatment of either PBS, sHDL or NanoMCL-12 in ApoE-/- mice (scale bar 300 µm) (Panel A). The expression of genes 
involved in cholesterol biogenesis in the liver at 24 h after administration of sHDLs or NanoMCL-12s at 136 µmol/kg 
in wildtype mice (Panel B) (n= 5/group). Serum concentration of ALT (Panel C), AST (Panel D) and triglyceride 
(Panel E) after 6-week treatment with either PBS, sHDLs or NanoMCL-12s in ApoE-/- mice (n=12/group). 
 
4.5 Discussion and conclusion 
In this study, we successfully established the NanoMCL system that mimics sHDLs in 
structure and function. The NanoMCL particles we selected were similar to sHDLs (about 12 nm) 
with a hydrophobic core and hydrophilic shell. Compared to sHDLs, micelles exhibited similar 
cholesterol efflux from macrophages (Fig. 4.2A), similar cellular uptake by liver cells (Fig. 4.2B 
and C), and had a more potent anti-inflammation effect in macrophages (Fig. 4.2D, E and F).  
Despite a high similarity in vitro, the performance of micelles differed when the two different types 
of nanoparticles were examined in normal rats. Administration of micelles led to greater extent of 
cholesterol mobilization and a longer duration of cholesterol elevation relative to sHDLs (Fig. 4.3) 
due to longer NanoMCL circulation in vivo. Administration of sHDLs and NanoMCLs led to 
mobilization of cholesterol into the infused particles and transfer of mobilized cholesterol to larger 
LDL and VLDL particles, yet all lipoprotein cholesterol levels returned to baseline 48 hours post-
dosing (Fig. 4.3B and C).  In our therapeutic experiment, both sHDLs and NanoMCLs reached 
atheroma after IV dosing and achieved a significant reduction of plaque burden following a 6-
week treatment of atheroma-bearing ApoE-/- mice. Surprisingly, NanoMCLs showed greater anti-
atherosclerosis efficacy relative to sHDLs, with a 40% atheroma area reduction compared to 21% 
for sHDLs. Following the 6-week treatment, there were no documented histological changes in the 
liver and no serum safety biomarkers were observed, indicating comparable safety of NanoMCLs 
and sHDLs at the therapeutic dose levels (Fig. 4.5). Thus, simple NanoMCL nanoparticles appear 
to function just like sHDL in vivo, providing an easy to manufacture and economic alternative to 
sHDLs as NanoMCLs are prepared without the need for expensive recombinant apoA-I proteins 
or peptides.  
The utility of HDL as a therapeutic target had been challenged in recent years due to 
failures of several cholesterol ester transfer protein (CETP) inhibitors in large phase III clinical 
trails.164, 216 These therapeutic agents inhibit transfer of cholesterol ester from HDL to LDL, 
resulting in increased levels of circulating HDL cholesterol rather than an increase in the numbers 
of functional HDL particles. Thus, chronic dosing with CETP inhibitors results in plasma 
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accumulation of larger, cholesterol ester-loaded HDL particles that have limited capability for 
additional cholesterol efflux.  In contrast, infusion of cholesterol-free sHDL nanoparticles has the 
proven ability to rapidly efflux an excess of cholesterol from peripheral tissues. After just 5 to 6 
infusions, the treatment leads to a drastic reduction in atheroma volume in CVD patients, as seen 
by intravascular ultrasound imaging in clinical studies.41, 217-218 Prior studies demonstrated that 
IVUS imaging studies are capable of detecting significant atheroma reduction in patients with a 
substantial plaque burden, while it is more difficult to measure atheroma reduction in “healthier” 
patients due to intrinsic errors in imaging techniques.219 Still one important clinical question 
remains: Can acute reduction in atheroma volume lead to a reduction in cardiovascular deaths, 
heart attacks and strokes. To address this question, a large phase III clinical trial is currently 
ongoing in 17,400 patients treated with either placebo or an sHDL drug  (CSL-112).203-204 In 
addition, significant interest in the field remains for the use of sHDL therapeutics for treating 
systemic inflammatory diseases like sepsis, lupus and rheumatoid arthritis.79, 220-221 Therefore, the 
NanoMCLs we describe here could be potentially useful beyond cardiovascular applications.   
Several other investigators have developed biomimetic HDLs for either treatment or 
imaging of atherosclerosis and for drug delivery purposes.69-77 For example, Marrache et al. 
reported the construction of a synthetic, biodegradable HDL-NP platform for detecting vulnerable 
plaques by targeting the collapse of the mitochondrial membrane potential that occurs during 
apoptosis.77 The particle has an average size of approximately 120 nm and contains a poly(lactide-
co-glycolide) polymer, cholesteryl oleate, and phospholipid with triphenylphosphonium (TPP) 
decorated with apoA-I mimetic peptide 4F. In addition, quantum dots (QDs) have been 
incorporated into a PLGA matrix for imaging purposes. In vitro evaluation of this technique 
showed a promising detection ability for optimal imaging and therapeutic potential as well as a 
favorable biodistribution and pharmacokinetics. Sanchez-Gaytan et al. developed a hybrid 
polymer/HDL nanoparticle composed of a lipid/apolipoprotein coating that encapsulates a PLGA 
core.75 This PLGA-HDL 30 to 90 nm sized nanoparticle displayed some characteristics of 
endogenous HDL, including preferential uptake by macrophages and had an effective in vitro 
cholesterol efflux capacity. Presence of a PLGA nanoparticle core also enables incorporation, 
sustained release and atheroma targeted delivery of therapeutic agents. PLGA-HDL nanoparticles 
were able to accumulate in atherosclerotic plaques and co-localized with atheroma macrophages 
in an ApoE-/- mouse model.  Thaxton et al. synthesized a spherical HDL nanoparticle with an Au 
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NP core-shell structure, in which the Au NP core serves as a size- and shape-controlling scaffold 
for constructing an HDL-like particle by surface attachment of phospholipids and apoA-I. The 
nanoparticles were designed to have a similar size to endogenous HDL and to mimic the general 
surface composition of HDL to enable physical binding of cholesterol and cellular cholesterol 
efflux in vitro.69, 78 Biomimetic HDL nanoparticles demonstrated the ability to accumulate in the 
atheroma and, in some instances, had local anti-inflammatory effects.79-80 However, to the best of 
our knowledge, neither the abilities of these biomimetic HDL to reduce atheroma in disease 
bearing animals have been confirmed and none of these nanoparticles have been compared head 
to head with the sHDLs that have been tested in clinical trials. In addition, most of biomimetic 
HDL nanoparticles have a larger particle size and density compared with endogenous HDL likely 
resulting in differences in biodistribution, HDL receptor interaction and hepatic uptake mechanism 
of mobilized cholesterol.  
With the growing tendency in the field to increase the complexity of nanomedicine designs, 
our approach to create a simple HDL-mimicking micelle appears to be almost “primitive”. Yet, 
simple ideas often win in clinical translation, as both manufacturing cost and quality of complex 
products are difficult to control. Both ingredients of NanoMCLs, PC and pegylated-PC, are 
approved excipients for parenteral administration. Moreover, the process of two-component 
mixing that results in the formation of nanoparticles with a target size of 12 nm capable of 
cholesterol efflux as determined by a cell-based bioassay is relatively straight forward. Thus, 
NanoMCL manufacturing could be established under quality scrutiny required for producing 
clinical grade material. There are multiple examples of simplistic products advancing to clinical 
development in the cardiovascular and inflammatory disease fields. For example, ETC-588, a type 
of blank liposome, has shown efficacy in ischemia patients in a Phase II trial working in 
combination with222222222222222 endogenous HDL that would efflux cholesterol from atheroma and 
deposit in circulating sink of blank liposomes for eventual elimination by the liver.223 A 
phospholipid emulsion, GR270773, was developed by GSK as a treatment for sepsis. It works by 
scavenging endotoxins (lipopolysaccharides) released by bacteria.222 There have also been micro-
emulsions of triglycerides and phospholipids (Intralipid®) that have been tested in clinical studies 
aiming to treat pharmacotoxicity.224-225 Synthetic HDL nanoparticles had been shown to bind 
endotoxins and inhibit inflammatory responses in human studies and able to rapidly regress 
atheroma in CVD patients.79, 226 As our simple NanoMCL system appears to have a higher capacity 
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for binding endotoxin and cholesterol as compared to sHDLs, NanoMCLs likely could provide an 
exciting translational opportunity for treatment of CVD, sepsis and other diseases involving 
scavenging hydrophobic molecules.  
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Chapter 5 : Development of sHDL based drug delivery system for glioma therapy 
5.1 Abstract 
Glioblastoma multiforme, GBM, is a fast-growing, aggressive type of central nervous 
system tumor that forms on the supportive tissue of the brain. Docetaxel (DTX) is a 
chemotherapeutic agent clinically used for treatment of various solid tumors. CpG, 
oligodeoxynucleotide, is toll-like receptor 9 (TLR9) agonist that can stimulate host immune 
response to tumor cells. Due to the intrinsic targeting property of sHDL through the interaction 
with scavenger receptor BI (SR-BI) expressed on GBM cells, DTX-sHDL-CpG nanoparticles were 
synthesized in this study to deliver chemotherapeutic drug (DTX) together with immune 
stimulatory molecule (CpG) for tumor inhibition.  By determining the expression of SR-BI on 
various cell lines and through cytotoxicity evaluation, the GL26 cell line was selected to establish 
the tumor model and DTX was selected as the drug to be loaded in sHDL. Formulation was further 
optimized based on stability of DTX-loaded sHDL, and apolipoprotein A-I (ApoA-I) mimetic 
peptide, 22A, and sphingomyelin (SM) were selected for final formulation. In vitro studies 
determined that 30% of sHDL particles could penetrate through blood-brain barrier model and 
could be successfully taken up by the cancer cells.  However, intravenous administration of sHDL 
didn’t show a significant improved therapeutic effect compared to free drug in the murine 
glioblastoma survival study. For intracranial injection groups, DTX-sHDL-CpG showed 1.17-fold 
increase of mean survival time (MS) compared to free drug, with 20% of long-term survivors.  
5.2 Introduction 
Glioblastoma multiforme (GBM) is the most aggressive primary tumor within the central 
nervous system. 227 Even after performing a surgical excision, chemotherapy, and radiotherapy, 
the prognosis of patients with GBM remains dismal. GBM commonly recurs, and often results in 
the death of the patient. Therefore, the development of effective treatment strategies to control the 
progression and survival of these gliomas is necessary.  
Chemotherapy is a commonly used clinical treatment for GBM. Although 
chemotherapeutic agents are directed to kill cancerous cells, the byproduct of their application 
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often results in the death of normal cells. Since their cytotoxic effects are not selective for 
cancerous cells, toxicity is a major issue to consider. Besides, many anti-cancer drugs have poor 
water solubility and a short half-life in vivo. 228 Thus, reduction of possible toxicity requires the 
delivery of higher specificity chemotherapeutic agents. In addition to chemotherapy, 
immunotherapy arises to be an attractive alternative strategy to correct the immunosuppressive 
environment in glioblastomas. CpG oligodeoxynucleotide is a TRL9 ligand expressed by most 
murine immune cells which can trigger immune rejection and induce long-term immunity against 
gliomas. 229 CpG loaded products have been explored as an effective treatment for glioma through 
intracranial injection. 230-232 Co-delivery of chemotherapeutic drugs and CpG can potentially 
achieve better tumor suppression compared to the individual use. 
Ongoing research has demonstrated that nanoparticles (NPs) show the ability to meet the 
need for targeted delivery of therapeutics and imaging agents (theranostics) into brain tumors. 233-
235 They are also widely used in co-delivery of different agents. 231 However, few NPs have met 
regulatory approval for clinical administration. HDL is a naturally occurring NP that, unlike many 
engineered NPs, circulates in plasma for long periods of time (T1/2 ~ 3-4 days)
20 which allows time 
for accumulation in hard to reach organs like the brain. It also has a major role in transport of 
cholesterol and other molecules, such as vitamin E, steroid hormones, signaling lipids, and micro 
RNAs.  It has been found that upon administration multiple drugs bind to HDL and other 
lipoproteins. 236,237 Several synthetic ApoA-I peptide-based sHDL, which are more cost-effective 
and easier to produce on a large scale, have been administered to humans in Phase I/II studies and 
are proven to be well tolerated and safe at high doses. 18, 112, 141  
HDLs are able to interact with the cell surface receptor, scavenger receptor class B-I (SR-
BI), which was reported to facilitate the uptake of cholesterol esters and anticancer drugs from 
HDL-like NPs to the cytosol via a non-endocytic pathway—thus preventing lysosomal degradation 
of the HDL-like NP payload. 238 SR-BI receptors have been reported to be overexpressed on 
several cancer cell lines which can facilitate the uptake of HDL by cells. 239 Therefore, HDL has 
been considered to be a suitable drug-delivery carrier for cancer therapy, capable of overcoming 
the current challenges within traditional chemotherapy, owing to their structural features, 
biocompatibility and intrinsic tumor targeting ability via receptor-mediated mechanisms. 141, 240-241 
One of the main challenges in achieving therapeutic efficacy in brain tumor patients is the low 
permeability of the blood brain barrier (BBB) to chemotherapeutic drugs. 242 Various HDL 
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particles were found to be able to overcome blood-brain barrier through micropinocytosis or SR-
BI mediated cell uptake expressed in caveolae. 243-245 Thus, with the unique targeting capabilities 
HDL particles might be able to facilitate the penetration of drugs through the blood brain barrier 
by encapsulating molecules in their hydrophobic core. Besides, due to its small size, HDL can 
diffuse among cancer cells better than other nanoparticles and enhance the accumulation of drugs 
in tumor cells.  
To test our assumptions, synthetic high density lipoprotein (sHDL) NPs were developed to 
effectively deliver chemotherapeutic agents and CpG to GBM cells in preclinical models. We 
assessed experimentally whether sHDL NPs will target GBM in vitro and in vivo, and if sHDL 
loaded with chemotherapeutic agents and CpG will induce GBM tumor regression and improve 
the therapeutic effect on tumor-bearing animals after administration through different routes. 
Several GBM cell lines expressing SR-BI were compared and used for evaluation. We also 
incorporated near-infrared fluorescent dyes and chemotherapeutic drugs as payloads into sHDL, 
enabling molecular imaging of invasive GBM cells and targeted drug delivery. A tumor-bearing 
animal model was established to evaluate the therapeutic effect of drug loaded sHDL. 
 
Figure 5.1: Schematic of DTX-sHDL-CpG for chemo-immunotherapy. (A) DTX-sHDL-CpG is formulated by 
incubation of CpG-cholesterol with preformed sHDL. (B) Intracranial injection of sHDL followed by release of DTX 
kills tumor cells. Release of CpG trigger DCs recruitment and recognition of tumor cells by T cells. 
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5.3 Materials and methods 
5.3.1 Materials 
Paclitaxel (PTX), docetaxel (DTX) and lomustine (CCNU) were purchased from Sigma-
Aldrich with purity over 99% (St. Louis, MO). ApoA-I mimetic peptides 22A 
(PVLDLFRELLNELLEALKQKLK) were synthesized by Genscript Inc. (Piscataway, NJ). The 
purity of peptide was determined to be over 95% by the reverse phase HPLC. 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and egg sphingomyelin (SM) 
were purchased from Avanti Polar Lipids (Alabaster, AL).  Fluorescent dyes (DiO and DiR) were 
purchased from Invitrogen (Carlsbad, CA). Additional reagents used were of analytical grade and 
obtained from commercial suppliers. Preparation and Characterization of drug-loaded sHDL and 
dye-loaded sHDL 
5.3.2 Preparation of drug-loaded sHDL and dye-loaded sHDL 
The drug loaded synthetic HDL (sHDL) was prepared by lyophilization method. Briefly, 
22A peptide, lipids and anti-cancer drugs with various weight ratios were dissolved and well mixed 
in glacial acetic acid, which was then removed by freeze-drying method. Lyophilized product was 
hydrated using 1M phosphate-buffered saline (PBS, pH 7.4) followed by thermal cycling varying 
from 50°C to 20°C for a minimum of 3 heat and cool cycles (10 minutes each) applying gentle 
shaking to obtain homogenous sHDL nanoparticles. Fluorescent dye DiD loaded sHDL was 
prepared by the same process. DTX-sHDL-CpG was prepared by incubating CpG-cholesterol with 
DTX-sHDL solution at room temperature for 4 hours after DTX-sHDL preparation. Alexa 647 
labelled sHDL was prepared by linking Alexa Fluro 647 (Thermo Fisher Scientific, Waltham, MA) 
per manufacturer’s instruction. NBD-labelled sHDL was prepared by mixing NBD-labelled DPPC 
lipids (Avanti Polar Lipid, Inc. Alabaster, AL) with 22A peptide.  
5.3.3 Particle Characterization 
Gel permeation chromatography (GPC) was used to separate particles based on their sizes. 
The purity and homogeneity of prepared sHDL was calculated by dividing area under the curve of 
sHDL to the total chromatography peaks’ area using a Shimadzu HPLC system equipped with a 
TSKgel G2000SWxl column (7.8 mm ID × 30 cm, Tosoh Bioscience LLC) and the detection 
wavelengths were set at 220 nm for quantification of ApoA-I mimetic peptide, 22A. The particle 
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size of drug-sHDL was measured by dynamic light scattering (DLS) on a Malvern Zetasizer 
(Westborough, MA). The sHDL morphology was assessed by transmission electron microscopy 
(TEM) after proper dilution of the original samples. The diluted sample solution was deposited on 
a carbon film-coated 400 mesh copper grid (Electron Microscopy Sciences) and dried for 1 minute. 
Samples were then negatively stained with 1% (w/v) uranyl formate, and the grid was dried before 
TEM observation. All specimens were imaged on a 100kV Morgagni TEM equipped with a Gatan 
Orius CCD. 
5.3.4 Western Blot 
Cell lysates were prepared by incubating GBM cells in T-75 tissue culture flasks with 
protease inhibitors and 1.4mL RIPA lysis buffer on ice for 5 minutes. Resulting cell lysates were 
centrifuged at 13000 RPM at 4°C for 10 minnutes and supernatants were collected to determine 
protein concertation in comparison to standard bovine serum albumin (BSA) protein 
concentrations through bicinchonicinc acid (BCA) assay. For electrophoretic separation of protein, 
twenty-five micrograms of total protein was resuspended in loading buffer (10% sodium dodecyl 
sulfate, 20% glycerol, and 0.1% bromophenol blue) and incubated for 5 minutes at 95°C for 10 
minutes to be loaded onto a 10% polyacrylamide gel. Proteins from the gel were transferred to 
polyvinylidence difuoride membrane and blocked with 5% nonfat milk in TBS-0.1% Tween-20 to 
be incubated with primary anti-SR-BI (1:1000) overnight at 4°C. The next day, blots were washed 
with TBS-0.1% tween-20 and incubated with secondary (1:000) antibody for two hours at room 
temperature. Blots were washed several times again with TBS-0.1% tween-20 and visualized 
under Biorad gel imaging software.  Band intensities were quantified using ImageJ software.  
5.3.5 Cytotoxicity 
Human, and mouse glioma cells were plated at 1,000 cells per well in 96-well plate 24 hrs 
prior to treatment. Cells were then incubated with free-sHDL, free HCPT, CCNU, PTX, DTX; 
HDLs loaded with HCPT, CCNU, PTX, and DTX for 48hrs. Cell viability was determined with 
CellTiter-Glo viability assay following manufacture’s protocol. IC50 values for each 
chemotherapeutic reagent were calculated from dose-response curves generated using graphpad 
prism.  
5.3.6 Cell uptake of sHDL 
To determine the cellular uptake of sHDL by glioma cells HF2303, CNS1 and GL26-Cit 
cells were plated onto glass cover slips coated with poly-L lysine in a 24-well plate 12 hours before 
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treatment. Cells were then treated with 0 ug, 3 ug, 10 ug and 30 ug of DiD-HDL in 0.4 mL of fully 
supplemented DMEM for 2 hours.  Cells were washed three times with PBS and fixed in 4% 
Paraformaldehyde for 30 minutes and mounted onto slides with Prolong Gold anit-fade solution. 
DiD-sHDL uptake was imaged with confocal microscopy (instrument info) at 63x with oli-
immersion lens and quantified using image J software.  
5.3.7 Establishment of BBB model 
Co-culture model was used to study the penetration of sHDL through BBB. Briefly, human 
astrocytes/ tumor cells were seeded on the underside of the 12-well transwell plate insert and 
incubated with medium overnight. On day 2, human brain membrane endothelial cells were seeded 
in the transwell insert and were cocultured with astrocytes or tumor cells. Medium was changed 
every day and the transendothelial electrical resistance (TEER) was measured over time until the 
value reached plateau. The liquid surface leakage test was conducted by observing the leakage of 
medium from insert to the bottom well over 24 hours. FITC-Dextran penetration was evaluated to 
confirm the formation of tight junction.   
5.3.8  Penetration of sHDL through BBB 
The component of sHDL was labelled with fluorescent dye separately. 22A peptide in 
sHDL was labelled with Alexa, lipids were labelled with NBD and the core was labelled with DiD. 
sHDL was added at either high peptide concentration (1mg/mL) or low concentration (0.1 mg/mL) 
into the insert of transwell plate with established BBB model. The fluorescence in the medium in 
inset or bottom well was measured to determine the penetration of different component of sHDL 
at various time points. The percentage of penetrated component was calculated. 
5.3.9 Stability Study 
In vitro study was performed to quantify the stability of DTX-sHDL particles for 
formulation screening purpose.  Briefly, different formulations of DTX-sHDL were suspended in 
PBS or human serum and incubated at 37°C with the DTX concentration of 1 mg/ml. At 0, 0.5, 1, 
2, 4, 8 and 24 hours after incubation, 100 μl mixture of each sample was collected and filtered 
through 0.22 μm membrane to separate precipitated drug.  After filtration, 50 μl of each sample 
was mixed with 450 μl acetonitrile to dissolve the all component of nanoparticles and precipitate 
proteins. After centrifuge, the drug content incorporated in sHDL was determined by UPLC 
analysis.  
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5.3.10 Anti-tumor effect in vivo  
Syngeneic tumors were established in C57BL/6J mice by stereotactically injecting 20,000 
GL26-WT, or GL26-Cit cells into the right striatum using a 22-gauge Hamilton syringe (1uL over 
1 minute) with the following coordinates: +1.00 mm anterior, 2.5 mm lateral, and 3 mm deep. 
Mice were either treated intratumorally with 0.5 mg/kg of free-DTX, DTX-sHDL, sHDL-CpG-
DTX, free-HDL NPs or saline 8, 11, 15, 18, 22 and 25 days post tumor implantation. Particles 
loaded with chemotherapeutic cargo were intratumorally delivered in 4.8 μL volume in three 
locations to depths of 3.1, 3.0, and 2.9 mm, at the coordinates detailed above. Mice were 
trascardially perfused when they showed signs of neurological deficits due to tumor burden. 
5.3.11 Statistical analysis 
Sample sizes were chosen based on preliminary data from pilot experiments and previously 
published results in the literature. All animal studies were performed after randomization. Data 
were analyzed by one- or two-way analysis of variance (ANOVA), followed by Tukey's multiple 
comparisons post-test or log rank (Mantel-Cox) test with Prism 6.0 (GraphPad Software). Data 
were normally distributed and variance between groups was similar. P values less than 0.05 were 
considered statistically significant. All values are reported as mean ± SD with the indicated sample 
size. No samples were excluded from analysis. 
5.4 Results 
5.4.1 SR-BI expression on glioma cell lines 
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Figure 5.2: Expression of scavenger receptor class B-1 (SR-BI) on rodent and human GBM cell lines and human 
GBM Stem Cells. 
Since sHDL has been reported to be able to interact with SR-BI receptor expressed on 
macrophage or liver cells to facilitate cellular uptake of sHDL, we would like to confirm the 
expression level of SR-BI on several glioma or glioma stem cell lines and select the cell line used 
for tumor model establishment in mouse.  Western blot was applied to determine SR-BI levels in 
cell lysates, and gel image together with quantification of the gel are shown in Fig. 5.2.  SMA560 
is a murine astrocytoma cell line and GL26 and CNS-1 are murine glioma cells. IN859, IN2045, 
MGG8, HF2303 and U251 are derived from human. BHK cells transfected with SR-BI was used 
as the positive control with astrocyte as the negative control. All glioma cells showed manifest 
expression of SR-BI compared to negative control. Human cells expressed higher level of SR-BI 
receptors compared to murine cell lines. To establish the mouse glioma model, GL26 was chosen 
in this study for in vivo efficacy assessment since more SR-BI was presented on GL26 cells than 
U251 cells. HF2303 (human), CNS1 (rat) and GL26 (mouse) cells were used for cell uptake and 
cytotoxicity studies in vitro.  
5.4.2 Penetration of sHDL through BBB in vitro 
 
Figure 5.3: Penetration of sHDL through BBB in vitro. Evluation of formation of tight junction and BBB model 
(PanelA-C); penetation of fluorescence labelled sHDL through BBB (Panel D-F). 
The most important factor limiting the application of anti-cancer drug in glioma treatment 
is the existence of the blood brain barrier, limiting penetration of IV administered 
chemotherapeutic agents and nanoparticles. Thus, we first examined if sHDL particles can 
penetrate the BBB in vitro using a transwell model. The BBB model was established by co-culture 
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of human brain microvascular endothelial cells (HBMEC) with either human tumor cells or 
astrocytes to mimic the biological structure of human BBB under normal and disease condition. It 
is important to confirm the formation of the BBB and establishment of tight junctions prior to 
penetration assessment. Normally, the resistance of insert membrane in transwell plate increases 
as cells numbers increases and reaches plateau. Transepithelial electrical resistance (TEER) was 
monitored over time after cells were seeded as shown in Fig.5.3A. TEER in both co-culture models 
kept increasing from day 0 to day 15 until a plateau was achieved at ~ 200 Ω/well indicating 
formation of a tight junction. In addition, FITC-dextran was added into the insert well and FITC 
fluorescence intensity in the well was determined to detect the passive diffusion of molecules 
through BBB. The liquid surface leakage test was conducted by observing the leakage of medium 
from the insert to the bottom well over 24 hours. As shown in Fig. 5.3B and C, there was only 
limited FITC-dextran or medium passing across the cell layer confirming formation of tight 
junctions and establishment of an in vitro model of the BBB. sHDL particles were prepared as 
described in section 5.3.2.  
To track the penetration of different components of sHDL, peptide, lipid and hydrophobic 
core of sHDL were fluorescently labelled with Alexa 647, NBD and DiD, respectively. sHDL 
particles were added into the insert at either low or high concentration (0.1 mg/mL or 1 mg/mL) 
to assess the concentration-dependence of BBB penetration and fluorescence in the bottom well 
was measured over time. In both models, tumor-endothelial model and astrocyte-endothelial model 
(Fig. 5.3D and E), fluorescence signal increased over time with sHDL incubation, demonstrating 
that sHDL can penetrate the BBB in vitro. The percentage of sHDL passing through the BBB for 
low concentration of sHDL was higher than high concentration indicating the saturation of, likely, 
receptor-mediated sHDL transport. Besides, peptide component in sHDL was shown to achieve 
higher penetration compared to lipid or DiD components, indicating some extent of dissociation 
of sHDL particles during incubation.  
To examine if BBB penetration is mediated by the SR-BI, the cells were pretreated with 
anti-SR-BI antibody (NB400-113, Novus biological) at 1:100 dilution for 1 h at 37°C. As shown 
in Fig 5.3F, after incubation with the anti-SR-BI antibody, the penetration of different sHDL 
components was not reduced, suggesting that BBB penetration is independent of SR-BI-mediated 
uptake mechanism. Thus, a different mechanism is likely responsible for sHDL penetration 
through the BBB such as transcellular lipophilic pathway and paracellular pathway.246 
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5.4.3 Cell uptake of sHDL by glioma cells 
We next investigated if molecules incorporated in sHDL can be uptaken by glioma cells 
when incubated together. sHDL particles were loaded with insoluble fluorescent DiD dye to 
represent hydrophobic drugs and incubated with three types of glioma cells at different 
concentrations.  Following 2 h incubation, cellular uptake of DiD was visualized by confocal 
imaging and quantified by flow cytometry (Fig. 5.4). The green signal is from cells and blue signal 
is from DiD. The fluorescence of DiD appears to distribute throughout cellular membranes and 
cytosol for all groups and increases with higher DiD-sHDL concentration. Thus, the uptake of DiD 
is dependent on sHDL concentration but it is not clear if DiD first diffused out from sHDL then 
got taken up by cells or was released after sHDL uptake by cells. When DiD uptake was quantified, 
GL26 cells exhibits strongest DiD signal at low sHDL concentration while human HF2303 cells 
achieves highest DiD uptake at high sHDL concentration, which may result from higher SR-BI 
expression on cells. Based on this observation, the cellular uptake of sHDL is at least partially 
mediated by SR-BI.  
 
Figure 5.4: Cell uptake of DiD-sHDL by GL26, CNS1 and HF2303 cells. 
 
5.4.4 Preparation and characterization of drug loaded sHDL particles  
To screen the ability of various chemotherapeutic agents incorporated in sHDL particles to 
exert cytotoxic effect in glioma cell lines, PTX, DTX and CCNU were loaded in the nanoparticles 
using co-lyophilization methodology. We have utilized the same composition of sHDL as was 
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previously optimized by us for delivery of anticancer agent triacetylated withaferin A, and anti-
inflammatory agent, T0901317247. DLS and GPC were used to examine particle size, homogeneity 
and purity. ApoA-I mimetic peptide (22A), phospholipids (DMPC and POPC) and 
chemotherapeutic agents were combined at 1:1:1:0.06 weight ratio in organic solvent, lyophilized 
and hydrated with aqueous buffer. The mixture was heated and cooled to facilitate particle 
assembly.  It was demonstrated that homogeneous particles were formed with average size of 10-
12 nm and purity >98% (Table 5.1, A-C). As particle size determined by DLS increased, the 
retention time of GPC running decreased accordingly.  All three drugs were shown to be 
successfully incorporated in sHDL at 2% loading and cytotoxicity of drug loaded sHDL were 
evaluated to select the most potent drug as model drug in this study.  
Table 5.1: The characterization summary of different 22A-sHDL particles. 
Group Formulations (weight ratio) RTa (min) Particle size (nm) PDIb Purity 
A 22A: DMPC: POPC:PTX (1:1:1:0.06) 7.6 12.1 ± 0.3 0.07 ± 0.01 99.2% 
B 22A: DMPC: POPC:DTX (1:1:1:0.06) 7.5 11.2 ± 0.4 0.15 ± 0.01 99.2% 
C 22A: DMPC: POPC:CCNU(1:1:1:0.06) 7.4 10.3 ± 0.1 0.05 ± 0.02 98.5% 
D 22A: SM (1:2) 7.9 9.5 ± 0.4 0.11 ± 0.01 99.0% 
E 22A: SM: DTX (1:2:0.05) 7.9 9.9 ± 0.1 0.07 ± 0.01 97.6% 
F 22A: SM: DTX (1:2:0.1) 7.9 9.4 ± 0.2 0.13 ± 0.06 97.2% 
G 22A: DPPC: DTX (1:2:0.1) 7.8 8.9 ± 0.1 0.15 ± 0.01 97.3% 
H 22A: DPPC: SM:DTX (1:1:1:0.1) 7.8 9.4 ± 0.1 0.14 ± 0.01 98.0% 
I 22A: DMPC: POPC: DTX (1:1:1:0.1) 7.4 11.1 ± 0.2 0.14 ± 0.02 99.7% 
J 22A: SM: DTX: CpG (1:2:0.05:0.0075) 8.1 8.6 ± 0.1 0.13 ± 0.02 97.9% 
 
5.4.5 Cytotoxicity and selection of model drug 
To select the most potent anti-cancer drug as the model drug in this study for glioma 
suppressing effect evaluation, cell viability of various cell types treated with three formulations 
were evaluated using the Cell Titer Glo assay method. GL26, HF2303 and U251 cell lines were 
incubated with either free drug or drug loaded sHDL at various concentrations. Half-maximal 
inhibitory concentration (IC50) of the different chemotherapeutic agents was obtained from an 
experimentally derived dose-response curve as plotted in Fig. 5.5.  
All drugs were shown to be toxic to all cell lines while blank sHDL achieved little cell 
killing effect ranging from 0.0001 uM to 1.0uM. For all three molecules, free drug and drug-sHDL 
have the comparable IC50 values on each cell line. Drug loaded sHDL-NPs did not display 
differences in the biological properties relative to free drug. The IC50 value for U251 cells is lower 
106 
 
than HF2303 and GL26 cells for all three molecules with or without sHDL formulation indicating 
that U251 is more sensitive to these three anti-cancer drugs. When different drugs were compared, 
DTX or DTX-sHDL had the strongest cell killing effect with lowest IC50 values on all cell lines. 
For example, the IC50 value of DTX-sHDL for GL26 cells is 0.00497 µM which is 5-fold lower 
than PTX-sHDL and 16,000-fold lower than CCNU-sHDL. Thus, DTX is the most potent agent 
out of three candidates tested, was selected as the model drug to be delivered by sHDL for brain 
tumor therapy. 
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Figure 5.3: Cytoxicity of anti-cancer drugs including CCNU, DTX and PTX on GL26, HF2303 and U251 cells with 
calculated IC50. 
5.4.6 Optimization of DTX-sHDL formulation based on loading and lipid composition 
Docetaxel (DTX) was chosen as the model drug in our study based on its lowest IC50 value 
in in vitro cytotoxicity evaluation. To further optimize the DTX-sHDL formulation with sufficient 
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loading and stability, we prepared DTX-sHDL particles using lipids with different transition 
temperature and size distribution, and purity of each formulation were summarized in Table 5.1E-
I. We first kept the peptide, lipid and drug ratio at 1:2:0.1 (w/w) and varied the lipid composition. 
In vitro stability test in PBS was conducted to select the most stable formulation for DTX retention 
as shown in Fig. 5.6A. All particles were incubated at 37°C after preparation and drug remained 
in particles overtime were determined. As gel transition temperature of phospholipids used to 
prepare sHDL increases (SM > DPPC > DMPC > POPC), lipids become more rigid and stability 
of DTX-sHDL particles in buffer and plasma increases. Following 24 hours incubation, more than 
60% of drug remained encapsulated in SM-based sHDL, while less than 40% of DTX remained in 
the particles for all other three formulations. Thus, SM was selected to form DTX-sHDL.  
In order to investigate the influence of drug loading on DTX retention in sHDL particles 
during 24hr incubation in either PBS or plasma, two formulations were prepared with changing 
loading amount of DTX between 1.67% and 3.34% (w/w). From the stability evaluation, DTX-
sHDL with low DTX loading resulted in slower drug release with 80% drug remained after 24-h 
incubation when compared to 60% drug remaining in sHDL with high loading (Fig. 5.6B). This 
trend was also confirmed in human serum stability evaluation for the same two formulations (Fig. 
5.6C). Thus DTX-sHDL with 22A, SM and DTX a weight ratio of 1:1:0.05 was selected as final 
formulation for in vivo efficacy evaluation. sHDL composed of same amount of peptide and lipids 
without drug was used as blank sHDL control.  
 
Figure 5.4: Stability of DTX-sHDL in PBS (Panel A and Panel B) and human serum (Panel C). 
 
5.4.7 Analytical characterization of DTX-sHDL and DTX-sHDL-CpG particles 
To develop the chemo-immunotherapeutic platform, CpG-cholesterol incorporated in 
sHDL nanoparticles. CpG-cholesterol was incubated with DTX-sHDL in PBS at room temperature 
(25°C) allowing the cholesterol moiety to insert into the lipid bilayer of sHDL and form DTX-
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sHDL-CpG. The final CpG concentration was 75 µg/mL. The anti-cancer evaluation was 
conducted in animals for sHDL, DTX-sHDL, DTX-sHDL-CpG. DLS and GPC characterization 
of the three formulation were summarized in Table 5.1 D, E, and J and Fig. 5.7A and B. 
Transmission electron microscopy (TEM) was also used to examine morphology of particles (Fig. 
5.7C). Both DLS and TEM results showed the homogeneous hydrodynamic size of ~ 10 nm and 
discoidal shape for “blank” sHDL, DTX-sHDL and DTX-sHDL-CpG, indicating the minimal 
impact of drug loading on the formation and homogeneity of sHDL particles. GPC curves 
demonstrated the high purity of sHDL, DTX-sHDL and DTX-sHDL-CpG solution after 
preparation. The peak of 22A peptide and CpG shifted to sHDL indicated the complete 
incorporation of 22A and CpG in sHDL.  
 
Figure 5.5: Characterization of black sHDL and DTX-sHDL particles with DLS (Panel A), GPC (Panel B) and TEM 
(Panel C). 
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5.4.8 In vivo anti-tumor efficacy 
 
 
Figure 5.6: Anti-tumor efficacy by DTX-sHDL-CpG chemo-immunotherapy. Animal survival after intravenous 
administration (Panel A) or intracranial administration (Panel B) of indicated formulations. 
Following in vitro evaluation of BBB penetration, cell uptake of sHDL, cytotoxity and 
formulation characterization, in vivo therapeutic effect of free DTX, DTX-sHDL, and DTX-sHDL-
CpG was evaluated using a brain-tumor bearing mouse model.  GL26 tumors were implanted 
stereotactically into the right striatum of C57BL/6 mice to develop glioma.  These mice were then 
treated intravenously, first with Free-DTX, DTX-sHDL or CpG-sHDL-DTX with Free-HDL as 
vehicle  control twice per week for three weeks starting 8d-post implantation. The survival Kaplan-
Meier curve was plotted in Fig. 5.8A. Administration of free DTX, DTX-sHDL and DTX-sHDL-
CpG all extend the mean survival (MS) time of animals significantly compared to saline group 
from 28 days to 31, 35, 34 days. However, there was no difference between the three treatment 
groups and neither sHDL formulation nor addition of CpG improved anti-tumor efficacy of DTX. 
This is possibly due to limited penetration of sHDL particles through BBB or instability of sHDL 
with immediate particle dissociation and drug release after administration.  
We next dosed the animals by intracranial injection using the same tumor model to bypass 
the BBB.  As shown in Fig. 5.8B, DTX-sHDL and mixing of CpG and DTX didn’t lead to better 
therapeutic outcome relative to free DTX with no increase in MS values. However, when DTX-
sHDL-CpG was given intratumorally, a notable increase in median survival of mice (MS: 55 DPI) 
compared to the free DTX (MS: 47 DPI), DTX-sHDL (MS: 38 DPI) and CpG-DTX (MS: 41 DPI) 
groups was observed, demonstrating the chemo-immunotherapy achieved the highest survival 
advantage because CpG incited immune response to tumor cells. Remarkably, there were two long-
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term survivors in DTX-sHDL-CpG group which enable intracranial administration of DTX-sHDL-
CpG a promising therapy for glioma. 
5.5 Discussion and conclusion 
 In this study, we constructed the DTX-sHDL-CpG delivery platform for glioma chemo-
immunotherapy with in vitro and in vivo evaluations.  The cell lines we selected all highly 
expressed the SR-BI receptor, which can interact with sHDL. sHDL was shown to be taken up by 
glioma cells after 2 hr incubation and pass through the BBB monolayer in Transwell cell models. 
During the course of this project we optimized the use of a number of sHDL-NPs of varied 
formulations. We constructed sHDL-NPs loaded with chemotherapeutic agents DTX that are 
known to be active against brain tumors. It was identified that intratumoral delivery of the sHDL-
NPs results in a significant increase in median survival with less systemic toxicity. Modifying the 
sHDL-NPs with immune stimulatory molecules such as CpG resulted in immune mediated anti-
glioma activity. 
Systemic administration of DTX-sHDL-CpG didn’t demonstrate an improved tumor 
inhibitory effect as we hypothesized. This could be caused by lack of particle distribution in brain 
or instability of sHDL system with fast dissociation of particles and release of incorporated drugs. 
Though in vitro studies showed obvious penetration of sHDL using cell co-culture model, it still 
does not fully symbolize the biological structure and function of the BBB in body. The formed 
tight junction in cell models can be leakier with TEER value of 200 Ω versus physiological value 
of more than 1,500 Ω/cm2, which has been measured in capillaries of rats. 248  To facilitate effective 
delivery of sHDL particles loaded with drugs, modifications of sHDL with targeting molecules or 
cell penetrating peptide or stabilization of the system by future optimization are alternative 
strategies, which can be tested later.233, 235 In the intracranial injection study, simple mixture of 
CpG and DTX didn’t perform better than free DTX drug which can be due to restricted exposure 
of CpG to dendritic cells which prevent the following activation of TLR9 regulated immune 
response. 229  By inserting CpG into sHDL, CpG can be stabilized and recognized by DC more 
readily, which may results from sHDL ultrasmall particle size (~10 nm), extended 
pharmacokinetics, and extensive uptake by metabolically highly active cancer cells that require a 
large amount of lipids and cholesterol for proliferation.249-250 In addition, DTX and CpG can be 
presented to the glioma microenvironment at the same time to achieve a synergic killing effect 
with different mechanisms. Although other conventional nanoformulations may also be applicable 
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to this approach, we believe that the sHDL system is particularly attractive for translation because 
of the ease of synthesis, established large-scale manufacturing, proven human safety, and 
nonimmunogenicity of the blank sHDL, as demonstrated in a number of clinical trials.11 
In conclusion, we have produced a new, generalizable framework for 
chemoimmunotherapy. By delivering chemotherapeutic agents together with immune activating 
molecules via nanocarriers in a manner that sensitizes tumor cells to immune activation, we have 
achieved potent antitumor efficacy, leading to elimination of established tumors in 40% of animals. 
Our approach may be readily applied to other hydrophobic chemotherapeutic agents known to 
induce tumor cell death. 251-252 Because there is intense interest in improving the patient response 
rate and therapeutic efficacy of immunotherapy combined with chemotherapy or radiation, our 
strategy presented here may have a wide-ranging impact in the field of drug delivery, 
nanotechnology, and cancer immunotherapy.  
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Chapter 6 : Conclusion, implications and future directions 
 
The work presented in this thesis has shown that both the route of administration and the 
formulation of apoA-I peptide significantly affect its pharmacokinetics and pharmacodynamics. 
To address the problem of short half-life of sHDL, sHDL-PEG nanoparticles were developed. By 
increasing the stability of sHDL particles, sHDL-PEG was shown to achieve longer circulation of 
phospholipids component and more cholesterol mobilization or efflux, this effect is dependent on 
PEG density and molecular weight. The results have broad impact on the field of sHDL design 
and nanoparticle drug delivery. In addition, NanoMCL, a structural and functional mimetic of the 
sHDL nanoparticle, was developed for the first time and proved to be more effective in relevant 
animal models compared to sHDL and also exhibited similar safety properties as sHDL. Due to 
the intrinsic targeting effect and amphipathic, bilayer structure, DTX-sHDL-CpG achieved a 
promising anti-tumor effect in animal model and sHDL can be applied as a drug delivery system 
for treatment of glioma or other cancer types. 
This research has important implications for thorough understanding of components of 
sHDL on cholesterol efflux and future development of sHDL-like nanoparticles for either 
atherosclerosis or other disease therapy. Despite that PEGylation has been investigated for years 
and researchers have modified apoA-I with PEG, this is the first time to modify the lipid 
component in sHDL with PEG and study the impact of PEG density and molecular weight on 
corresponding effects. The study in Chapter 3 underlines the importance of sHDL remodeling by 
endogenous lipoproteins in vivo in regards to sHDL’s PK and pharmacological effect. Hence, 
strategies for minimizing sHDL in vivo remodeling, such as crosslinking ApoA-I or lipid 
components, could potentially improve sHDL PK properties and efficacy. Thus, understanding the 
forces driving lipoprotein remodeling in vivo and developing strategies to minimize it could lead 
to the design of more stable and efficacious sHDL based nanomedicines. In addtion, because of 
the simplicity and ease of preparation, NanoMCL could prove to be a valuable alternative to sHDL 
in treatment of ACS and other inflammatory diseases. Significant interest in the field remains for 
the use of sHDL therapeutics for treating systemic inflammatory diseases like sepsis, lupus and 
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rheumatoid arthritis. Therefore, the NanoMCLs we describe here could be potentially useful 
beyond cardiovascular applications.  As our simple NanoMCL system appears to have a higher 
capacity for binding endotoxin and cholesterol as compared to sHDLs, NanoMCLs likely could 
provide an exciting translational opportunity for treatment of CVD, sepsis and other diseases 
involving scavenging hydrophobic molecules.  
In this study, serum cholesterol levels were detected to indicate the cholesterol efflux effect 
of sHDL from peripheral tissues, but it is unknown where exactly the cholesterol is from and future 
studies may include the determination of cholesterol levels in different tissues or organs to 
investigate how much of the cholesterol accumulated in the plaque or macrophages get removed. 
Since NanoMCLs were administered systemically through IV injection without specific targeting 
to plaque, modification of NanoMCL with targeting molecules to macrophage or artery plaque can 
potentially improve the anti-atherosclerosis effect of NanoMCL following this study. This can be 
another direction for future investigation. As mentioned above, we have not examined the impact 
of pegylation of sHDL or the constructed NanoMCL system on the anti-inflammatory and anti-
thrombotic properties, thus evaluations in other disease areas are suggested.  
This thesis figures out the importance of lipid component in sHDL in relation to its efficacy 
and provides the possible strategies to improve the cholesterol mobilization ability of sHDL. 
Future stuties built on the research presented will lead to expanded application and benefit of sHDL 
systems. 
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